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The syndrome of cardiac chest pain with a positive exercise tolerance test but angiographically normal
coronary arteries (cardiac Syndrome X) is a common clinical scenario. There is now a good evidence
base, suggesting that these patients are relatively insulin resistant and have abnormalities of coronary
and peripheral vasomotor function. I begin by examining the background of insulin resistance along
with its link to endothelial function, its measurement and potential aetiology along with its established
link to atheromatous coronary disease. Chapter 2 introduces cardiac 'Syndrome X' by looking, in a
balanced way, at the evidence for ischaemia, as well as the evidence for insulin resistance and
endothelial function in these patients. I postulate that underlying insulin resistance in these patients leads
to general abnormalities of vascular function and therefore reduced vasodilator capacity in the coronary
bed as the substrate for myocardial ischaemia.
I performed a study in which women with cardiac 'Syndrome X' were initially compared with a healthy
control group to examine differences in their metabolic measures, anthropometric measures and
peripheral microvascular function. I then went on to perform a randomised double-blinded placebo-
controlled trial during which metformin or placebo was administered for 8 weeks to women with cardiac
'Syndrome X'. The recruitment protocol and methods used are described in chapter 3.
The differences between women with cardiac 'Syndrome X' and healthy controls are discussed in
chapter 4. I show that after correction for age and body mass index, there exists significant differences
between the groups in terms of indices of insulin resistance, some lipid parameters, some serum markers
of endothelial function and serum leptin.
The process of laser Doppler imaging in conjunction with iontophoretically-applied acetyl-choline and
sodium nitroprusside is used to assess peripheral microvascular function, and this is discussed in chapter
5. In particular, the reproducibility of these measurements both between arms, and several weeks apart is
validated. I go on to show that there is a significant difference both in the endothelium-dependent and
independent peripheral microvascular vasodilating response, between women with cardiac 'Syndrome
X' and controls, in chapter 6.
I demonstrate in chapter 7 that administration of metformin to women with cardiac 'Syndrome X'
results in significant improvement in some indices of insulin resistance, some lipid measures, some
serum markers of endothelial function and body mass. Furthermore, in chapter 8, improvement in
endothelium-dependent microvascular function and in some ischaemic-measures is shown following
metformin administration. These findings are summarised and discussed in chapter 9.




Chapter 1 Insulin Resistance - Measurement, Aetiology and Link to
Cardiovascular Disease
Introduction to insulin resistance 8-10
The Metabolic Syndrome 11
Measuring insulin resistance 12-16





Insulin resistance and atheroma coronary angiographic data 28
ultrasound data 29-30
Insulin resistance and CHD prospective trials 31-36
Chapter 2 Cardiac 'Syndrome X' - Myocardial Ischaemia, Insulin
Resistance and Vascular Dysfunction
Myocardial ischaemia and vasomotor dysfunction 44-46
Cardiac'Syndrome X' patient characteristics 47-49
prognosis 49-52
Evidence for an ischaemic basis lactate experiments 53-57
cor. sinus oxygen saturation 58
reperfusion oxidative stress 58
ultrastructure 59
Potential non cardiac aetiologies for chest pain 60-62
Modalities for diagnosis ETT 63-64
LV dysfunction (ECHO) 65
thallium scintigraphy 66-67
MRI/nuclear SPECT 68-69
Aetiology of microvascular angina 70
- impaired coronary vasodilator response 71-74
- a generalised systemic vasodepressor response 75-76
- a correlation? 77-78
- insulin resistance 79-83
- serum markers of endothelial dysfunction 84-86
- oestrogens 87-89
1
Chapter 3 Metformin in Insulin Resistance and Syndrome X (MIRS) Study
- Trial Design and Methods
Hypotheses for MIRS Study 100-101
Recruitment for Study normal angiograms 102-104
positive ETT 105-106
Exclusion criteria 107-109




administration of metformin 116
week 8 visit 117-118
Dropouts 119
Recruitment of control subjects 120-121





laser Doppler imaging 129
statistics 130
Chapter 4 Assessment at Baseline and Comparisons Between Healthy






Chest pain and anti-anginal use among 'Syndrome X 'group 145-146
Menopause and obstetric data 147
Glucose and indices of insulin resistance 148-150
Lipids 151-153
Serum endothelial cell markers 154-157
C-reactive protein and leptin 158-159
Oestrogen measures 160-161
Correcting for age and BMI
- regression analysis 162-166
- excluding group members to equalise age 167-170
Correlations between measured variables 171
- fasting insulin and anthropometric measures 172-173
- fasting insulin and lipid measures 174
- fasting insulin and serum endothelial markers 175
- fasting insulin and C-reactive protein 176
Summary 177-179
2
Chapter 5 Assessing Peripheral Microvascular Response
Assessing vascular function 182-183
Vasomotor dysfunction in microvascular angina 184
Measuring vascular function by LDI iontophoresis 185-186
principles of LD1 187-188
protocol used 189
hyperaemic response 190-192
Calculating the LDI response 193
-skin resistance 194
-baseline 195
Inter-arm variation of response 196-203
Temporal variation 204-210
Summary 211
Chapter 6 Examining the Difference in Microvascular Function Between
Women with 'Syndrome X' at Baseline and Healthy Controls
Acetylcholine (endothelium-dependent) response 215-218
Nitroprusside (endothelium-independent) response 219-221
Correcting for differences in age and BMI 222
Correlating ACh with SNP response 223
Correlating microvascular function to insulin sensitivity 224
Correlating LDI measures to serum endothelial markers 225
Summary 226
Chapter 7 Effects ofMetformin on Metabolic Parameters in Women
with Cardiac 'Syndrome X'
Background of biguanides 228-230
Tolerability and side-effects of metformin 231
Effects of metformin on lactate 232-235
Baseline characteristics of metformin/placebo groups 236-237
Presentation of results 238
Effects on glucose/indices of insulin resistance 239-245
lipid profile 246-248






Chapter 8 Effects of Metformin on Peripheral Microvascular Function
and Clinical Measures of Ischaemic Burden in Women with
Cardiac 'Syndrome X'
Baseline characteristics 266
Presentation of results 267
Effect of metformin on LDI microvascular function 268-274
Effect of metformin on ischaemic measures
- chest pain and GTN use 275-276
- treadmill performance 277-278
- Duke Score 279-281
Summary 282-283
Chapter 9 Summary, conclusions and discussion 284-297
Appendix 1 Patient Consent Form
Appendix 2 Study Information Sheet
Appendix 3 Publication - Insulin resistance as a contributor to myocardial ischaemia
independent of obstructive coronary atheroma - a role for insulin sensitisation ?
Heart Dec 2004 Vol 90(12) 1379-83
Publication - Microvascular function, metabolic syndrome and novel risk factor
status in women with cardiac syndrome X.
American Journal of Cardiology - in press
Publication - Effects of metformin on microvascular function and exercise tolerance
in women with angina and normal coronary arteries: a randomised double-blind
placebo controlled study
Journal of the American College of Cardiology - in press
Appendix 4 Published abstracts presented at international meetings
4
FOREWORD
There is mounting evidence that hyperinsulinaemia, as a surrogate marker for insulin
resistance, is an independent cardiovascular risk factor. As well as the promotion of
atherogenesis, there is evidence to suggest that insulin resistance has a role in the pathogenesis
of vasomotor disturbances often seen in tandem with atheromatous plaques. It is known that
insulin is important in the endothelial production of nitric oxide and abnormal vasomotor
function may be related to blunted nitric oxide production, at least in part, which would
manifest in an insulin resistant state.
Cardiac 'Syndrome X' is a label used to describe patients with ischaemic-type chest pain,
indirect evidence of myocardial ischaemia and unobstructed coronary arteries. These patients
form a heterogeneous group and although a significant proportion has non-cardiac chest pain,
there is good evidence to suggest that at least a subgroup has genuine myocardial ischaemia.
Theories regarding the aetiology of ischaemia in these patients include reduced vasodilator
reserve as a result of microvascular endothelial dysfunction. This may be related to insulin
resistance, which has been demonstrated in patients with 'Syndrome X'.
Chapter one of this thesis introduces the concept of insulin resistance and its measurement.
The current level of knowledge regarding intracellular insulin signalling and the potential
mechanisms for the aetiology of insulin resistance are presented. Finally, the relationship
between insulin resistance, general atheroma and coronary artery disease is examined with the
final section focusing on the prospective data looking at the risk of coronary heart disease with
surrogate markers of insulin resistance.
Chapter two discusses cardiac 'Syndrome X' and microvascular angina looking at the
evidence for an ischaemic basis and potential causes of non-cardiac pain. Various clinical
tools for non-invasive demonstration of ischaemia are discussed. The potential aetiology and
pathogenesis are reviewed with reference to insulin resistance, oestrogen deficiency and
vascular dysfunction. This culminates with the hypothesis that patients with microvascular
angina are insulin resistant leading to abnormal vascular function which is responsible for the
generation of ischaemia. Following on from this, insulin sensitisation should improve markers
of insulin resistance, vascular function and perhaps even symptoms in this patient group.
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Chapter three then follows on to describe the recruitment, study protocol and methods used
within the double-blind placebo-controlled trial looking at:
• the differences between women with microvascular angina and normal control subjects, in
terms of metabolic parameters, risk factor profile and peripheral microvascular function.
• effects of 8 weeks of metformin therapy in women with microvascular angina in terms of
their microvascular function, features of the metabolic syndrome and ischaemic
measures/symptoms.
Chapter four presents some of the differences between the cohort of women with 'Syndrome
X' at baseline and a group of healthy controls. Data on clinical, anthropometric and metabolic
variables are presented in this chapter.
Chapter five introduces the concept of measurement of peripheral vascular function and
specifically expands upon the methodology of laser Doppler imaging in conjunction with
iontophoresis of vasoactive substances, which was the method used in the trial. Data showing
the reproducibility of this method are presented. Chapter six deals with the differences seen in
peripheral microvascular function between healthy controls and the group of women with
'Syndrome X' and looks at some of the correlations which exist between peripheral vascular
function and some metabolic variables.
The impact of metformin upon clinical, metabolic and anthropometric measures is presented
in chapter seven and chapter eight deals with the differences seen in peripheral microvascular
function following treatment with metformin.









Insulin resistance is pivotal in the pathogenesis of type 2 diabetes mellitus. It has also
been described in several other conditions, to varying extents, including polycystic
ovarian syndrome, Cushings syndrome, exogenous steroid therapy, obesity and
pregnancy. The importance of type 2 diabetes mellitus is well established as a
cardiovascular risk factor, but only over the last 2 decades has the risk of patients with
subclinical glucose intolerance and even normal glucose tolerance but insulin
resistance, been investigated.
The term 'insulin insensitivity' was first used by Himsworth and Kerr in 1939 when
distinguishing between type 1 and type 2 diabetes mellitus (1). The term 'insulin
resistance' refers to an impaired biological response to insulin. The most well known
in-vivo effect of insulin is its effect on glucose metabolism, some of which is
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Despite several effects on glucose metabolism, insulin resistance is a term that usually
refers specifically to reductions in insulin-mediated glucose uptake. However, this is
only one function of this peptide hormone, and its actions on glucose and lipid
metabolism reach much further. One of the most important roles of insulin in terms of
its relation to cardiovascular disease is thought to be its influence on the endothelial
cell monolayer. The endothelium is intimately involved in vascular homeostasis
through its many functions. One of the most important is the modulation of vascular
tone via mediators including nitric oxide (NO). Insulin appears to have a critical role
in this modulation with a significant local and systemic vasodilating effect. Insulin-
mediated vasodilation has been shown to correlate with whole body insulin sensitivity
in healthy subjects (2). Furthermore, this property does not seem to be independent of
insulin's effect on glucose metabolism. The vasodilating effect of insulin is
significantly augmented when glucose is co-infused, as measured by plethysmography
and this suggests that the vascular and metabolic effects of insulin are closely coupled
(3). A simplified pathway for its effect on NO is shown in figure 1.2 below.
Fig 1.2
Part of intra-cellular pathway
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The vasodilating effect of insulin is manifest via intermediates including nitric oxide
(NO) on the cellular level. Indeed, correlations in healthy individuals, between whole
body insulin sensitivity (in terms of insulin-mediated glucose uptake) and basal NO
production, as demonstrated by vasoconstrictor responses to N-monomethyl-L-
arginine (L-NMMA), have been described (4). This vascular relationship of insulin to
endothelial dysfunction mediated by impaired NO production may have an important
position in the pathogenesis of cardiovascular disease, the incidence of which is
increased in insulin resistant states (5).
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The Metabolic syndrome
The metabolic syndrome, now also called the 'Insulin resistance Syndrome' was first
described by Reaven almost 30 years ago, but since that time the definition has been
refined and augmented (6). It is now clear that it consists of a cluster of inter-related
cardiovascular risk factors including hypertension, dyslipidaemia, central obesity and
disturbances of fibrinolysis with abnormalities of glucose and insulin metabolism at
the core, as illustrated in figure 1.3. Low-grade systemic inflammation has more
recently been linked with cardiovascular events using the marker of serum C-reactive
protein (CRP) (7). CRP also has associations with other features of the insulin
resistance syndrome (8) and some have argued for its inclusion as part of the
syndrome (9).
Data exist showing that subjects with the metabolic syndrome have a higher risk of
cardiovascular disease and an increased cardiovascular mortality (10). This would be
expected given the various cardiovascular risk factors encompassed. However,
hyperinsulinaemia, a marker of insulin resistance, is also shown to confer independent






The gold standard technique for measuring insulin resistance is the hyperinsulinaemic
euglycaemic clamp technique, developed by Andres et al (12). Exogenous insulin is
infused intravenously at a fixed rate along with glucose and the rate of glucose
infusion is adjusted frequently to keep the serum glucose at a steady state. The
amount of glucose infused over a unit time reflects whole body insulin-mediated
glucose uptake and as such is a measure of insulin sensitivity (M). This technique is a
research tool and is cumbersome, time consuming, expensive and fairly invasive to
use. Furthermore, it is a non-physiological model.
A less invasive method of quantifying insulin resistance is that termed the minimal
model. This involves an intravenous glucose tolerance test with frequent measures of
serum glucose and insulin, usually via an indwelling venous catheter. A calculated
index of insulin sensitivity (Si) is generated on entering these values into a computer
model (13). There is reasonably good correlation between Sjand M provided subjects
do not have diabetes (for reasons stated below). Although this method is more
practical, it remains time-consuming and relatively expensive and therefore, it too has
a very restricted role outside of research.
A method termed the 'Homeostasis Model Assessment' (HOMA) relies on the fact
that basal serum insulin and glucose concentrations are determined by a feedback loop
involving systemic insulin resistance and islet beta-cell function. Fasting insulin and
glucose are measured and input into the formula:
HOMA-1R = [insulin x glucose] / 22.5
This method has also been shown to have favourable correlations with clamp-derived
estimates of whole body insulin sensitivity - the correlation co-efficient of variability
between HOMA-IR and hyperglycaemic clamp was robust (r2=0.69, p<0.01) (14).
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A more clinically relevant method for calculating insulin resistance is the use of
fasting or post-glucose load insulin levels. In general, as peripheral tissues become
insulin resistant, beta-islet cells in the pancreas compensate by increasing insulin
secretion. Therefore, higher insulin levels should be markers for systemic insulin
resistance. However, this relationship breaks down after many years, and in type 2
diabetes, beta-cells that have been hyper-secreting insulin "burn out" with falls in the
levels of insulin secretion. For this reason, patients with diabetes may have lower
insulin levels than subjects with subclinical insulin resistance and normal glucose
tolerance, despite having higher levels of systemic insulin resistance.
Despite this potentially paradoxical relationship, insulin levels do have a place in the
calculation of total body insulin resistance. It has been shown that when subjects are
divided into categories of glucose tolerance status, namely normal, impaired or type 2
diabetes, fasting insulin levels correlate reasonably well with formally measured
insulin resistance as assessed by the clamp technique within each group (15). The
correlation, as expected, is strongest in those with normal glucose tolerance, as these
subjects will tend to have the most active beta-islet cells. In subjects with normal or
even impaired glucose tolerance, but not in the diabetic population, post-glucose load
insulin levels also correlated reasonably well with total body insulin resistance (15).
Some groups have made use of a simplified index of insulin resistance termed
'Admission Index of Insulin Resistance' (AIRI) for in-patients, based on the product
of serum insulin x glucose concentrations. This has been used to calculate insulin
resistance in the non-diabetic population at the time of acute hospital admission, and
was adopted by Stubbs et al, in a study looking at acute coronary syndromes (16). The
confounding influence of stress hormones with their physiological insulin antagonism,
in this index, is potentially problematic. However, the AIRI was related to insulin
levels, which were subsequently measured during an oral glucose tolerance test (17),
although no direct clamp correlations are described.
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It is known, however, that the relationship between fasting insulin and insulin
resistance is not linear, but hyperbolic. For this reason transforming fasting insulin
levels both logarithmically and reciprocally has been proposed as a more accurate
surrogate measure of insulin sensitivity. An index known as the QUICKI (quantitative
insulin-sensitivity check index) incorporates both of these transformations and is
calculated as :
QUICKI = 1 / [log(insulin) + log(glucose)].
Another measure using the log (HOMA-IR) uses this mathematical principle and has
been found to be useful. These are discussed further below.
The best data looking at surrogate measures of insulin resistance and their correlation
to the gold-standard clamp technique is by Mather et al (18). This group looked at a
total of 152 lean, obese and diabetic subjects and performed over 250 hyper-
insulinaemic clamps. These data looking at the various indices described above have
shown that the logarithm-transformed measures such as the QUICKI and log(HOMA-
IR) produce a normal distribution unlike the measures such as HOMA, fasting insulin
and reciprocal insulin measures These log-transformed measures were also accurate in
terms of their repeatability, comparing favourably with repeatability of the index
derived from the hyperinsulinaemic clamp.
As regards the correlation with clamp data, the fasting insulin, reciprocal insulin index
(40/insulin) and the HOMA-IR did not have as good a relationship as did the log-
transformed indices (log [fasting insulin] ,QUICKI and log [HOMA-IR]). Good,
statistically significant, correlations between clamp indices and the QUICKI and log
[HOMA-IR] in obese subjects and subjects with type 2 diabetes, were observed.
These are presented in table 1.1 below. The strength of the correlation depended on
the dose of insulin used in the clamp for each group. The optimal correlation is shown
only, with the dose of insulin used.
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Table 1.1:
Correlations between clamp-derived indices of insulin resistance and other surrogate
measures (18).
Dose of Insulin log [insulin] log [HOMA-IR] QUICKI
(mU/m2.min)
lean subjects (n=69) 40 r=-0.41 r=-0.38 r=-0.36
obese subjects (n=53) 120 r=-0.73 r=-0.72 r=-0.73
type 2 diabetes (n=6) 600 r=-0.87 r=-0.93 r=-0.94
However, as can be seen, less good correlations (although still statistically significant)
were seen in lean insulin sensitive subjects. This is thought to be a statistical
consequence brought about by the greater variability of current insulin assays at the
lower end of the insulin range (18). Finally, the changes in insulin resistance brought
about by intervention (such as treatment with troglitazone) were seen to be as readily
picked-up by the QUICKI and log [HOMA-IR] indices as the clamp. This would
imply that these measures would have some use in prospective trials involving
manipulation of insulin resistance.
The use of a fasting insulin level or other similar index seems to be a reasonably good
surrogate marker for insulin resistance, as long as subjects are non-diabetic and
comparisons are limited to subjects within the same category of glucose tolerance.
However, logarithmically transformed indices such as the QUICKI and HOMA-IR
appear to be superior in their normal distribution, repeatability and correlation with
the hyperinsulinaemic euglycaemic clamp. It should be noted that this correlation
between clamp-derived indices of insulin resistance and other surrogate measures,
does seem to somewhat break down when describing insulin sensitive subjects.
The strengths and weaknesses of these various surrogate markers as presented in
table 1.2.
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Minimal Model Less invasive than clamp
Time-consuming
Expensive
HOMA-IR Requires only xl fasting sample
Non-linear distribution





Requires only xl fasting sample
Normal distribution
Good repeatability
Requires only xl fasting sample
Poor correlation with clamp in insulin sensitive
population
Non-linear distribution
Repeatability not as good as log-based indices
Reciprocal
AIRI
Requires only xl fasting sample
Non-linear distribution
Non-linear distribution
Simple - can be measured immediately with Repeatability not as good as log-based indices
one sample Confounding effects of stress hormones
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The Aetiology of Insulin Resistance
The increased risk of type 2 diabetes in those with a diabetic first-degree relative is
well recognised and suggests a genetic predisposition to insulin resistance. However,
environmental factors play a part. For example, the observation that insulin resistance
is much more prevalent in the over-weight population suggests that obesity also has a
central role.
Any genetic basis for the development of insulin resistance is likely to be mediated by
mutations leading to impaired insulin signalling at the molecular level. The network
chain of polypeptides involved in insulin signalling at the receptor, post-receptor and
gene transcription level are only poorly understood at present. However, some
important aspects of the molecular biology have been identified in recent years.
Insulin signalling
The insulin receptor (InR) consists of 4 subunits : 2 extra-cellular alpha subunits to
which the insulin molecule binds and 2 intracellular beta subunits. Insulin binding is
known to cause phosphorylation of the beta subunits on tyrosine residues by its
adjacent beta subunit. In this activated form the InR phosphorylates several other
downstream proteins including the Insulin Receptor Substrate family (IRS 1-4). Once
phosphorylated, IRS is able to bind to other proteins, the most important of which
discovered so far is Type 1A phosphatidylinositol 3-kinase (PI 3-kinase). Insulin-
stimulated glucose uptake is mediated by GLUT4 translocation to the cell surface and
it is known that the complex formed by the association of IRS and PI 3-kinase is
essential to this role (19). The intermediates between this activation and GLUT4
translocation are not entirely clear but appear to involve Protein Kinase B (PKB) and
isoforms of Protein Kinase C (PKC). Experiments have shown that expression of
PKB and PKC within certain cells promotes GLUT4 translocation and blocking the
function of these kinases inhibits this GLUT4 translocation (20) (21).
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Pathways independent ofPI 3-kinase
The pathways, however, are not as straight forward as outlined above. Other
influences, not fully understood at present, are also interacting with this system. For
example, reduced PI 3-kinase activation does not always lead to attenuation of
downstream signalling by PKC and PKB, as would be expected (22). There is much
redundancy built into the network such that only partial PI 3-kinase activation is
needed to fully initiate downstream signalling.
PI 3-kinase activation can be promoted by other means and Interleukin-4 (IL-4) is a
cytokine that can do this. However, PI 3-kinase activated by this means fails to
augment GLUT4 translocation and this suggests that additional signalling pathways
must be present (23). This is also insinuated by the data showing that naturally
occurring mutant insulin receptors which still activate PI 3-kinase fail to influence
GLUT4 translocation (24). There is also evidence that PI 3-kinase independent
mechanisms exist for GLUT4 translocation in that cells treated with wortmannin (a PI
3-kinase inhibitor) can still exhibit enhanced GLUT4 translocation when treated with
insulin and phosphatidylinositol triphosphate (PI(3,4,5)P3). This effect is not seen in
PI(3,4,5)P3-treated cells alone nor in combination with wortmannin (25).
A pathway independent of PI 3-kinase has been proposed on the basis of experiments
showing that the tyrosine phosphorylated InR can cause tyrosine phosphorylation of a
cellular protein termed 'Cbl' in addition to IRS. This Cbl phosphorylation occurs in
the presence of a facilitating protein, Cbl adapter protein (CAP) (26), and non¬
functional mutations of CAP inhibit GLUT4 translocation (20). This pathway is
thought to function in parallel with the PI 3-kinase system and it appears to be
involved in the interactions of GLUT4 vesicles and the cell membrane.
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Lipid Rafts and Intracellular GLUT4 Trafficking
The cell membrane is composed of a phospholipid bi-layer but has specialised areas
with distinct lipid and protein structures. Such areas are termed lipid raft
microdomains and are thought to facilitate specialised functions (27). Such lipid rafts
are thought to be important in the exocytosis of intracellular vesicles containing the
GLUT4 transporter especially those microdomains containing the protein caveolin.
Experimental disruption of these lipid rafts by cellular expression of dominant
caveolin mutant protein results in inhibition of insulin-mediated GLUT4 translocation
(28). The phosphorylated cbl protein is known to migrate intracellularly towards lipid
raft domains rich in the protein flotillin and this process is thought to be dependant on
CAP (29). Here it is thought to recruit a protein complex termed CrkII-C3G. The C3G
component is thought to be vital in activating a further protein named TC10, which is
a small GTP-binding protein (30). There is experimental evidence that mutant forms
of TCI 0 also have an inhibitory influence on the translocation of GLUT4 in response
to insulin (28).
These data all point towards a parallel signalling system working independently of PI
3-kinase and although PI 3-kinase activation is a prerequisite for GLUT4
translocation, successful enhancement of this translocation requires this parallel
system involving CAP-Cbl, TC10 and the lipid raft to be intact.
Down-regulation ofInsulin Signalling
There are also down-regulating pathways operating at different levels. It is known that
if the InR or IRS-1 is subjected to phosphorylation of serine or threonine residues in
place of tyrosine, their function is attenuated. InR with serine/threonine
phosphorylation exhibits less tyrosine kinase activity and IRS-1 is does not interact
with PI 3-kinase as a consequence of serine/threonine phosphorylation. A number of
enzymes that catalyse serine/threonine phosphorylation are known to exist. These
include mitogen-activated protein kinase (MAP Kinase), atypical protein kinase C
(PKC) and several others but their exact role in-vivo is not known (20). There is also
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a family of enzymes identified termed protein tyrosine phosphatases (PTPases), which
can de-phosphorylate the InR thus reducing its tyrosine kinase activity and attenuating
insulin signalling. High levels of PTP1B (a specific PTPase) have been described in
some insulin resistant humans. Information on its exact in-vivo role is lacking (31).
Increasing amounts of data are becoming available about the intricacies of
intracellular insulin signalling and an increasing number of molecules and their roles
within the system are being discovered on a month to month basis. This is an area
which is growing rapidly and it is likely that our understanding of the signalling
network is will evolve considerably in the forth-coming years. Figure 1.4 below
summarises some of the key steps and molecules involved in this complex system.
20




Mechanisms of Insulin Resistance - Potential Targets
Genetic Mutations
The network propagating and regulating insulin signalling is intricate. Potentially, any
genetic mutation that influences the expression, availability or function of any
polypeptide within this network, could affect insulin signalling. Animal models have
proved useful in studies and data are relatively lacking in human models of disease.
As each polypeptide within the network is coded on 2 chromosomes, an individual
can be heterozygous or homozygous for any given mutation. In general, heterozygous
mutations tend to be phenotypically almost normal, in that because of the degree of
redundancy built in to the system, enough functional polypeptide is usually made
available from the one functioning allele. For phenotypic differences to manifest,
there needs either to be homozygous mutations or more commonly, compound
heterozygous mutation (different mutations affecting the same allele). Phenotypic
insulin resistance is probably most common in those with heterozygous mutations
affecting several proteins within the network, leading to a polygenic model of insulin
resistance. However, it possible for a heterozygous single allele mutation to produce
significant insulin resistance. In theory, a mutated polypeptide could interfere with the
function of the normally-expressed dominant polypeptide and therefore create a much
greater defect in insulin signalling than would otherwise be expected.
Clinical insulin resistance caused exclusively by mutations affecting the insulin
receptor itself are very rare, but have been described in humans. Mutations are able to
negatively influence InR expression, insulin-binding or InR tyrosine kinase activity
and result in a variety of clinical syndromes in humans (32). In animal models, mice
with homozygous InR knockout exhibit severe insulin resistance and do not live long
(33). However, those who are heterozygous have no measurable insulin resistance at
all - a pointer to the built-in redundancy. This is also true of IRS-1 with homozygous
knockout mice being insulin resistant but heterozygotes showing no significant defect
in insulin signalling (34). However, mice heterozygous for both the InR and IRS-1
knockout develop insulin resistance and diabetes in a multi-hit polygenic fashion (35).
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It is likely that these principles apply in humans at least to some extent, with the
majority of inherited insulin resistance being mediated in this polygenic multi-hit
manner. Mutations can improve insulin sensitivity as well, at least in mice. PTPases
attenuate insulin signalling by de-phosphorylation on tyrosine residues and PTP1B
knockout mice are known to exhibit enhanced insulin sensitivity and less obesity (36).
These specific examples studied in animal models shed some light onto potential
mechanisms. Every polypeptide within the network of insulin signalling is vulnerable
to mutation and this creates a huge possible substrate on which genetic mutations are
potentially capable of modifying insulin signalling and influencing clinical parameters
of insulin sensitivity.
Hyperinsulinaemia
Reduced peripheral insulin sensitivity, caused by whatever means, results in an
increase in the beta islet cell activity initially, as a compensatory mechanism and
leading to hyperinsulinaemia, which itself is used as an index of insulin resistance.
However, there is evidence to suggest that chronic hyperinsulinaemia has detrimental
effects on insulin sensitivity in the longer term. It is known that long-term exposure of
cells to insulin results in a dampening of insulin signalling which is mediated by
serine and threonine phosphorylation of IRS-1 (21) . This in turn attenuates the
ability of IRS-1 to associate with PI 3-kinase as well as reducing it tendency to be
phosphorylated on tyrosine residues by the activated InR.
The exact mechanism by which this serine/threonine phosphorylation takes place is
poorly understood but several protein kinases capable of serine/threonine
phosphorylation have been identified and furthermore inhibition of protein kinase C
(one such enzyme) has been shown to reduce insulin resistance (37). It has been
hypothesised that Insulin-like Growth Factor (IGF) receptors, which can be activated
by high concentrations of insulin, may be responsible for the activation of
intracellular protein kinases which subsequently phosphorylate IRS-1 and InR on
serine and threonine residues, thereby attenuating insulin signalling (20). If a
feedback circuit like this does exist, then potentially a vicious cycle of insulin
resistance may a play a part in the amplification of insulin resistance as shown in
figure 5.
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Figure 1.5: Schematic showing how hyperinsulinaemia could potentially be involved





















It has been known from animal models for some time that high dose salicylate has
beneficial effects on insulin resistance and glucose tolerance (38).With an anti¬
inflammatory effect leading to enhanced insulin sensitivity, it is reasonable to infer
that pro-inflammatory pathways and cytokines may interact with insulin signalling.
Weight is added to this by the observation that the pro-inflammatory cytokine Tumour
Necrosis Factor alpha (TNF-a) is increased in adipose tissue of obese insulin resistant
subjects. Furthermore, it is known that TNF-a is an inhibitor of tyrosine
phosphorylation of IRS-1 and InR and, in animal models, neutralisation of TNF-a
improves insulin sensitivity by increased tyrosine phosphorylation of InR (39). This
effect of TNF-a is thought to be due to its promotion of serine and threonine
phosphorylation of IRS-1 (40) with subsequent dampening of insulin signalling,
thereby potentiating insulin resistance. The interaction of the many other pro¬
inflammatory cytokines with insulin signalling remains obscure.
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Adipose Tissue and Lipids
The insulin resistance syndrome includes dyslipidaemia and central adiposity as
central features. The dyslipidaemia encompasses hypertriglyceridaemia, high levels of
LDL-cholesterol, low levels of HDL-cholesterol and high circulating levels of non-
esterified fatty acids (NEFAs). It is known that obese individuals are more insulin
resistant compared to lean subjects (41). Furthermore, the distribution of adipose
tissue appears crucial with central visceral deposits correlating closely with insulin
resistance. Although the exact mechanism of this association is unclear, it has been
suggested that visceral adipocytes are more sensitive to catecholamine-induced
lipolysis and less sensitive to insulin-mediated anti-lipolytic stimuli (42). This would
tend to increase whole-body rates of lipolysis and thus levels of circulating NEFAs
which are able to render peripheral tissues insulin resistant by mechanisms discussed
below.
Skeletal Muscle
Most recently, the lipid content of skeletal muscle has been studied and several groups
have found that levels of insulin resistance are correlated with intracellular lipid
within myocytes (intramyocellular lipid - IMCL). This has been demonstrated non-
invasively by proton magnetic resonance spectroscopy and shown to be a valid
association not only in obese individuals independent of whole body mass (43), but
also in lean insulin resistant offspring of patients with type 2 diabetes (44). Studies
looking at weight loss and the effects of IMCL depletion specifically on whole body
indices of insulin resistance have found that improvements in insulin sensitivity
correlate with the loss of IMCL, suggesting that IMCL may have a central aetiological
role in systemic insulin resistance (45). The mechanism by which this potentially
occurs is not known.
Non-esterified Fatty Acids
It has been known for some time that insulin resistance is almost invariably associated
with high circulating levels of NEFAs. Whether this is merely an association, or the
cause or effect of insulin resistance, has been the subject of debate. Insulin promotes
glucose transport into cells by its effect on the cell membrane glucose transporter
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protein GLUT4. This occurs in many cell types including adipose tissue. Glucose is
essential in adipocytes for the process of triglyceride formation in which glycero¬
phosphate (formed from glucose) is esterified with fatty acid chains. The cycle of
triglyceride lipolysis and esterification goes on constantly within adipocytes and the
enzymes involved are insulin dependant. Resistance to insulin in adipose tissue
pushes the direction of the cycle in favour of lipolysis as well as reducing glucose
transport into adipocytes affecting the availability of glycerol-phosphate, needed for
fatty acid esterification. Insulin resistance can therefore potentially promote increased
levels of circulating NEFAs by this method.
Conversely, it is known that high concentrations of NEFAs can promote resistance to
insulin-mediated glucose uptake. This has been demonstrated during lipid infusions
which raise serum NEFAs, by reducing whole body glucose disposal during
hyperinsulinaemic, euglycaemic conditions (46). The mechanism by which this
occurs is at least in part due to substrate competition described by Randle in 1963 in
which relatively high levels of fatty acid oxidation are postulated to inactivate
pyruvate dehydrogenase leading to intracellular glucose-6-phosphate accumulation
and ultimately a reduction in glucose uptake. (47). More recently, a non-oxidative
mechanism has been described in which high concentrations of NEFAs not only
reduce glucose disposal and oxidation under hyperinsulinaemic conditions, but also
significantly attenuate the expected increases in glucose-6-phosphate and glycogen in
calf muscle. These in-vivo data were collected using nuclear magnetic resonance
spectroscopy. The observed attenuation in muscle glucose-6-phosphate by high levels
of fatty acids, which is contrary to what the Randle Hypothesis would predict, tends to
suggest that the defect lies at the level of glucose transport or phosphorylation (48).
The cellular mechanism by which NEFAs potentially attenuate glucose transport as
suggested by Roden et al (48) has been investigated. It is known that insulin
signalling is dampened in the presence of high NEFA concentrations. This is manifest
by reduced activation of the IRS - P13-kinase complex in response to insulin under
these conditions (49). Ultimately this will lead to a reduction in GLUT4 translocation
resulting in decreased glucose uptake.
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Obesity
Obesity characterised by adipocyte hyperplasia and hypertrophy, has a complex
relationship with insulin resistance. Being overweight is certainly associated with
insulin resistance and this is likely to be at least in part mediated by higher circulating
levels of NEFA. However, there are mechanisms by which NEFA promote insulin
resistance and potentially a positive feed-back loop in which levels of insulin
resistance could be amplified exists.
Summary
There are several different mechanisms by which insulin resistance may be
propagated with genetic influences forming a background on which environmental
influences such as body fat distribution and systemic inflammation can interact.
However, it is clear that these influences do not act in isolation and it is likely that
they work together, with even the possibility of positive feed-back and amplification
once the processes to promote insulin resistance have been initiated.
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Insulin Resistance and Atheromatous Disease
Coronary Angiographic Data
Several studies have looked at patients who have undergone cardiac catheterisation
and have found links between markers of insulin resistance and atheromatous disease.
Tsuchihashi et al, looking at 95 non-diabetic subjects with abnormal coronary
angiography, showed that 24% had insulin resistance by their criteria (serum insulin
>= 60.4 IU/L 120mins after 75g oral glucose load). Levels of insulin resistance
showed a close linear relationship to the stenosis score, suggesting that the degree of
insulin resistance is correlated to the severity of the atheromatous disease (50).
Takezako et al looked at a group of 66 subjects with abnormal coronary angiograms
and divided them into 3 tertiles according to their Gensini Score of coronary artery
disease severity. They found that patients in the highest tertile were more insulin
resistant (51). Shinozaki et al showed that patients with angiographically documented
coronary artery disease were significantly more insulin resistant than their counter¬
parts with no coronary artery disease. Severity of atheromatous disease was correlated
well with insulin resistance (52).
These data suggests that insulin resistance in itself is a risk factor for coronary
atheroma. This is independent of other factors within the insulin resistance syndrome
as no differences among subgroups examined for lipids, hypertension and uric acid
were found (50;51;53) The level of insulin resistance is related to the severity of
atheromatous disease observed in these studies.
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Non-invasive Ultrasound Data
In addition to data from coronary angiograms, there are several studies, which have
looked at non-invasive ultrasound data of the common or internal carotid artery.
Investigators have measured intima-medial thickness, which is a guide to the degree
of atheroma in a vessel. The Insulin Resistance Atherosclerosis Study (IRAS)
investigators showed that the minimal model index of insulin resistance was
positively correlated with carotid intima-medial thickness (IMT) in both Hispanics
and non-Hispanic whites, but not in the Black population. The association is stronger
in the internal carotid rather than the common carotid artery (54). They demonstrated
approximately a 30pm decrease in IMT with every 1MU increase in insulin
sensitivity in the white Hispanic and non-Hispanic populations. The effect was
attenuated by approximately 20% when corrected for other cardiovascular risk factors
but remained independently significant.
Shinozaki et al, looked at a population with normal coronaries angiographically (a
mixture of patients with vasospastic angina and controls) with similar findings.
Common carotid intima-media thickness was correlated to insulin resistance in both
groups (55). More recent data from Hedblad et al showed that although an insulin
resistant population had a greater IMT, the association between IMT and insulin
resistance was obliterated when other features of the insulin resistance syndrome were
taken into account (most notably hypertension) (56). These studies tend to suggest
that insulin resistance is a risk factor for atheroma in general, although independently
this effect is likely to be modest at best.
These invasive angiographic and non-invasive ultrasound data are summarised in
table 1.3 overleaf.
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Table 1.3: Cross-sectional studies
looking at markers of IR and general
and coronary atheroma
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tertile in terms of fasting insulin,







38 lean non-diabetic Steady state
subjects with varying plasma












































Those with coronary disease more
IR than those without both in
normal and impaired glucose
tolerance groups.
Coronary atherosclerosis score
correlated to 2 hour insulin area
in subjects with normal glucose
tolerance (r=0.78, p<0.05)
Negative assoc between IMT and
insulin sensitivity in Hispanics
and white population (not in
Black population).
30pm decrease in internal carotid
IMT with every 1MU increase in
insulin sensitivity (attenuated by
20% when adjusted for
cardiovascular risk factors)
Correlation seen between IMT
and 2 hour insulin area in patients
with vasospastic angina (r=0.45,
p<0.01)
Significant difference in IMT
between IR and non-IR subjects.
(0.78mm Vs 0.754mm - p<0.001)
HOMA-IR index assoc with 1MT
but not after correction for other
features of IR syndrome
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Insulin Resistance and Coronary Heart Disease
The preceding section has highlighted the association between insulin resistance and
atheromatous disease. This link does translate into clinical outcomes, as shown in
many prospective trials looking at insulin resistant subjects free from coronary heart
disease (CHD) at baseline and following them up for cardiac events. Because of the
large numbers involved in these large epidemiological studies, indices of insulin
resistance based on fasting serum insulin were most commonly used. Several studies
indicate that insulin resistant subjects are more likely to develop coronary heart
disease than their insulin-sensitive counter-parts. There has been some controversy as
to whether the increased risk applies to men, or women or both groups. These studies
have been summarised in table 1.4
The AR1C investigators looked at a 13446 strong cohort of patients with and without
diabetes, and followed them up for 4-7 years. They were able to demonstrate that non-
diabetic women in the highest quintile of insulin concentration at baseline (thus
highest levels of insulin resistance) had a multi-variable adjusted relative risk of the
development of coronary heart disease of 2.82, compared to women in the lowest
quintile of insulin concentration. However, this same trend was not observed in the
non-diabetic men within this cohort. As expected, subjects with diabetes, and
therefore the highest levels of insulin resistance, showed a significant trend for the
development of coronary heart disease. A relative risk of 3.45 and 2.52 was conferred
upon women and men respectively, compared with non-diabetic subjects irrespective
of their levels of insulin resistance (57).
In contrast to the ARIC investigators, The Quebec Cardiovascular Society Study did
find a prospective correlation between baseline insulin-resistance and CHD in men.
Depres et al collected data from 2103 men and followed them for 5 years. The 91
non-diabetic men in this group who developed ischaemic heart disease (IHD) were
matched with 105 controls within this cohort and were found to have baseline insulin
concentrations 18% higher than them. When corrected for other cardiovascular risks,
the link between insulin levels and IHD remained significant, with an odds ratio of 1.6
31
(1.1-2.3) for the risk of IHD with every 1 standard deviation increase in insulin level
within this population (58).
The 914 year data from the Helsinki Policeman Study also supported the concept that
plasma insulin levels correlate well with CHD risk. 982 men were followed up
prospectively and higher insulin levels were associated, independently of other risk
factors, with the development of CHD (59). There was a non-linear relationship, with
the subjects in the top decile of insulin having the highest rate of development of
CHD events. In the 22 year follow-up data, the measure of insulin resistance used
was area under the curve (AUC) of insulin response. This was grouped together with
other factors relating to the insulin resistance syndrome including AUC glucose,
triglyceride levels, mean blood pressure and body mass index (BMI), to produce a
single insulin resistance factor. This single factor, although not strictly a measure of
insulin resistance on its own, was correlated positively with risk of both CHD (age-
adjusted hazard ratio 1.28) and stroke (age-adjusted hazard ratio 1.64) (60).
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Table 1.4: summary of prospective trials looking at insulin
resistance and coronary heart disease




IR related IR related




13446 men + women
(diabetic included) 4-7 years Fasting insulin
Middle-aged population
yes
Diabetics had greater incidence CHD
Linear trend for quintiles of fasting
insulin and CHD incidence
Quebec City (58) 2103 men
(45-76 yrs)
5 years Fasting insulin yes
Fasting insulin levels 18% higher in
men who develop CHD compared
with matched controls who did not,







9 V2 years yes
to 2 hour OGTT
Highest incidence CHD in top decile








Age-adjusted hazard ratio for IRF*
was l .28 with regard to CHD risk and
l .64 with regard to stroke risk
Paris Prospective
Study (61) 7164 men
(43-54 yrs)
11.5 years Fasting insulin yes
Fasting plasma insulin positively
associated with risk of CHD death
independently of other risk factors
Paris Prospective
Study (62) 6903 men
(43-54 yrs)
2 hour post-glucose
15 years insulin level yes
Fasting insulin not an independent
predictor of CHD death. 2 hr post-
glucose load insulin levels in highest




647 men + women
Middle-aged
population
Those in highest quintile of insulin










[RF** predicted CHD events in men





11.5 years Random insulin levels yes
Men in highest decile of insulin levels
had 2-fold increase in CHD events
compared with men in other 9 deciles
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1052 40 year-old men
Significant independent association
Danish Study (66) and women 17 years Fasting insulin yes yes
between fasting insulin and CHD
Australian Study
(67)




load insulin levels yes
Highest and lowest quintiles of insulin




5 years Fasting insulin
Men in top 20% of insulin levels had
increased CHD in univariate analysis.
Significance was lost when corrected




all 40 years-old 12 years
Post-glucose insulin
levels
11 men developed CHD and their






63 months Fasting insulin yes
Fasting insulin level independently
associated with risk of CHD event. 2
hr post-glucose insulin level lost
significance when corrected for other
risk factors
HOMA-IR 1R conferred a relative risk of 2.18 on
4748 men and women
Malmo Study (71) 6 years (IR defined as > 75 yes yes coronary events and 1.62 on all-cause
(non-diabetic)
percentile) mortality even when adjusted for
other cardiovascular risk factors.
494 non-diabetic Hyper-insulinaemia was the only
Fasting insulin
TRACE Study patients with significant variable after multi-variate
6-8 years (IR defined as in upper yes yes
Group (72) confirmed myocardial analysis in predicting death (Relative
quartile)
infarction risk 1.54, p=0.04)
*
IR factor comprised BMI, Subscapular skinfold thickness, AUC Insulin, AUC glucose, mean blood pressure, triglycerides, maximal
0(2) uptake
** IR factor reflected BMI, waist:hip ratio, triglycerides, fasting insulin and fasting glucose levels
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The Paris Prospective Study 10 year follow-up data showed a similar trend with
fasting plasma insulin being positively associated with annual risk of CHD mortality,
after analysis by a multivariate Cox model, amongst the 7164 men studied after 10
years (61). However, in the 15-year follow-up of the non-diabetic subjects in this
group, fasting insulin level ceased to be a significant independent predictor for CHD
mortality, but a 2 hour post-glucose insulin levels above the 5th quintile was a
significant independent predictor of CHD death (62).
Several other long-term prospective trials, looking at insulin resistance and CHD risk,
have been published and a summary of these is shown in table 3. As can be seen,
there is much more data from studies in male subjects. 2 out of the 5 studies looking
at women did not find an association between insulin resistance and CHD. Out of all
the studies looking at men only 3 out of 14 did not find a similar association.
The large number of prospective studies provide good evidence, and it is now
generally accepted that insulin-resistance is at least a modest independent
cardiovascular risk factor, with much more evidence existing for men than women.
Insulin resistance rarely occurs on its own, without other cardiovascular risk factors,
but even correcting for these, insulin resistance has its place as an independent risk
factor. A feature that emerged in most of the prospective data is the non-linear
relationship between levels of insulin resistance and CHD risk. Several studies
divided individuals into quartiles, quintiles and even deciles of insulin resistance.
Such studies showed a significant CHD risk in those in the top division compared to
all others, or sometimes just those in the bottom division (57;59;62;63;65;67;71;72).
This statistical trend suggests that only individuals with the highest levels of insulin
resistance are at increased risk of CHD.
A Meta-analysis by Ruige et al in 1997 looked at the available evidence linking
insulin levels (as a marker of insulin resistance) with rates of cardiovascular event
including myocardial infarction, coronary death and ECG abnormalities. A total of 17
studies were identified by authors with 12 providing enough data to calculate an
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overall relative risk. The authors found that hyperinsulinaemia is a weak independent
predictor of cardiovascular disease with a relative risk of 1.18 conferred on those at
the 75th percentile of serum insulin compared to those at the 25th percentile (95%
confidence intervals 1.08-1.29) (11). However, given the non-linear association
already alluded to, this relative risk is likely to be greater in magnitude if the 90th or
95th percentile is compared to the 25th percentile.
It has been known for some time that the cardiovascular risk of individuals with type
2 diabetes is higher than those without. The primary risk of a diabetic individual is
equivalent to the risk of a non-diabetic individual who has had a coronary event (73).
Patients with type 2 diabetes are by definition all insulin resistant, but the level of
resistance varies to some degree. Inchiostro et al showed that even amongst
individuals with diabetes, indices of insulin resistance are significantly higher in those
patients with IHD compared to those without. Total cholesterol and hypertension were
also important correlates. However, after correction for age and duration of diabetes,
only insulin sensitivity was correlated to the age of onset of IHD (74). This would
tend to suggest that insulin resistance, itself, is the important factor in conferring
cardiovascular risk in patients with type 2 diabetes.
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CHAPTER 2
Cardiac Syndrome X -
Myocardial Ischaemia, Insulin Resistance and Vascular Dysfunction
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Myocardial Ischaemia and Vasomotor Dysfunction
Traditionally, myocardial ischaemia is synonymous with coronary artery disease in
which lumen-narrowing atheromatous plaques limit myocardial blood flow during
times of increased metabolic demand, resulting in myocardial lactate production
which is thought to be responsible for the production of angina pectoris. However,
coronary angiography, which identifies diseased coronary arteries, is an anatomical
investigation. Although it provides information about the coronary circulation, which
if diseased, may correlate with the potential for ischaemia, is does not provide any
direct physiological measure of myocardial ischaemia.
Vasomotor Abnormalities in Atheromatous Coronaries
There is evidence that myocardial ischaemia can at least in part be due to functional
abnormalities of vascular function. During times of increased myocardial metabolic
demand, coronary artery and microvascular vasodilation takes place by means of
physiological autoregulation. This process can be impaired leading to a potential
mechanism of impaired vasodilator reserve and thus ischaemia. These abnormal
vasomotor responses are known to occur in atheromatous coronary arteries. For
example Gage et al have demonstrated that patients with coronary artery disease
develop coronary vasoconstriction in stenotic coronary arteries in response to bicycle
exercise during coronary angiography. This is in contrast to normal coronary arteries
(in the same group of patients) in which vasodilation was observed during exercise.
Administration of intra-coronary nitrate abolished this vasocontrictive effect and
resulted in less evidence of ischaemia (1). This suggests that it is likely to be a
clinically important phenomenon. Similar finding were presented by Gordon et al
again showing that diseased coronary segments are much more likely to undergo
vasoconstriction in response to bicycle exercise during angiography. Paradoxically,
intra-coronary acetyl choline, which produced vasodilation in the smooth coronary
segments, caused vasoconstriction in a significant number of atheromatous segments
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(2). The same sort of paradoxical vasocontrictive response has been reported in
patients undergoing angiography with atrial-pacing induced tachycardia. Those
patients with smooth coronaries tended towards coronary vasodilation with a resultant
increase in coronary blood flow as assessed by Doppler velocity recordings. This
contrasts with the response in those with significant coronary atheromatous disease, in
whom vasoconstriction and a reduction in coronary blood flow was recorded (3).
These three studies all point to the same phenomenon in which atheromatous coronary
artery segments tend to paradoxically vasoconstrict or at least fail to vasodilate
normally during times of increased myocardial demand. This leads to a demonstrable
reduction in coronary blood flow and results in exacerbation of ischaemia in a
myocardial substrate already experiencing higher metabolic demand, as illustrated
below in figure 2.1
Fig 2.1















To prove this abnormal vasomotor response has an independent role in myocardial
ischaemia is difficult, because of co-existing flow-limiting atheromatous plaques
which provide a physical obstruction and are thus capable of producing ischaemia
alone.
However, there exists a group of patients with smooth unobstructed coronary arteries
in whom there is evidence of myocardial ischaemia as manifest clinically by typical
symptoms and the results of non-invasive investigations. This is the patient group
termed as "Syndrome X" and at least a subset of these patients will have
microvascular angina, which is thought to be due to dysfunctional vasomotor
responses in the coronary microcirculation. This group of patients afford us the
opportunity to study functional vessel abnormalities without the influence of co¬
existing obstructive atheromatous disease.
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Cardiac Syndrome X and Microvascular Angina
There is a well recognised clinical syndrome in which inducible myocardial ischaemia
can manifest despite angiographically undiseased coronary arteries. Indeed, it has
been reported that up to 30% of diagnostic angiograms identify normal coronary
arteries in some series. The term "Cardiac Syndrome X" was first used by Kemp in
1973 to describe this patient group (4). The 3 essential clinical features that Kemp
described were:
• Typical anginal-type chest pain
• Unobstructed coronary arteries angiographically
• Positive exercise stress test
In the absence of clinical or angiographic evidence of coronary artery spasm.
In practice, patients who fulfil these criteria form a large heterogeneous group
encompassing those with genuine myocardial ischaemia as well as a probably larger
proportion with non-cardiac pain. The reason for this mixtures lies with the lack of an
accessible 'gold-standard' method for the demonstration of ischaemia. The stress
ECG is the most widely used tool for assessment of myocardial ischaemia in clinical
practice. However, the exercise tolerance test (ETT) is a relatively non-specific test
(as well as relatively insensitive) which requires subjective interpretation even in
patients with coronary disease (5). These features mean that is not uncommon for
patients with non-cardiac pain to have 'false positive' ETTs and therefore be included




A significant number of diagnostic coronary angiograms demonstrate no significant
obstructive disease - up to 30% in some reports. The series of 99 patients followed-up
by Kaski et al is fairly typical of those reported in the literature although their patients
fulfilling the 'Syndrome X' criteria had a particularly stringent emphasis on there
being at least 1mm of ST depression on an exercise ECG. They found a female bias
of almost 80% with almost 62% of the 78 women being postmenopausal. 35 of these
women (45%) had a hysterectomy performed an average of 8 years before the onset of
chest pain (6).This female dominance has been reported in previous studies (7;8). In
series in which this female dominance was not apparent the ECG criteria tended not to
be applied so rigorously (9-11) and potentially therefore many more subjects with
non-cardiac pain were included.
Hypertension
Although patients with hypertension were excluded from the series by Kaski et al,
only 11 out of 138 (8%) patients initially screened had a blood pressure
>140/90mmHg. Eight of the 99 patients followed-up developed hypertension. Rates
of hypertension therefore seem comparable with the general population. Most patients
had a normal resting ECG (81%) with the remainder having T wave abnormalities or
minor ST segment changes and ambulatory ECG monitoring demonstrated transient
ST-segment depression in 64 patient (65%). About half of these episodes were
associated with symptoms of chest pain and 78% with a preceding tachycardia (6).
Metabolic perturbances especially high indices of insulin resistance have been




Coronary angiography yields information about the coronary artery lumen and can
exclude obstructive disease but this does not necessarily rule out 'sub-angiographic'
atheroma. It has been shown that a significant proportion of patients deemed to have
'normal coronaries' in fact have non-lumen encroaching plaques. This proportion was
as high as almost half in a group of 44 patients with previously normal coronaries and
chest pain (12). A smaller series reported by Cox et al demonstrated sub-angiographic
atheroma in 6 out 9 patients with normal coronaries undergoing repeat angiography
because of unstable anginal symptoms (13). Wiedemann et all looked at 30 patients
with cardiac 'Syndrome X' and showed that although all subjects had smooth
unobstructed coronary arteries angiographically, only 12 (40%) had coronary arteries
that were deemed normal by intra-vascular ultrasound. The remainder of the patients
had either sub-angiographic atheromatous plaques (10 patients) or intimal thickening
(8 patients) (14).
Prognosis
It had long been thought that having angiographically normal coronary arteries
confers a benign long-term prognosis. For example, Kaski et al reported no cardiac
deaths or myocardial infarcts in a cohort of 99 such patients with an average seven
year follow-up (6). Kemp et al looked at 3136 patients with normal coronary
angiograms and found a 7 year survival rate of 96%. This did drop to 92% for the 915
patients with mild, non-obstructive disease (15). However, more recent data suggest
that these patients do have adverse cardiovascular outcomes especially if risk factors
are present (16).
Foussas et al reported one sudden cardiac death and two more non-fatal myocardial
infarctions in a series of 160 patients (1.9% event rate) with normal coronary arteries,
during a mean follow-up period of 2.5 years (9). Similarly Isner et al reported 3
sudden deaths and 4 non-fatal myocardial infarcts a group of 121 patients (5.8% event
rate) with the same characteristics after mean follow-up of over 4 years (7). Lichtlen
et al followed 176 patients with normal coronaries for an average of over 12 years and
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found similar rates of adverse events with 14 myocardial infarcts and 2 cardiac deaths
(9.1% event rate) (17). Most recently, data published by the Women's Ischaemia
Syndrome Evaluation (WISE) group showed that women with normal coronary
arteries but non-invasive evidence of myocardial ischaemia (on magnetic resonance
spectroscopy) had rates of cardiovascular events similar to that of a control group
with known coronary disease, and a much increased rate compared to a group with
angiographicaliy normal coronaries and no non-invasive evidence of ischaemia.
However, there were no reported myocardial infarctions or deaths within all women
with normal coronary arteries over the 3 year follow-up and this similarity in
cardiovascular events between the group with coronary disease and the group with
normal coronaries but non-invasive ischaemia, appears to have been driven by
recurrent admission with angina and repeat coronary angiography (18).
A very small proportion of patients with angiographically normal coronary arteries go
on to develop significant coronary atheromatous disease (19). Cox et al looked at 138
consecutive patients with normal or almost normal coronaries. 24 patients during a
five year follow-up required repeat angiography for ongoing symptoms. Only 2 of
these had progressed to significant levels of coronary obstruction and these were
patients with minimal disease at baseline with multiple cardiac risk factors and left
bundle branch block on ECG (20).
Overall it appears that the cardiac risk of patients with normal coronaries is not as
benign as once thought. Several series have shown that some of these patients do go
on to have adverse cardiovascular events and in any case, the ongoing burden of
symptoms requiring hospital admissions and even repeat coronary angiography is
very significant. Those that do go on to have an adverse event tend to do so several
years after their angiogram and often have a higher cardiac risk-factor profile (17).
However, the concept of myocardial infarction in normal coronaries does exist (21)
presumably due to non-lumen encroaching unstable plaque rupture or vasomotor
disturbance.
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A subgroup of patients with 'Syndrome X' has a less good prognosis. Orpherk et al
followed such a group and found that of the 19 in whom left ventricular function was
reassessed after four years, those with constant or rate-dependent left bundle branch
block (LBBB) demonstrated a significant deterioration in left ventricular ejection
fraction (22). Some have suggested that these patients with LBBB are in fact a
subgroup with early cardiomyopathy.
Summary
Although 'Syndrome X' encompasses a heterogeneous group, there is at least a subset
who have myocardial ischaemia and the evidence for this is discussed below. Many
series demonstrate a female dominance and a postmenopausal presentation. Most
have a normal resting ECG and a significant proportion may have sub-angiographic
coronary atheroma. Insulin resistance has been reported by several groups with the
evidence presented later in this chapter. The long-term prognosis in these patients is
generally not as good as previously thought and some patients do have adverse events.
Studies looking at long-term prognosis are summarised in table 2.1 below. These
patients tend to have a higher cardiac risk profile and therefore this may be related to
sub-angiographic coronary atheroma.
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Table 2.1: Summary of studies looking at prognosis in patients with normal coronary arteries
Study Population Characteristics Mean/median
follow-up
Outcomes
Kaski et al (6) 99 patients
80% female
mean age 48.5 yrs
angina and normal CA 7 yrs
Minimum of 1mm ST-segment
depression on ETT






angina and normal CA
40% women with +ve ETT
10% men with +ve ETT
2.5 yrs 1 cardiac death
2 non-fatal MI
59% ongoing symptoms
41% on anti-anginal Rx
Isner et al (7) 121 patients
60% women
mean age 49 yrs
angina and normal CA 4.3 yrs 3 with sudden death
4 non-fatal MI
80% ongoing symptoms
64% on anti-anginal Rx
Lichtlen et al 176 patients
(17) 35% women
mean age 48.3 yrs
angina and normal CA
18% with +ve ETT
12.4 yrs 2 cardiac deaths
12 non-fatal Ml
81% ongoing symptoms
Kempetal(15) 3136 patients angina and normal CA 7 yrs 96% survival with normal CA
915 patients angina with mild coronary
disease
92% survival with mild
coronary disease
Opherk et al 19 patients with
(22) repeat ECHO
angina and normal CA 4 yrs Significant LV dysfunction
developed in patients with
constant and rate-induced




74 women angina and normal CA
14 women with abnormal NMR
spect
60 women with normal NMR
spect
3 yrs no deaths/Ml
36% and 21 % rate of re-
admission for angina and repeat
angiography, respectively for
women with abnormal NMR
spect compared to 7% and 3%





mean age 51.1 yrs




NMR Spect - nuclear magnetic resonance spectroscopy
LBBB - left bundle branch block
CA - coronary arteries
2 cardiac deaths
5 non-fatal MI
5 admissions for angina
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Evidence for Ischaemia in Cardiac 'Syndrome X'
Although some clinicians remain sceptical about the very existence of myocardial
ischaemia with normal coronary arteries, several groups have demonstrated metabolic
and indirect markers of myocardial ischaemia in subgroups of those labelled with
'Syndrome X'.
Myocardial Lactate Production
Resting myocardial substrate metabolism varies according to being in either the
fasting or fed state. The fasting state tends to favour myocardial lipid uptake (mostly
free fatty-acids) whereas post-prandially carbohydrate uptake dominates. During
periods of increased myocardial workload, glucose uptake is enhanced with little
change in free fatty-acid (FFA) uptake. Carbohydrate oxidation is therefore
responsible for producing the majority of the 'extra' energy required under these
circumstances. In an ischaemic myocardium, inadequate blood supply (and therefore
oxygen) leads to the pyruvate formed during glycolysis not being oxidised, but
converted to lactate by the action of lactate dehydrogenase (24). Reduced lactate
extraction or even lactate production, reflected by coronary sinus lactate concentration
> arterial lactate concentration, has therefore been used as a marker of myocardial
ischaemia by several groups. It is perhaps the closest measure to a 'gold standard' for
physiological demonstration of ischaemia that is available. Unfortunately, although it
may be a fairly specific marker for ischaemia is it not particularly sensitive and will
therefore miss a proportion of those with myocardial ischaemia (25).
Several groups have demonstrated lactate production during pacing experiments
designed to mimic exertion, with an increased chronotropic response. This in itself is
evidence for ischaemia in a subgroup of patients with 'Syndrome X'. Correlating ST-
segment depression with lactate production in an individual patient is difficult.
Boudoulas et al showed that as a group, those subjects with normal coronaries who
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exhibited significant (2mm) ST segment depression to incremental pacing all
produced lactate during pacing, although some lactate-producers did not show any
ST-segment shift (26). This may be due to the relative lack of sensitivity of ST-
segment change as a marker for ischaemia.
Mammohansingh et al added to these observations with 17 subjects all of whom had
ST-segment depression during an exercise test despite normal coronaries. They found
that although 14 out of 17 experienced chest pain during atrial pacing, only 4
exhibited abnormal lactate metabolism (27). The threshold used for ST segment
depression in the Mammohansingh series was lower than that used by Boudoulas.
This resulting reduced specificity may account for the patients labelled as having a
positive ETT who did not exhibit lactate production.
Greenberg et al demonstrated lactate production in a subgroup of patients with normal
coronaries (10 out of 17). This group showed much smaller increases in myocardial
blood flow (as measured by thermodilution) compared to those in whom lactate was
not seen. They also showed an unchanged coronary vascular resistance in contrast to
non-lactate producers who exhibited a 32% decrease in vascular resistance at high
rates of atrial pacing (28). Similar findings by Opherk et al demonstrated lactate
production in their selected patients with normal coronaries and positive stress test in
contrast to their control group, during atrial pacing. A much blunted increase in
coronary blood flow (as measured by the argon concentration method) and increase in
calculated coronary resistance were also observed in this patient group compared to
control subjects (29).
The metabolic evidence for ischaemia in patients with normal coronaries is by no
means undisputed. There is at least one report showing no evidence in these patients
of abnormal lactate responses despite reduced coronary flow reserve. This was in
contrast to those with documented coronary disease in whom abnormal lactate
extraction was seen. Only three out of 14 patients with normal coronaries showed a
significant drop in coronary sinus pH and coronary sinus oxygen saturation consistent
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with ischaemia despite most experiencing anginal pain during pacing and 11 out of 14
developing ischaemic ECG changes (30). Such reports result in ongoing controversy
about the ischaemic basis for some patients with 'Syndrome X', but this whole field is
likely to remain in dispute until a more sensitive marker for ischaemia is found to act
as a 'gold-standard'. The studies looking at lactate as a marker for ischaemia in
'Syndrome X' are summarised in table 2.2 overleaf.
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Table 2.2: Summary of the studies looking at myocardial lactate metabolism as a
marker for ischaemia in patients with angina and normal coronary arteries
Study Patient
Numbers
Characteristics Stress Groups Compared Results
POSITIVE STUDIES




Angina and normal CA






chest pain during pacing
(Group A) and 28 did not
(Group B)
Group A had significantly lower





mean age 41 yrs






20 non-producers (Group B)
Significantly more ST-depression in
Group A. Every patient with ST
depression >2mm was in Group A.
Every patient with <1 mm ST
depression was in Group B.
Mammohans ingh
et al 1975 (27)
17 patients
94% women






14 patients -chest pain
3 patients - no chest pain
4 patients (all in chest pain group)
exhibited abnormal lactate






mean age 52 yrs
Angina and normal CA Atrial pacing at
160 bpm
10 lactate producers (Group
A)
17 non-producers (Group B)
Group A had attenuated increases in
coronary blood flow during pacing
compared to Group B (14% Vs 75%)
and no reduction in coronary
vascular resistance compared to a
fall of 32% in Group B
Egashira et al 9 patients Angina and normal CA Intracoronary 9 patients
1993 (32) 38% women with electrically positive papaverine lOmg 6 healthy controls
mean age 59 yrs stress test
All 9 patients had net myocardial
lactate production associated with
chest pain (67%) and ECG changes
(67%). No lactate production/chest
pain or ECG changes in controls.
Mohri et al 1998 36 patients Angina and no more Incremental dose
(33) 58% women than mild coronary intracoronary
median age 63 yrs disease (no stenosis ACh
>50%)
17 lactate producers (Group
A)
19 non-producers (Group B)
All Group A patients had either large
artery coronary spasm or
'microvascular spasm' (defined by
ECG changes or chest pain without
large epicardial spasm)
Cannon III et al 22 patients Angina Coronary sinus
1983(34) 23% women 73% normal CA pacing at 150
mean age 51 yrs 27% with non- bpm
obstructive coronary
disease
9 patients - chest pain
(Group A)
13 patients - no chest pain
(Group B)
Group A patients had lower lactate
extraction compared to Group B
(25.0 Vs 45.6 mmol/L.min). Group
A patients also had lesser increases
in cardiac vein flow and lesser
decrease in coronary resistance
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mean age 51 yrs




22 patients - chest pain
(Group A)
8 patients - no chest pain
(Group B)
Group A patients had lower lactate
extraction compared to Group B
(30.5 Vs 69.7 mM.ml/min). Group A
patients also had lower cardiac vein
flow and higher coronary resistance











24 patients - chest pain
(Group A)
26 patients - no chest pain
(Group B)
Group A patients had lower lactate
extraction compared to Group B
(28.3 Vs 51.3 mM.ml/min). Group A
patients also had lesser increases in










mean age 47.4 yrs +ve ETT
8 subjects
5 controls (with atypical pain
and -ve stress test)
Significant myocardial lactate
production in the 8 subjects but not
the control group. (Increase in
lactate 3.9 Vs 0.8 pmol/lOOg.min)
NEGATIVE STUDIES











10 controls (with atypical
pain and -ve stress test)
No differences in lactate metabolism
seen between rest and pacing in
either group






No differences in lactate extraction
between the 2 groups at any time
and no evidence of lactate
production in SX group.










9 controls (with coronary
disease)
No difference in lactate metabolism
for the subjects. In contrast, the
controls with coronary disease
showed marked reduction in lactate
extraction.
ETT - exercise tolerance test
CA - coronary angiogram
ACh - acetyl choline
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Coronary Sinus Oxygen Saturation
Crake et al (39) have looked at coronary sinus oxygen saturation as a potential marker
of ischaemia. In the normal subject, increasing myocardial demand in response to
incremental atrial pacing, leads to a transient fall in coronary sinus oxygen saturation
with a return to normal fairly quickly as autoregulation adjusts blood flow. This return
to normal is not seen in those with coronary disease, with oxygen saturation
remaining low and falling further in response to an increasing heart-rate. This is due
to physical obstruction limiting flow in the coronary arteries preventing
autoregulation.
A similar fall in coronary sinus oxygen saturation has been observed in some patients
with 'Syndrome X' in response to incremental pacing (2 out of 10) but no clear
correlation with ECG changes was observed (39).
Markers ofReperfusion Oxidative Stress
One study involving small numbers (9 patients with 'Syndrome X') has shown an
association between ST-segment depression and reperfusion markers of ischaemia.
Buffon et al measured levels of lipid hydroperoxides and conjugated dienes, as
indicators of ischaemia-reperfusion oxidative stress, in the great cardiac vein before
and after incremental pacing. All 9 patients showed ST-segment depression and
compared with controls had marked increases in the levels of these two markers in the
great cardiac vein (40). These markers have been demonstrated in reperfusion during
angioplasty in patients with obstructive coronary disease (41), and with their detection
in this group with 'Syndrome X' suggests a genuine ischaemic basis for the ECG
changes and symptoms in these 9 patients. No other group has looked at these
markers to date, and it does seem from their data that these molecules are more
sensitive than myocardial lactate for the detection of ischaemia.
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Ultrastructure
An even more invasive means for the identification of myocardial ischaemia is
endomyocardial biopsy and direct examination of cells for ischaemic damage. Such a
technique was employed by Opherk et al with biopsy specimens obtained from 18
patients with 'Syndrome X'. Although specimens looked normal under light
microscopy, the majority showed abnormalities under electron microscope
examination. This mostly took the form of varying degrees of mitochondrial swelling
consistent with subtle ischaemic damage. There were no observed abnormalities of
the microvascular vessels (29). However, data from Suzuki et al do suggest some
changes around small vessels. This group looked at 21 patients with normal coronary
arteries despite ST-segment changes during atrial pacing, and demonstrated sclerosis
of arterioles and peri-vascular fibrosis in 95% of subjects. Furthermore, electron
microscopy showed proliferated and deformed smooth muscle cells in the media layer
of the small vessel walls, suggesting that there may be structural changes in the
vasculture of 'Syndrome X' patients (42). Of note, however, neither the study by
Orpherk nor the study by Suzuki compared these findings to either normal controls or
subjects with coronary disease and known ischaemia.
Summary
From the above data, it is clear that there is certainly a subgroup of patients satisfying
the criteria for Syndrome X', who exhibit some metabolic evidence of ischaemia.
Even amongst the invasive investigations, no one good sensitive test for detection of
physiological ischaemia has emerged and a lot of the controversy that exists in this
field is a result of the lack of a good 'gold-standard' for the demonstration of
myocardial ischaemia. Although myocardial lactate production perhaps remains the
closest test we have to a 'gold standard', even this lacks sensitivity. Furthermore,
there is some correlation but no practically useful relationship to ECG changes.
The data available show that we are unable to conclude that all patients with ECG
changes will exhibit lactate production as a more direct marker of ischaemia (27).




It is generally believed that the majority of patients fulfilling criteria for 'Syndrome
X' experience non-cardiac pain. There are many other aetiologies which can closely
mimic ischaemic-type pain even fulfilling many of Heberden's original
characteristics. The task of distinguishing between these patients remains challenging.
Oesophageal Pain
The oesophagus has always been a major culprit implicated by its ability to reproduce
typical anginal-type symptoms. Both acid reflux and oesophageal spasm can induce
ischaemic-type chest pain. The effect of GTN in relaxing smooth muscle and
relieving the pain of oesophageal spasm further confounds the difficulty. When
groups of patients with 'Syndrome X' are examined specifically for oesophageal
abnormalities, a significant proportion of them will prove positive. Furthermore,
simple acid-suppression therapy is often effective in relieving symptoms (43).
To complicate things further, Chauhan et al have described a so-called 'cardio-
oesophageal' reflex. They demonstrated that instillation of acid into the oesophagus of
35 'Syndrome X' patients resulted in reduced blood flow in the left anterior
descending coronary artery by Doppler measurements, compared to 24 heart
transplant patients (with effective cardiac denervation). Although the mechanism is
unclear the authors hypothesised that this effect depends upon a neural reflex which is
abolished when the heart is denervated (44). Other upper gastro-intestinal pathology
can frequently masquerade as anginal-type chest pain and vice-versa. It is as well-
recognised phenomenon that some patients presenting with myocardial infarction
have symptoms that are compatible with indigestion.
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Musculoskeletal Pain
Musculoskeletal chest pain is another important aetiology which must be considered
for patients presenting with 'Syndrome X'. A series of 40 such patients (some with
minor coronary disease) were examined for rheumatological disorders including
fibromyalgia and costochondritis. Such a diagnosis was able to be confirmed
clinically in 40% of this group compared to a control group with coronary disease in
which only one out of 40 was diagnosed (45).
Psychological Abnormalities
Some take the view that patients with 'Syndrome X' have psychological
abnormalities. Wielgosz et al reported that patients with normal coronaries who had
ongoing pain, had high hypochondriasis scores and suggested that they has an
exaggerated preoccupation with personal health (46) which could lead to an increased
tendency to complain about symptoms. This was not examined in relation to a control
population and it is conceivable that these patients' anxieties relate to ongoing
symptoms, ongoing contact with the medical profession, and invasive investigations.
It would be useful to compare hypochondriasis scores with a population with
documented coronary disease. Others suggest have suggested that the incidence of
pain disorder is higher in this population (47).
Increased Pain Perception
Some have reported alterations in the way this patient group perceive pain suggesting
an increased cardiac sensitivity. 29 out of 36 patients (81%) with normal coronaries
and chest pain, reported pain during intra-coronary contrast injection and right heart
catheter manipulation and pacing, as opposed to only 2 out of 33 with coronary
disease. This was despite a higher cutaneous pain threshold in the 'Syndrome X'
group and led the authors to hypothesise about neurally-mediated abnormal pain
responses to cardiac stimuli in this group (48). Similarly, abnormal cardiac pain
perception was hypothesised by another group who were able to reproduce chest pain
in 34 out of 36 patients with 'Syndrome X' (94%) with intra-cardiac catheter
manipulation compared to much lower figures in patients with mitral valve and
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coronary disease (49) . However, these studies were not blinded and are extremely
susceptible to reporter bias which may lead to distorted results.
The neural link to pain perception has been examined by functional brain imaging
using positron emission tomography (PET), as a measure of regional neuronal activity
during chest pain. Patients with 'Syndrome X' tended to have a distinct pattern of
brain activity as compared with other groups including those with obstructive
coronary disease and silent ischaemia (50). This has led some to conclude that chest
pain in this group of patients has a significant 'supra-tentorial' element. In keeping
with a neurally-mediated component to pain, Cunningham et al, in a small pilot study,
demonstrated positive effects on exercise capacity and quality-of-life indicators in
patients with 'Syndrome X' after a three month training course on transcendental
meditation (51).
It is therefore evident that while some direct metabolic markers for ischaemia are
present in a subgroup of patients with 'Syndrome X', a large proportion also have
evidence of non-cardiac organic pathology and others may have psychological
components to their pain. Others, still, may contribute to their symptoms by virtue of
neurally-mediated abnormalities of increased cardiac sensitivity and or pain
perception. This group of patients is a heterogeneous group and discrimination
between those with presumed myocardial ischaemia and those without remains very
difficult in everyday clinical practice. The studies quoted above, showing potential
non-cardiac mechanisms for pain in these patients, all used varying entry
requirements and as a result recruited significant numbers of patients with non-cardiac
pain. Very few of these trials stuck to rigid criteria including definite demonstration of
ischaemia either invasively or non-invasively.
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Clinical Modalities for Discrimination between Microvascular Angina and Non-
Cardiac Pain
It is neither practical nor ethical to look for markers of ischaemia or signs of coronary
vasomotor dysfunction discussed previously in this chapter, when assessing patients
with chest pain and normal coronary arteries. It is important to attempt to distinguish
between patients with myocardial ischaemia and those with non-cardiac pain. This
distinction avoids the incorrect label of 'angina' as this can have significant
implications. In fact, many non-cardiac causes are symptomatically treatable and
these patients ought not to be exposed unnecessarily to anti-anginals and their
potential side-effects, whenever possible.
This requires demonstration of myocardial ischaemia usually by a non-invasive
indirect marker. However, this is often a very difficult clinical situation because
established indirect, non-invasive markers of ischaemia can prove unhelpful.
Exercise Tolerance Test
This is a well-established test in the investigation of coronary disease but its relative
lack of sensitivity means that inevitably some patients with coronary disease fail to
exhibit ECG changes during exercise (5). Because of this, it is conceivable that some
patients with chest pain and normal coronary arteries will have myocardial ischaemia,
despite a negative ETT. This is borne out by some of the pacing/lactate experiments
of the 1970s and 1980s, in which it became clear that some of these 'false positive'
ETTs occur in patients with more invasive metabolic evidence of ischaemia such as
myocardial lactate production (26;27). The data from Boudoulas suggest that, if we
assume abnormal lactate metabolism is relatively specific for ischaemia, clear ECG
changes on ETT were also specific (all patients with >2mm ST-segment depression
produced lactate). However, ST-segment depression lacked sensitivity (especially
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with a 2mm threshold), as there were patients who produced lactate (with therefore a
presumably ischaemic basis) who did not fulfil ECG criteria. Having a 2mm
threshold, although reducing sensitivity does increase specificity for myocardial
ischaemia.
Therefore, it seems reasonable to assume that any subject with angiographically
normal coronary arteries and clear 2mm of ST-segment depression on exercise ECG
is likely to have an ischaemic basis for their symptoms presumably due to
microvascular angina. The group with borderline or no ECG changes remains difficult
to characterise due to the relative lack of sensitivity of this test. There will be some
subjects with microvascular angina and many with non-cardiac pain. This contrasts
with the data presented by Mammohansingh in which they used a threshold of ST-
segment depression of 0.5mm. Lowering this threshold markedly reduces the
specificity of the test with only 4 out of 17 patients in this group exhibiting abnormal
lactate responses (27), however, this may be in part due to the lack of sensitivity of
lactate production for myocardial ischaemia.
Similar problems were identified by Epstein et al. This group labelled patients with
microvascular angina by means of impaired coronary vasodilator reserve (using
techniques involving great cardiac vein flow under basal and stimulated conditions)
and exercise-induced left ventricular dysfunction. Out of 115 patients categorised in
this way, only 10% had ischaemic ST-segment changes on exercise - a sensitivity of
less than 9% if one presumes that all 115 of these patients have microvascular angina
(52). Cannon et al have also reported figures of over 75% for patients with
microvascular angina (characterised by the same abnormal coronary vasodilator
responses) having normal exercise ECGs (53). The difficulty in distinguishing those
patients with myocardial ischaemia and "false positive" exercise tests due to
presumed microvascular disease, from the 'true' false positive exercise tests (patients
with non-cardiac pain) was highlighted by this group - if ECG criteria alone are used
for the diagnosis of microvascular angina, a large proportion of patients will be
missed and many more may be wrongly diagnosed.
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Stress ECHO/Markers ofLVDysfunction
In patients with coronary disease, regional wall motion abnormalities as detected by
stress Echo are generally seen earlier than ECG changes and therefore tend to be a
more sensitive marker for ischaemia. Zouridakis et al looked at dobutamine-stress
echocardiography in patients with chest pain and normal coronaries. 33 subjects all
with a positive stress test and normal coronary arteries were studied. Although chest
pain was reproduced in 14 patients (42%) and ST-segment changes in 15 patients
(45%), none of the subjects studied developed significant regional wall motion
abnormalities (54).
However, another study using adenosine as pharmacological stress in 9 patients with
microvascular angina showed global impairment of diastolic function as manifest by
technetium blood-pool imaging and trans-mitral Doppler flow changes. There was no
change in systolic function in these patients (55). This diastolic dysfunction was
postulated to be a possible manifestation of global subendocardial ischaemia.
LV function as assessed by resting and exercise-gated blood-pool scintigraphy by
Cannon et al (in a group thought to have microvascular angina as manifest by normal
coronaries and abnormal coronary vasodilator reserve) demonstrated reduced LV
ejection fraction in comparison to those without abnormalities in vasodilator reserve
and normal subjects (56).
The lack of discrete wall motion abnormality on Echo suggests that either these
patients do not develop myocardial ischaemia during the stress Echo or that stress
Echo is not sufficiently sensitive to identify ischaemia. This may be true, but
obstructive coronary disease is usually focal with segmental variation and this makes
it more amenable to producing a regional wall motion abnormality as the affected
segments are easily visualised against the normally-moving (non-ischaemic)
segments. The functional vasomotor defect in microvascular angina may be a more
generalised process and this lack of localisation may make techniques such as stress
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Echo less useful. It has been postulated that global diastolic dysfunction and subtle
global reductions in LV ejection fraction as assessed by radionuclide blood-pool
techniques in the studies above may be markers of ischaemia.
Thallium Scanning
Radionuclide perfusion scintigraphy is a useful modality in demonstrating relative
myocardial perfusion defects and their degree of reversibility in the investigation and
assessment of coronary disease. Sensitivity of this technique in predicting coronary
disease has been reported as high as 91% (57). Its role in identifying patients with
myocardial ischaemia amongst those labelled with 'Syndrome X' is less clear.
Although perfusion scintigraphy is a relatively sensitive test, it can lack specificity for
coronary disease with defects described in patients with left bundle branch block (58),
permanent pacemakers (59) and even sarcoidosis (60).
A series of 100 patients with normal coronary arteries and typical angina was looked
at by Tweddel et al. They reported varying degrees of abnormal thallium perfusion in
98% of these patients. Out of this group, only 30 had ECG changes on exercise.
Although those with ECG changes tended towards bigger defects, no clear correlation
between perfusion defects and a positive ETT was observed (61). In a more selected
group (with definite ECG changes) thallium scintigraphy identified reversible defects
in 18 out of 33 patients (55%) with normal coronaries and chest pain. The presence of
systemic hypertension did not influence the rate of thallium defects (54).
Looking at Tweddel's relatively unselected group, it is difficult to believe that 98% of
these patients had myocardial ischaemia as a cause of their symptoms and without a
control group it is difficult to estimate the prevalence of perfusion defects in the
asymptomatic normal population. Nonetheless, it is likely that a significant proportion
of this group did have myocardial ischaemia, but it would seem that the relative lack
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of specificity of thallium scintigraphy leads to over-representation of abnormal
myocardial perfusion in this group of patients.
An Italian group looked a more stringently defined group with 35 patients exhibiting
normal coronaries but all with a positive stress test. They included 32 patients with
atypical pain and a negative ETT as a control group. Only 3 patients from the control
group showed any perfusion defects (4 segments in total) during stress with
reversibility in 1 patient and reverse distribution (segments hypo-perfused at rest
compared to stress) in another 4 patients. This compares to 27 patients from the
patient group in whom stress defects were apparent (40 in total). Over half of the
affected segments showed reversibility and there was a much higher prevalence of
reverse distribution with 33 segments affected (62).
Earlier studies in the late 1970s and 1980s conflicted as to the prevalence of perfusion
defects. Meller et al found only 4 patients (15%) with perfusion defects with only 2
being reversible out of a series of 27 patients selected on the basis of a normal
coronary angiogram and chest pain. ECG changes were seen in 10 out of these 27
patients. Looking at the 4 patients with abnormal perfusion imaging, 50% of them had
a positive ETT only (63). In a similar population of 41 patients, 11 abnormal thallium
perfusion scans (27%) were found by Berger et al. 3 of these 11 with abnormal
perfusion imaging had a positive ETT. A significant number of those with perfusion
defects had other cardiac abnormalities including bundle branch block and mitral
valve prolapse which may contribute to the abnormal imaging (64). Kaul et al found
significantly different perfusion in a group of 44 patients with normal and minimally-
diseased coronaries and chest pain (9 of whom had positive ETTs) as compared with
45 normal subjects free from chest pain. ECG changes on exercise did not correlate
with the presence of abnormal thallium imaging (65).
Thallium scintigraphy appears non-specific and even in an unselected group there will
tend to be a very high proportion of 'Syndrome X' subjects with perfusion defects
(61). In a more selected group in terms of ECG changes, there does appear to be a
difference in the frequency of perfusion defects as compared to a 'control' group with
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atypical pain. The difficulty in this area is that perfusion defects have never been
correlated with more definite invasive measures of ischaemia such as abnormal
myocardial lactate metabolism. Due to this, studies have compared perfusion defects
on thallium scintigraphy to ECG changes, which are known to be lacking in
sensitivity and specificity. Very little in the way of definite conclusions as to the
usefulness of thallium scanning in the 'Syndrome X' population, can therefore be
drawn from the available data. It does appear that a positive result will not aid
discrimination between cardiac and non-cardiac pain and there are no strong data to
suggest that a negative result seems to be more predictive of a non-cardiac aetiology.
Magnetic Resonance Imaging/Nuclear SPECT
Magnetic resonance imaging (MRI) is a high resolution technique that potentially
may be more sensitive to ischaemic changes within the myocardium. It has been
shown using MRI quantitative perfusion index, that patients with 'Syndrome X' fail
to augment myocardial blood flow in the sub-endocardial region but augment
normally epicardially in response to intravenous adenosine. Normal augmentation was
seen both in the endocardium and epicardium in normal control subjects. These data
do suggest that these patients fail to vasodilate normally in the subendocardium (66).
A relatively new technique uses phosphorous-31 nuclear magnetic resonance (31P-
NMR) spectroscopy to identify metabolic evidence of ischaemia non-invasively.
Phosphocreatine is required within the myocardium for normal function, and it has
been demonstrated in animals, that a loss of phosphocreatine (PC) and a decrease in
the phosphocreatine : adenosine triphosphate (ATP) ratio occurs during myocardial
ischaemia (67). 31P-NMR spectroscopy has been employed in patients with coronary
disease successfully to demonstrate transient ischaemia during hand-grip exercise
(68).
Recently its use in evaluating ischaemia in women with chest pain and normal
coronaries has been studied. In a group of 35 women, it was found that 20% showed
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non-invasive evidence of ischaemia by this method, when compared with age-
matched controls (69). This group were not selected for by ECG changes, and it is
therefore likely that the relatively low proportion of women showing evidence of
ischaemia reflects the likelihood of non-cardiac pain in the majority of these patients.
Further work correlating ECG changes with this method would be useful.
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Aetiology and Pathogenesis of Microvascular Angina
Although still a contentious issue, most now believe that myocardial ischaemia is at
least a contributing factor for a subgroup of patients with normal coronaries and
typical anginal pain. How they are further characterised in terms of a positive ETT,
reversible scintigraphy defect, direct or indirect metabolic markers, stress LV
dysfunction or even abnormal coronary vasodilator reserve, remains even more
controversial because no one test has reliable levels of sensitivity or specificity and
therefore a 'gold-standard' is lacking. The approach adopted by most clinicians is one
of excluding other obvious causes of chest pain and employing other available
investigations such as the ETT and perfusion scintigraphy in combination perhaps
more than once.
Vasomotor Dysfunction
Accepting an ischaemic basis after the demonstration of normal epicardial arteries in
the absence of inducible spasm, would seem to implicate the coronary
microcirculation by default as responsible for limitations on coronary blood flow.
This is the view taken by most investigators (31) and some believe that it is
specifically the arterioles at the level of approximately 200 micron diameter that are
dysfunctional. In fact some groups have used inclusion criteria based on abnormal
coronary flow reserve when conducting studies to further characterise these patients
with presumed microvascular angina (53).
The hypothesis adopted by most investigators in this field is that angina in these
patients is due to vasomotor abnormalities which lead to a reduced vasodilator
capacity. Therefore, a relative shortage of blood flow during times of increased
metabolic demand leads to ischaemia. Such abnormal vascular responses have been
documented in the coronary vascular bed by several groups.
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Impaired Coronary Vasodilator Response
Abnormalities of myocardial lactate metabolism as a marker for ischaemia have been
documented by several groups in conjunction with an impaired coronary blood flow
response to vasodilator stimuli, in patients with 'Syndrome X'. These studies include
those by Greenberg et al (using thermodilution with incremental pacing) (28), Opherk
et al (measured by the argon method in response to dipyridamole infusion) (29) and
Cannon et al (by great cardiac vein catheterisation and atrial pacing) (36).
This group of studies tends to suggest that this impaired vasodilator response is
metabolically significant in the production of ischaemia. Moreover, there some
evidence to suggest that this impaired coronary vasodilator response is associated
with sub-angiographic coronary disease. Wiedemann et al undertook a study of
coronary vasodilation as assessed by ultrasound diameter measurements of coronary
arteries during exercise. All patients studied fulfilled the diagnostic criteria for cardiac
'Syndrome X' but only those patients with sub-angiographic atheroma and intimal
thickening, as assessed by intra-vascular ultrasound, demonstrated coronary
vasoconstrictor responses to exercise. Those with normal coronary intra-vascular
ultrasound studies showed normal vasodilator responses during exercise. (14). This
tends to suggest that the abnormal vasomotor responses are associated with evidence
of sub-angiographic coronary disease.
Several groups have looked at coronary vascular flow reserve in subjects with
'Syndrome X' and some important studies are summarised below in table 2.3.
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Table 2.3: summary of studies looking at coronary vascular dysfunction in 'Syndrome X'






10 pts with chest
pain and normal
CA - with definite
ischaemia
(produced lactate)
17 pts with chest









10 pts with definite ischaemia had
attenuated increases in CBF (14%
Vs 75%) and no reduction in
CVR (Vs 32% reduction) with
pacing compared to those without
definite ischaemia











and CBF using i.e.
Doppler
no significant increase in CBF
after i.e. ACh Vs significant
increase in control group. Similar
increase in CBF seen with i.e.









12 pts with SX but
without sub-
angiographic disease








Group B had coronary
vasodilation on exercise Vs
Group A in whom
vasoconstriction of approx 17.5%
was seen with exercise






17 pts had no significant increase
in CBF (>100% resting value) or
a vasocontrictive response. Only
6 pts had significant increase in
CBF with ACh. 6 pts did not
show significant increase in CBF
with ACh or dipyridamole.




and. normal CA and -
veETT









in CBF in SX group compared to
controls (103% Vs 345% at top




Chauhan et al 1997 35 pts with SX
(72)
17 controls with i.e. ACh (also given
atypical chest pain i.e. papaverine /







in CBF in SX group compared to
controls (124% Vs 361% at top
dose i.e. ACh). Reduced
vasodilation to papaverine also
(185% Vs 411%).
Sanderson et al 12 pts with SX Compared against Cold pressor test CA diameter on Reduced coronary vasodilation in
(73) 'normal' response of angiography. CBF all 12 pts (7/12 had
vasodilation 12% +/- and CVR also vasoconstriction or no change at
1%. calculated all) - compared to normal
response. Also a fall in CBF and
an increase in CVR
Sutsch et al 1992 12 patients with 6 controls 0.5mg/kg iv CFR by coronary Increased improvement in
(74) 'microvascular dipyridamole sinus coronary flow in control group





CVR - coronary vascular resistance
CBF - coronary blood flow
SX - syndrome X (angina, normal coronary arteries and positive exercise tolerance test)
ETT - exercise tolerance test
CA - coronary artery
CFR - coronary flow reserve
IVUS - intravascular ultrasound
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Abnormalities to pharmacological vasodilators have been reported in the coronary
circulation in some patients with 'Syndrome X'. These are summarised in Table 3
also. All studies demonstrate abnormalities of endothelium-dependent vasodilation
(mostly in response to intracoronary ACh) (32;70-72). However, results are mixed
when it comes to characterising the endothelium-independent response. At least 2
groups have shown no difference in the vasodilatory response to intracoronary nitrate
in patients with 'Syndrome X' compared to controls (32;70) but others have shown
impairment in this response with endothelium-independent vasodilators, suggesting
that vascular dysfunction may extend to the smooth muscle and not just involve the
endothelium (71 ;72;74).
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A Generalised Systemic Vasodepressor Response?
There is now much data supporting vascular dysfunction in patients with 'Syndrome
X' outwith the coronary vascular bed. Some of these data are summarised in table 4
below. Patients with chest pain and normal coronary arteries, already characterised as
having attenuated coronary vasodilation in response to rapid atrial pacing and
dipyridamole infusion, also exhibited reduced peripheral vasodilator responses to
forearm ischaemia, as measured by plethysmography, compared to normal controls.
Furthermore, there was a significant correlation between the attenuation in coronary
and peripheral vasodilation (75).
Several groups have documented attenuated brachial artery 'endothelium-dependant'
vasodilator responses (reactive hyperaemia post ischaemia) in patients with
'Syndrome X' as compared with normal subjects. These responses were measured by
high-resolution ultrasound and no differences in response to sublingual nitrate was
noted between the groups (76-78).
One group looking at flow-mediated dilatation post forearm ischaemia using laser
Doppler fluximetry did not find any differences between subjects with 'Syndrome X'
and controls despite significant differences in their coronary vasodilator reserve, as
assessed by coronary sinus thermodilution techniques (74). They did note, however,
that resting peripheral flux (degree of vasodilation) was lower in the subjects with
microvascular angina, although the hyperaemic response did not differ. This
difference in resting vascular tone itself may have some significance.
The endothelium-independent response in this group of studies was looked at using
sublingual nitrate in most cases. No significant difference in the nitrate response was
seen in these studies leading the authors to conclude that there was no difference in
the endothelium-independent response (76-78), in contrast to some of the coronary
studies above.
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Table 4: Summary of trials looking at peripheral vascular function in patients with 'Syndrome X'.
Study Patient group Control group Technique used Results
Bellamy et al 1998
(77)
Botkeretal 1996 (76)
Lekakis et al 1998 (78)
Sax et al 1987(75)
Sutsch et al 1992 (74)
7 pts with SX
57% women
mean age 58 yrs
21 pts with SX
76% women
mean age 56 yrs
11 women with SX
(Group A)
mean age 60.2 yrs
Kidawa et al 2003 (79) 52 pts with SX
65% women
mean age 45 yrs
16 pts with SX
56% women





















FMD of the brachial artery in
response to hand ischaemia
(reactive hyperaemia) and
calculation of blood flow
using Doppler
FMD of brachial artery in
response to forearm ischaemia
(reactive hyperaemia) and
calculation of blood flow
using Doppler.
FMD of brachial artery in
response to forearm ischaemia
(reactive hyperaemia)
FMD of brachial artery in
response to forearm ischaemia
(reactive hyperaemia) and
measurement of Doppler
pulsed wave velocity between
carotid and femoral arteries
(measure of arterial stiffness)
Forearm plethysmography in
response to forearm ischaemia
(reactive hyperaemia)
laser Doppler fluximetry in
response to forearm ischaemia
Negative FMD in SX group
compared to controls (-0.78% Vs
+3.46%) p<0.05. No difference in
response to sublingual GTN. No
difference in blood flow changes.
No difference in FMD but
significantly higher increase in
blood flow in controls compared
with SX group (452% Vs 342%) -
p<0.05. No difference in dilatation
in response to sublingual GTN.
Significantly increased FMD in
healthy controls (7.9%) compared
to SX group (1.9%) - p<0.05.
Attenuation in FMD in SX group
similar to that seen in group with
coronary disease (3.3%) - p=ns. No
significant difference in dilatation
after sublingual GTN in all 3
groups.
Smaller increase in FMD of SX
group compared to controls (6.6 Vs
11.1%)- p<0.001. Similar
vasodilation seen after sublingual
GTN. Increased pulsed wave
velocity values in SX group (9.3 Vs
8.2 m/s) - p<0.001
Reduced peak forearm flow in SX
group compared to controls (39.9
Vs 31.7 ml/min.dl) - 21 %
reduction - p<0.05
Similar hyperaemic response in
both groups but resting cutaneous
Doppler flux greater in patient
group
SX - 'Syndrome X' - angina with normal coronary arteries and a positive stress test (>1mm ST-segment depression)
FMD - flow-mediated dilatation
GTN - glyceryl trinitrate
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A Correlation Between the Coronary and Peripheral Vascular Dysfunction?
If such a correlation exists, then assessment of patients with 'Syndrome X' would
potentially be revolutionalised. Although measuring coronary flow reserve invasively
has been used extensively as a research tool, it is unlikely to ever enter routine clinical
practice. If peripheral vascular dysfunction could be used as a surrogate marker for
vascular dysfunction in the coronary bed, it would perhaps be possible to categorise
patients with cardiac 'Syndrome X' as having microvascular angina or non-cardiac
pain on the basis of their peripheral vasomotor response.
However, whether or not there is any correlation between the vasomotor responses in
the peripheral and coronary vascular beds remains inconclusive. Bottcher et al used
high-resolution ultrasound to measure brachial artery vasodilation and brachial artery
blood flow, post transient forearm ischaemia (reactive hyperaemia). They also looked
at myocardial blood flow increase in response to dipyridamole infusion using positron
emission tomography (PET). They found no correlations between the peripheral and
coronary response in subjects with coronary disease, cardiac 'Syndrome X' nor
healthy controls (80). A similar negative result was reported by Sutsch et al, albeit in
small numbers, calculating coronary flow reserve by thermodilution (in response to
dipyridamole) and comparing to cutaneous laser Doppler fluximetry (74).
However, earlier data from Anderson et al did show some association between the
behaviour of coronary and brachial arteries in patients undergoing coronary
angiography. This group looked at the coronary vasomotor response to intra-coronary
acetylcholine (ACh) and found that those subjects whom exhibited a coronary
vasoconstrictor response, had attenuated brachial artery flow-mediated vasodilatation,
as assessed by high resolution brachial artery ultrasound (4.8% Vs 10.5%), compared
to those who had a coronary vasodilation response to ACh (81). More support for a
correlation between coronary and peripheral vascular responses comes from data by
Sax et al. They calculated minimum peripheral resistance after forearm ischaemia
using plethysmography as well as minimum coronary resistance, calculated by
coronary blood flow determined by thermodilution in response to intravenous
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dipyridamole. Their results showed a robust correlation between peripheral minimum
resistance and coronary minimum resistance (r=0.74) for 13 subjects in whom data
were collected (75).
Much of the controversy in this area may relate to the type of vasculture studied.
Anderson et al compared brachial artery function to coronary artery function and as
these 2 arteries are in the same order of diameter, a significant correlation was found.
However, Bottcher's group was looking at coronary flow in response to dipyridamole
by PET, and this is much more likely to be influenced by smaller vessels at the
arteriole level. It may, therefore, be no surprise that this was not correlated to brachial
artery function in any group of patient studied. When using a technique such as PET
or coronary thermodilution to make measurements of coronary flow, a peripheral
measurement such as plethysmography or laser Doppler may be better suited to make
direct comparisons, as was used in the Sax data (75).
Although the weight of evidence does appear to support a generalised systemic
vasomotor disturbance in patients with presumed microvascular angina, there still
remains some conflicting evidence. Whether such a systemic disorder is present in
'Syndrome X' has important implications in future testing as discussed earlier - if
these vasomotor disturbances are able to characterise patients with microvascular
angina, it may be possible to use them in order to aid diagnosis in patients with
'Syndrome X' and help discriminate between those with non-cardiac pain. Invasive
tests of coronary vascular function are inappropriate as a clinical tool but systemic
cutaneous measures of vascular function are much less invasive and may be adapted
for clinical use in the future.
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Insulin Resistance
Several groups have demonstrated insulin resistance in patients with 'Syndrome X'
relative to control subjects. The hyperinsulinaemic euglycaemic clamp is the gold
standard technique for measuring insulin resistance and has been employed by several
investigators. Several groups have demonstrated reduced whole body glucose uptake
in patients with 'Syndrome X' compared to controls suggesting relative insulin
resistance (82-84).
Other groups have demonstrated insulin resistance using surrogate markers including
the insulin response to an intravenous glucose tolerance test in postmenopausal
women (85), the minimal model assessment of insulin resistance in non-obese men
and a mixed sex group (86;87), and post-glucose load insulin levels in a mixed sex
group (88-90). In addition, several groups have not only demonstrated higher indices
of insulin resistance but also significant dyslipidaemia in patients with 'Syndrome X'
as compared to healthy control subjects (85-87;90).
However, there are reports in the literature of no association between 'Syndrome X'
and insulin resistance, one using the clamp technique (91) and the other making use of
the minimal model of assessment of insulin resistance (92). The balance of evidence,
however, does favour this link to insulin resistance and the negative findings of the 2
studies may reflect the heterogeneity within this group of patients or patient selection.
These findings are summarised in table 5 below.
The implications of insulin resistance within this group are important because of the
potential link to endothelial dysfunction. A close correlation between insulin
sensitivity and endothelial nitric oxide (NO) synthesis is seen in healthy volunteers
(93). A similar correlation is seen between insulin sensitivity and vasoconstrictor
responses to N-monomethyl-L-arginine (an NO inhibitor), in a mixed group of men
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Table 5: Summary of trials looking at indices of insulin resistance in patients with 'Syndrome X'




Botker et al 1993 (82) 11 patients with >lmm ST-
segment depression or
LBBB development on
ETT and normal CA
64% women
mean age 55 yrs
9 controls with non-
cardiac pain
75% women




GDR 2.9 mg/kg per min in patient
group Vs 4.9 mg/kg per min in
control group (41% reduction in SX
group (p<0.01)
Vestergaard et al 1995
(84)
9 patients with >lmm ST-
segment depression on
ETT and normal CA
78% women
mean age 48 yrs
7 controls with chest
pain but normal ETT
and normal CA
86% women




Significantly higher fasting insulin
in SX group compared to controls
(43 Vs 22 pmol/L. (p<0.02)
GDR 13.4 in SX group compared to
18.2 mg/kg per min in control
group - 26% reduction in SX group
(p<0.02)
Botker et al 1997 (83) 8 patients with chest pain,
>lmm ST-segment
depression on ETT and
normal CA
75% women








Whole body glucose uptake lower
in SX group (15.6) than in controls
(23.1 pmol/kg/min) - 32%
reduction (p<0.05)
Godsland et al 1995
(85)
20 postmenopausal women
with chest pain, >lmm ST-
segment depression on
ETT and normal CA





mean age 57 yrs
Minimal model by IV
glucose tolerance test
Incremental insulin area 27.6 in SX
group compared to 19.8 pmol/L per
min in control group (39% increase)
Si 1.89 in SX group Vs 3.09 ml/pU
per min in control group (39%
reduction) - p<0.05
Swan et al 1994 (86) 14 non-obese men with
chest pain, >lmm ST-
segment depression on
ETT and normal CA
mean age 46.6 yrs
38 healthy male
volunteers
mean age 47.3 yrs
Minimal model by IV
glucose tolerance test
Fasting insulin 30% higher in men
with SX (p<0.05)
Si 31% lower in men with SX
(p<0.05)
Botker etal 1997 (87) 20 patients with chest pain,
>lmm ST-segment
depression on ETT and
normal CA
75% women
mean age 56 yrs
2 age/gender matched




Minimal model by IV
glucose tolerance test
Si lower in SX group (0.86 - 41%
lower) and vasospastic angina
group (0.96 - 35% lower) than in
control group (1.47 min"'/per
pmol/L x 10") p<0.05
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17 patients with positive
ETT and normal CA
53% women
mean age 49.3 yrs
21 patients with SX
(angina, +ve stress test and
normal CA)
62% women
mean age 53.9 yrs
2 age/gender matched













AUC insulin significantly higher in
SX patients (6.89 - 58%) and CAD
patients (9.63 - 121%) compared to
controls (4.35 min.pmol/ml x 103)
p<0.05
Median insulin values higher in SX
group at 60 mins (59% higher -
p<0.01) and at 120 mins (112%
higher - p< 0.005)
Dean et al 1991 (90) 11 patients with chest pain,
>lmm ST-segment
depression on ETT and
normal CA
36% women







AUC insulin significantly higher in
SX patients (10.44) than controls
(6.71 min.mU/L x 103) — 56%
increase (p<0.01)
Fuh et al 1993 (94) 20 patients with angina,
+ve ETT and normal CA
60% women
mean age 56 yrs
20 healthy volunteers
60% women




Patients with SX relatively
hyperinsulinaemic and
hyperglycaemic during oral glucose




Quionones et al 1996
(91)
10 patients with chest pain,
>lmm ST-segment
depression on ETT and
normal CA
90% women




mean age 53 yrs
Hyperinsulinaemic,
euglycaemic clamp
(1.0 mU/kg per min)
Almost identical GDR in patients
and controls (25.9 Vs 27.2 pmol/kg
per min
Cavallo Perin et al
2000 (92)
10 patients with chest pain,
>2mm ST-segment
depression on ETT and
normal CA
50% women




mean age 46 yrs
Minimal model by IV
glucose tolerance test
No differences in Si between the
SX and control groups (5.76 Vs
7.54 min.pmol/ml x 10~4), nor any
difference for AUC (insulin)
CA - Coronary arteries Si - insulin sensitivity
SX - Syndrome X ETT - exercise tolerance test
AUC - Area under the curve GDR - glucose disposal rate
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Including patients with diabetes, hypertension and healthy volunteers (95).
Furthermore, the vasodilating effect of insulin is amplified in the presence of
metabolically active glucose in healthy subjects (96). This observation, together with
findings that insulin augments blood flow in lean subjects points towards a key role
for insulin and glucose metabolism in maintaining vasodilator tone in vessels via NO.
This is supported by the observation that exogenous insulin therapy appears to
improve endothelial function in patients with type 2 diabetes (97).
The post-receptor signalling mediators involved in the production of NO in response
to insulin in many ways parallels those which regulate insulin-mediated glucose
transport via GLUT4 translocation. It appears that activation of phosphatidylinositol
3-kinase (PI3-kinase) is crucial in this signalling pathway. Cells expressing an
inhibitory mutant of PI3-kinase have a much attenuated NO response to insulin.
Downstream mediators of this effect may include protein kinase B (PKB) also known
as Akt (98), possibly by phosphorylating endothelial nitric oxide synthase (e-nos) (99)
- see figure 2. However, other pathways may also be involved and remain to be
characterised.
It is therefore possible that insulin resistance may contribute to the endothelial
dysfunction observed in patients with 'Syndrome X'. Whether it is important in the
pathogenesis of microvascular angina remains to be elucidated. No trials have looked
at insulin-sensitising modalities in relation to 'Syndrome X, and such studies looking
at endothelial function, subjective assessment to symptoms and objective measures of




Schematic outlining insulin receptor and NO
production coupling in endothelium
eNOS
IRS: insulin receptor substrate
PI 3-kinase: phosphatidylinositol 3-kinase
PKB: protein kinase B
eNOS: endothelial nitric oxide synthase
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Serum Markers of Endothelial Dysfunction
Endothelin-1
There is much data in the literature pertaining to abnormalities of Endothelin-1 (ET-1)
in patients with 'Syndrome X'. ET-1 is a potent vasoconstrictor and works in tandem
with nitric oxide in maintaining normal vascular tone (100). Several groups have
demonstrated significantly higher circulating levels of this peptide in this patient
group compared to healthy individuals under resting conditions both in venous and
arterialised blood. Furthermore, there are data showing that the augmentation in ET-1
release to stresses, is higher in the 'Syndrome X' group compared with controls.
These 'stresses' include pacing-induced tachycardia and a glucose load as part of an
oral glucose tolerance test. Much of these data are summarised below in table 6. There
are data showing that ET-1 may be elevated as a response to ischaemia (101), but it
would be difficult to explain the higher basal levels of ET-1 seen in patients with
'Syndrome X' on this basis.
Data from Cox et al suggest that in fact endothelin levels may correlate with the
degree of coronary vascular dysfunction. They showed a robust association between
baseline arterial endothelin-1 levels and the fall in coronary vascular resistance (r2 =
0.44) during fast atrial pacing in 19 patients with angina and angiographically normal
coronary arteries. This relationship was indicative of a smaller fall in coronary
vascular resistance with greater levels of ET-1 at baseline (102). These data suggest
that as well as impaired vasodilation in part due to reduced NO production potentially
as a consequence of insulin resistance, a component of active vasoconstriction (as a
consequence of increased ET-1) may play a role in the abnormal vascular responses
seen in patients with 'Syndrome X'.
It is likely that the increased levels of ET-1 are due to production within the arterial
tree, rather than a reduction in the clearance of ET-1 from the venous circulation. This
is supported by data showing a higher level of ET-1 within the arterial system
compared to the venous system in patients with 'Syndrome X', which is the opposite
of what is seen in healthy controls (103).
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There is some preliminary data suggesting that hyperinsulinaemia in conjunction with
hypertriglyceridaemia may have a causal role in the elevation of endothelin-1 (103).
Insulin resistance is a well-recognised feature of cardiac 'Syndrome X' as discussed
in table 5. However, it is also known that patients with cardiac 'Syndrome X' do share
other features of the Metabolic Syndrome and there are certainly reports of
hypertriglyceridaemia in the cardiac 'Syndrome X' cohorts that have been studied
(87; 104). These metabolic perturbances may have a causal effect in the generation of
abnormally high circulating endothelin-1 levels in cardiac 'Syndrome X'. (85), and
therefore be directly related to vasomotor dysfunction in this way.(86)
One group did not find any significant difference in the venous levels of ET-1
between patients with 'Syndrome X' and healthy controls. They did however show
reduced vasoconstriction peripherally in response to administered ET-1 in patients
with 'Syndrome X'. They suggested that in these patients, over-activity of the
endothelin system had resulted in downregulation of the endothelin receptor in the
peripheral vasculture (105).
All of these data point to an important role for endothelin-1 in modulating the
vascular responsiveness seen in patients with 'Syndrome X'.
Other Serum Markers
As well as abnormalities of Endothelin-1 there are data demonstrating increases in
other serum endothelial cell markers including Vascular Cell Adhesion Molecule (V-
CAM), Intercellular Adhesion Molecule (I-CAM), von Willebrand Factor (vWF) and
Plasminogen Activator Inhibitor-1 (PAI-1) in patients with 'Syndrome X', compared
to healthy controls (106; 107). These findings are not unanimous among the studies in
this area with data from some groups showing no difference in some of these markers
(104). This suggests that as well as endothelial cell dysfunction manifesting as
vasomotor abnormalities in 'Syndrome X', there may be a more generalised problem
affecting endothelial production of mediators.
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Table 6: Summary of trials looking at endothelin levels in patients with 'Syndrome X'.
Study Patient group Control group Technique used Results
Lanza et al 1999 (108)
Kaskietal 1995 (109)
Kaskietal 1998 (110)
Piatti et al 1999 (111)
13 pts with SX
77% women
mean age 52 yrs
40 pts with angina and
normal CA (93% with
+ve ETT)
75% women
mean age 56 yrs
24 pts with SX and




13 pts with SX
62% women












9 pts with metabolic
syndrome (MS)














ET-1 levels higher in SX pts
(arterial and coronary sinus).
Significant increase in ET-1 in
coronary sinus of SX pts only,
after pacing (2.01 Vs 2.22
pg/ml)
ET-1 levels higher in SX group
compared to controls (3.84 Vs
2.88 pg/ml)
Plasma ET-1 higher in SX
group compared to controls (3.7
Vs 2.96 pg/ml) - p=0.02, but no
difference between controls and
pts with negative ETT
Higher ET-1 levels in SX group
compared to controls (8.19 Vs
3.67 pg/mlO - p<0.01. Similar
finding in MS group.
However, nitrite/nitrate levels
higher in MS group compared
to SX/controls
Desideri et al 2000
(104)
Newby et al 1998
(105)
24 pts with SX
88% women
mean age 54 yrs
10 pts with X
73% women













Plasma ET-1 similar at baseline.
Significantly higher ET-1 at
90mins post glucose-load in SX
patients compared to controls
(p<0.010)
no difference in ET-1 levels
between SX and controls
(4.8pg/ml Vs 4.0pg/ml)





From the epidemiological data, 'Syndrome X' appears to be a female dominated
condition when ECG criteria are strictly applied. This has led some to suggest a
hormone-related aetiology, specifically that 'Syndrome X' is an oestrogen-deficient
state. This view is supported by the observation that the majority of women with
'Syndrome X' experienced symptom onset around the time of menopause and that the
incidence of hysterectomy in this patient group has been observed to be four times
that of the general population (112). Furthermore, there have been reports of
improvement in symptoms and ECG changes in women treated with hormone
replacement therapy (HRT) (113; 114).
The vasoactive properties of oestrogens are well-documented. It has been shown,
using plethysmography, that sublingual oestradiol augments peripheral blood flow in
postmenopausal women (115). Furthermore, intra-arterial oestrogen also potentiates
the vasodilator effects of intra-arterial ACh and nitrate acutely, with more pronounced
effects on those with vascular risk factors (116). The effects on the coronary vascular
bed are also favourable with intra-coronary oestradiol reversing the coronary
vasoconstrictor response and potentiating the increase in coronary blood flow after
ACh (ultrasound measurements) in postmenopausal women with coronary atheroma
(117; 118).
With such documented acute improvements in vasodilatation with oestrogens, it can
be seen why oestrogen deficiency has been implicated as a contributor to vascular
dysfunction which may lead to ischaemia as a result of reduced vasodilator capacity.
In fact, the administration of HRT transdermally both acutely and in the short-term (6
weeks) has been shown to improve peripheral vascular function by means of high
resolution brachial artery ultrasound (119). However, this improvement in endothelial
dysfunction is probably common to all postmenopausal women after HRT, not just
those with 'Syndrome X'. Whether it affects pathogenesis in 'Syndrome X' is more
controversial (120) as no improvements in exercise capacity or ECG changes are seen
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in this group after HRT (114). Because of the lack of improvement in objective
measures in these women, it has been suggested that HRT may have primarily a
symptomatic effect, with potential roles attributed to myocardial adenosine
metabolism, a direct hormone-related analgesic effect or a central psychological effect
(114).
The effects of both insulin resistance and oestrogen deficiency may go some way to
explaining the observed common characteristics of those presenting with potential
microvascular angina i.e. a high proportion of obese postmenopausal females.
Although other factors may be at work, a 'double-hit' of oestrogen deficiency and
insulin resistance may explain the observed bias towards these patients.
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Figure 3:
Outline of the potential
contributing factors to the
abnormal vasomotor responses
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Metformin in Insulin Resistance and Syndrome X (MIRS) Study
This double-blind randomised placebo-controlled study was undertaken at Glasgow
Royal Infirmary between February 2000 and February 2002. There were 2 main
components to the trial:
1. To compare women with cardiac 'Syndrome X' to healthy controls in terms of
their metabolic parameters and peripheral microvascular function.
2. In women with cardiac 'Syndrome X' to investigate the changes in metabolic
parameters, microvascular function and exercise test responses following 8
weeks treatment with metformin, compared to placebo.
Given the points discussed in the previous two chapters, the main general hypotheses
were formulated:
• Coronary vascular dysfunction is an aetiological factor in microvascular angina
• Patients with microvascular angina have generalised vasomotor abnormalities in
the systemic as well as coronary vascular beds.
• Resistance to the vascular effects of insulin is at least in part responsible for the
vascular dysfunction observed in microvascular angina.
• Patients with microvascular angina, being relatively insulin-resistant, exhibit other
features of the metabolic syndrome
• Taking a level of 2mm ST depression as threshold for a 'positive' exercise test
will allow improved specificity of the ETT for ischaemia at the expense of
sensitivity.
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• Improving indices of insulin resistance by an insulin sensitising modality will
improve vascular function and reduce symptoms in patients with microvascular
angina.
The specific hypotheses we wanted to test in terms of this trial were:
• Women with 'Syndrome X' have different metabolic characteristics from age-
matched control subjects, namely higher indices of insulin resistance and perhaps
other features of the insulin resistance syndrome.
• If myocardial ischaemia in women with microvascular angina is caused by
vasomotor disturbance leading to impaired vasodilator reserve, women with
'Syndrome X' will have impaired peripheral vascular function compared with
age-matched healthy control subjects.
• Assuming insulin resistance has a causal role for vascular dysfunction, levels of
insulin resistance should be correlated to peripheral endothelium-dependent
microvascular function.
• 8 weeks of metformin therapy should improve levels of insulin sensitivity in
women with microvascular angina and therefore vascular function. There is
evidence that just 8 weeks of metformin is sufficient to demonstrate
metabolic/endocrine effects in patients with polycytic ovaries. (1;2). This may
lead to an improvement in symptoms in these women with 'Syndrome X'.
The study was carried out following the guidelines set out in the 'Declaration of
Helsinki' and ethical approval for the study and its full protocol was obtained from
the appropriate local authority.
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Recruitment of Patients with 'Syndrome X'
The aim of recruitment was to identify women who fulfilled the criteria for
'Syndrome X' and invite them to participate. These were outlined in chapter two but
in essence they consist of:
• Anginal-type chest pain
• Unobstructed epicardial arteries
• ECG changes during exercise typical of myocardial ischaemia
Coronary Angiography
I identified, retrospectively, all patients who underwent diagnostic coronary
angiography in Glasgow Royal Infirmary between the period January 1998 and June
2001, on the basis of their angiogram reports as written by a consultant cardiologist.
These were angiograms performed for the evaluation of ischaemic-sounding chest
pain and all those patients undergoing angiography for other reasons (for example
before valve surgery or to investigate left ventricular dysfunction) were excluded. All
patients had been reviewed prior to angiography by a consultant cardiologist who had
deemed symptoms sufficiently consistent with an ischaemic basis to warrant
diagnostic coronary angiography. Potential recruits to the MIRS Study were those
with smooth unobstructed epicardial arteries. Subjects with minor coronary atheroma
were excluded as were those who had evidence of catheter-induced coronary spasm
during angiography.
The flow chart below shows the numbers involved. As shown a total of 2630 coronary
angiograms were performed during this period of 42 months. 288 of these identified
smooth unobstructed coronary arteries and 226 of these subjects were female (78%).
Surprisingly more women than men underwent diagnostic coronary angiography
during this period (61% Vs 39%). However, the proportion of women in whom
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I aimed to maximise the number with true microvascular angina and therefore genuine
myocardial ischaemia, and keep to a minimum the subjects with non-cardiac pain. In
practice this is very difficult to achieve given the specificity and sensitivity problems
with the exercise tolerance test that have already been alluded to. In the past, studies
which have applied strict electrocardiographic (ECG) criteria (>2mm ST depression)
have proved specific and presumably this kept subjects with non-cardiac pain to a
minimum. This is demonstrated by Boudoulas et al - they recruited in this manner
and found that all of their 14 subjects exhibited abnormal lactate metabolism during
pacing-induced tachycardia : an indicator of myocardial ischaemia (3). Although, this
approach ensures specificity (very few subjects with non-cardiac pain will be
included), it is at the expense of sensitivity (many subjects with genuine myocardial
ischaemia will be excluded). Demonstrating this point, Mammohansingh et al used
much less stringent ECG criteria (>0.5mm ST depression) and found that only 3 of
this 14 recruits exhibited abnormal lactate metabolism under the same circumstances
(4).
In order to achieve a balance between sensitivity and specificity I used a threshold
level of 1mm of planar or down-sloping ST depression during exercise. Inevitably,
this led to a number of patients with non-cardiac pain being recruited but was
sensitive enough to identify sufficient numbers of individuals with myocardial
ischaemia.
Figure 3.2:
Chart showing how the
threshold taken for ST-segment
depression affects specificity
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The casesheets of the 226 women with unobstructed smooth coronary arteries were
pooled and the pre-angiogram exercise tolerance test result was examined. An ETT
had been performed in 154 (68%) of women in whom subsequent angiography was
normal. In 72 (32%) women in whom a treadmill ETT was not performed the vast
majority had pre-angiogram thallium scintigraphy as an alternative non-invasive
investigation, although in a significant number of women a diagnostic angiogram was
sought without any prior non-invasive testing. These women generally had a very
typical history for myocardial ischaemia with a significant risk factor profile.
Women who had thallium scintigraphy alone, without a standard treadmill ETT were
not included. This was primarily to standardise the patients recruited and because
ECG criteria rather than perfusion defects were used later in the study as the outcome
measures.
Only 71 of the 154 women (46%) who underwent treadmill stress testing had a
documented positive ETT. The stress ECG tracings were examined in all cases and a
positive test was one in which at least 1mm of non-upsloping ST segment depression
was seen during exercise. Of the remainder whom underwent treadmill testing 50
women (32%) had an inconclusive test in which either target heart rate was not
achieved or only borderline ECG changes were documented. 33 women (21%) had a
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I chose to limit our patient group to females alone. Most investigators have described
a female bias in 'Syndrome X' and this is reflected in my own experience, with 14%
of women having normal coronaries compared to 6% of men. Numbers recruited
therefore are likely to have a female bias. Hormonal factors may be important in
microvascular angina, as discussed in chapter 2, and oestrogen deficiency in females
has been reported within 'Syndrome X' (5). Although looking at hormonal influences
was not one of the main objectives of the MIRS Study, characterising the study
population in terms of menopausal status, HRT use and gynaecological history was
deemed important, and the inclusion of what would likely have been a relatively small
number of males in the study would confound these issues. In a randomised study of
this size, inclusion of males may have resulted in potential male : female differences
between the active group and the placebo group and the conclusions that I could draw
in comparing the groups would have to take into account these differences. Therefore
it was my intention to recruit females alone so that any differences seen in
microvascular function and clinical parameters could be attributed to more easily to
the observed metabolic changes rather than having to take hormonal/sex issues into
account.
Type 2 Diabetes
Patients with type 2 diabetes were excluded because they are, by definition, insulin
resistant. Therefore any conclusions about sub-clinical insulin resistance in women
with chest pain and normal coronary arteries would be difficult and problems would
be encountered by concomitant therapy such as other insulin-sensitisers and insulin
itself. Impaired vascular function has been demonstrated in subjects with type 2
diabetes by a variety of methods including venous occlusion plethysmography (6),
high resolution brachial artery ultrasound (7) and more recently laser doppler imaging
(8). Therefore any inferences about vascular function in this patient group would be
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confounded by patients with known type 2 diabetes. Patients were, therefore,
excluded on the basis of a pre-existing diagnosis of type 2 diabetes documented in the
casesheet or by means of a fasting plasma glucose <7.0mmol/L (World Health
Organisation criteria) taken during an assessment visit.
Hypertension
Patients with existing uncontrolled hypertension (blood pressure >150/90 mmHg)
were excluded from the study on the basis of data demonstrating abnormal vascular
responses in subjects with hypertension, as assessed by both plethysmography (9) and
high resolution brachial artery ultrasound (10). All subjects underwent transthoracic
echocardiography and were excluded if significant left ventricular hypertrophy was
seen (interventricular septum or posterior wall thickness >12mm). Normotensive
subjects without echocardiographic evidence of left ventricular hypertrophy were
included in the study.
Table 3.1:
Table summarising the




Patients fulfilling criteria for
cardiac 'Syndrome X'
Uncontrolled hypertension or left ventricular
hypertrophy on ECHO (150/90 mmHg)
Significantly abnormal resting ECG (incl LBBB*)
Structurally abnormal heart
Renal impairment (creatinine > 130pmol/L
Hepatic impairment (transaminases > x2 upper limit of
normal)
Previous history of lactic acidosis
* left bundle branch block
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Other Criteria
Patients with a significantly abnormal resting electrocardiogram (including left bundle
branch block) were excluded. This was primarily because ST-segment changes during
exercise were an important piece of data and this is uninterpretable in patients with a
grossly abnormal resting ECG. Those with other potential cardiac contributors to
chest pain were not recruited. This included those with cardiomyopathy and any
degree of valvular heart disease identified either during casesheet inspection or during
the baseline echocardiogram.
Those subjects with abnormal renal or liver function were also excluded. This was
because these patients could potentially be commenced on metformin during the
treatment period. As renal impairment and abnormal liver function are contra¬
indications to metformin therapy, these patients were not included. The definition
used were :
Abnormal renal function - serum creatinine >130mmol/L
Abnormal liver function - AST or ALT > twice the upper limit of normal
Cigarette smokers were not excluded.
109
Final Numbers
On the basis of the recruitment protocol 71 women were identified as suitable
candidates for inclusion in the MIRS Study, having had a positive ETT and
unobstructed coronary arteries on angiography (see figure 4). These 71 women were
examined for exclusion criteria discussed. Only 2 women out of these 71 subjects had
significant hypertension with one subject having documented left ventricular
hypertrophy on echocardiography. 2 subjects had type 2 diabetes. No subjects with
significant valve disease were identified. These 4 subjects were excluded leaving a
total of 67 suitable candidates for participation in the MIRS Study.
All 67 of these women were written to with details of the proposed study and a
stamped-addressed envelope was provided for reply to indicate whether they would
be willing to attend for a screening visit to Glasgow Royal Infirmary. Replies were
obtained from 62 women (93%) and all but 3 were willing to attend for the
assessment visit. At the assessment visit 2 women did not want to participate further
and 1 was excluded due to a high fasting blood glucose. No patients were excluded on
the basis of abnormal liver or renal function. This left 56 women who were entered
into the study protocol which is described in the next section (see figure 4).
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Figure 4:







1 with uncontrolled hypertension
1 with LVH
2 with type 2 diabetes
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As can be seen from the above schematic 59 women, in whom smooth unobstructed
coronary arteries and a positive ETT were recorded, accepted the invitation to attend
Glasgow Royal Infirmary for an assessment visit. The purpose of this was to provide
patients with information about the main trial, to make some baseline measurements,
to take some history and make a final decision about eligibility for the study.
Assessment Visit
Patients were contacted by telephone and arrangements were made for them to attend
the Royal Infirmary. During this visit which lasted approximately 30 minutes several
objectives were accomplished:-
• History of chest pain character and frequency was documented
• Other history including co-morbid conditions, drugs, family history and
gynaecological history
• Blood pressure measurement
• Fasting blood glucose and hormone profile (FSH, LH and oestradiol)
• Blood taken for liver function and urea and electrolytes
• Brief explanation of the study background and objectives
• If willing to take part and eligible - informed consent was obtained at this stage
(consent form in appendix 1)
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• Written information about the study was provided both to the patient and the
general practitioner (copies shown appendix 2)
• Anti-anginals were minimised and discontinued for the majority of patients where
possible (see table 2). As can be seen, the vast majority of vasoactive /
metabolically active drugs were discontinued. Aspirin, cholesterol-lowering
therapy and HRT were not changed.
• Arrangements were made for the first baseline visit in 4 weeks time with
instructions asking patients to fast from midnight the night before
• Patients provided with a chest pain chart to document frequency of anginal pain
The general practitioner was informed of the patient's participation in the study along
with some background information regarding the study objectives. Any treatment
which had been suspended for the purposes of the study was also disclosed. A copy of
this letter was placed in the patient's hospital casesheet.
Table 3.2: Medication at assessment and during study (including 4 week wash-out period)
Drugs Assessment During study
Aspirin 41 (73%) 41 (73%)
Beta-B lockers 16(29%) 1 (2%)
Amlodipine 7 (13%) 1 (2%)
Diltiazem 19 (34%) 3 (5%)
Nitrates 14 (25%) 5 (9%)
Nicorandil 5 (9%) 3 (5%)
Statin 22 (39%) 22 (39%)
HRT 14 (25%) 14 (25%)
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Baseline Investigation Visit
Patients were met at the Cardiology department at 8:30am on the day of the baseline
visit. Fasting overnight was confirmed. After this a series of procedures was
undertaken which took most of the morning to complete. At 1pm subjects were
permitted to have a light lunch prior to the treadmill test. All other investigations were
completed before this. Procedures undertaken during the morning :
• Trans-thoracic echocardiogram
• Assessment of peripheral endothelial function using a laser Doppler imager to
document changes in forearm cutaneous perfusion in response to incremental
doses of topically applied sodium nitroprusside (SNP) and acetyl choline
(ACh). These vasoactive drugs were delivered non-invasively by
iontophoresis. The method is expanded upon in chapter 5.
• Fasting blood tests after the endothelial function tests. These included :





endothelial serum markers (von Willebrand factor (vWF), intracellular cell
adhesion molecule (I-CAM), vascular cell adhesion molecule (V-CAM),
tissue plasminogen activator (tPA), and D-dimer
lactate
• Oral glucose tolerance test with blood collected for measurements of glucose,
insulin and free fatty acids at 60 minutes and 120 minutes.
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Blood pressure recordings x3 with an average recorded
• Character of chest pain assessed with objective questionnaire and frequency of
chest pain and GTN use derived from chest pain chart.
• Treadmill exercise test using the full Bruce Protocol
Chest Pain Assessment
Frequency of chest pain was judged by the chest pain chart which was completed
during the 4 week run-in period prior to the baseline visit. The 'Daily Pain Index' was
calculated by adding up the total number of episodes of chest pain and dividing by the
number of days during which recording was made. A similar 'Daily GTN Index' was
calculated by summing the number of times GTN was used and dividing by the
number of days during which recording was made. The Canadian Cardiac Society
(CCS) index of angina severity was also recorded. This numerical index ranges from
1 (minimal angina at maximal exertion) - 4(severe angina at rest). At the end of this
visit patients were supplied with a further chest pain chart to document symptoms
over the 8 week treatment period and a date for follow-up investigations decided.
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Administration of Metformin/Placebo
Packs were dispensed from pharmacy at Glasgow Royal Infirmary and given to
patients with instructions at the end of day 1 investigations. The study was double-
blinded and packs of metformin and placebo were randomised in using a 2x2 method.
The metformin and identical placebo were supplied by Merck and packaged by
Pharmacy at North Glasgow University NHS Trust. The metformin packs were
numbered 1-60 and patient names recorded against the appropriate number dispensed.
The randomisation codes were held by pharmacy throughout the study and were only
made available after all the data had been collected and analysed.
The dose of metformin used was 500mg once daily for 1 week building up to 500mg
twice daily thereafter for the remainder 7 weeks of treatment. This system was used to
introduce metformin gradually and minimise side-effects. 130 tablets were dispensed
to each patient with written instructions. Patients were warned about potential side
effects especially gastro-intestinal disturbance and reassured that they ought to
persevere with the study medication as the majority of these side-effects are transient.
Patients were, however, asked to record any side-effects.
Patients were asked not to start any new or discontinue any existing therapies during
the study period. Compliance with metformin/placebo was checked at the end of the
study by means of pill-counting. 8 weeks of therapy using this regime ought to require
105 tablets and therefore 25 tablets should remain at the end of the treatment period
assuming all doses were administered and no wastage occurred.
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Follow-up Investigation Visit
The same investigations were performed in the follow-up visit after 8 weeks of
treatment with either placebo or metformin, with the exception of the
echocardiogram. The CCS angina index, the daily chest pain index and the daily
GTN-use index was also calculated for each patient during the 8 week treatment
period as described for the baseline visit. The remainder of the tablets were collected
and the number recorded. The patients were recommenced on their pre-study
medication, although in a significant number of individuals a clinical decision was
made not to do this, because of a lack of any symptomatic difference on and off
treatment.
In all cases the general practitioner was contacted and the results of fasting glucose,
cholesterol, blood pressure measurements and treadmill mill test performance was
conveyed. The treatment regime post-study was also recorded in this letter, along with
any other recommendations regarding blood pressure therapy, cholesterol-lowering
agents and treatment for ongoing chest pain.
At the end of the study patients were discharged from follow-up except in a few cases
where follow-up was required for specific reasons such as blood pressure monitoring
or excessive ongoing symptoms. Routine outpatient follow-up was arranged at the
general cardiology clinic at Glasgow Royal Infirmary for these individuals.
117
Figure 3.5:
Flowchart to illustrate the
MIRS study patient visits
56 subjects enrolled
into MIRS study
31 4 week run-in period off
■I anti-anginals
56 subjects attend for






59 patients attend for
pre-trial assessment
2 subjects declined to
participate, 1 subject
excluded due to type
2 diabetes
gS 8 week trial period with
21 10 drop-outs.
46 subjects attend for
Visit 2
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Drop-outs From Study Protocol
As can be seen from the flow-chart (figure 5), 56 women entered the study protocol,
attended for baseline investigations and were dispensed either metformin or placebo.
As is inevitable with clinical research, not all of these 56 women completed the full
course of treatment for 8 weeks.
There were 10 patients who did not complete the study protocol and therefore did not
have a set of follow-up investigations performed. The reasons for drop-out are varied
and listed below:-
• 2 patients uncontactable through home address, telephone number and G.P.
• 4 patients who stopped treatment because of side-effects, all of which were gastro¬
intestinal
• 1 patient was admitted to hospital with a prolonged episode of chest pain and the
study medication was discontinued by the admitting physician
• 2 stopped the medication themselves because of ongoing non-specific symptoms
during the treatment period which pre-dated the study
• 1 patient stopped the treatment because she felt unwell during an upper respiratory
tract infection and did not restart
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Recruitment of Control Subjects
It was my intention to make comparisons between data collected on women with
'Syndrome X' and normal healthy controls. To this end I aimed to recruit between 20-
30 control subjects. This was done by placing an advertisement in the Glasgow
University newsletter outlining the study and asking for volunteers to come forward.
The inclusion criteria were:
• Women aged between 40-65 years
• Peri-menopausal or postmenopausal
• No history of chest pain or any other cardiac problem
• No history of diabetes or hypertension
By the use of advertisement 25 women came forward and were able to attend
Glasgow Royal Infirmary for the study investigations. The protocol for the control
subjects was much simpler than for the women with 'Syndrome X'.
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Control Subject Study Protocol
Subjects were requested to attend the Royal Infirmary fasting in the morning. In this
state the following procedures were performed:
Brief history was obtained to document personal and family history of heart
disease, diabetes and blood pressure as well as menopause status.
Assessment of peripheral endothelial function using a laser Doppler imager to
document changes in forearm perfusion in response to incremental doses of
topically applied sodium nitroprusside (SNP) and acetyl choline (ACh). These
vasoactive drugs were delivered non-invasively by iontophoresis.
Fasting blood tests after the endothelial function tests were completed.





endothelial serum markers (von Willebrand factor (vWF), intracellular cell
adhesion molecule (I-CAM), vascular cell adhesion molecule (V-CAM),
tissue plasminogen activator (tPA), and D-dimer
lactate
Control subjects did not have an exercise tolerance test.
Methods
Clinical Symptom Parameters
Assessment of chest pain frequency and the effect of metformin was an important
outcome on which the MIRS trial focused. By definition this is a very subjective
measure and therefore, attempts to objectify it as much as possible were put in place.
Making this measurement as objective as possible makes comparisons between
treatment groups feasible.
Patients were supplied with a chart which they used as a 'chest pain diary'. They
recorded on this chart every significant episode of chest pain that they experienced.
They also recorded the number of times they used their glyceryl trinitrate (GTN)
spray. By this means, a 'chest pain index' and a 'GTN index' could be calculated by
dividing the number of episodes recorded by the total number of days of the chart
duration. Therefore a chest pain or GTN index of 1.0 implies an average of one
episode of chest or GTN use per day, during the period examined. A separate chart
was given to each patient for both the 4 week run-in period prior to the baseline visit,
and the 8 week period of the study, prior to visit 2.
Chest pain frequency and severity was also assessed using the Canadian
Cardiovascular Society (CCS) Index. This is an index numbered 0-4 which is applied
as below:
Class 0: Asymptomatic
Class 1: Angina with strenuous Exercise
Class 2: Angina with moderate exertion
Class 3: Angina with mild exertion
- Walking 1 -2 level blocks at normal pace
- Climbing 1 flight of stairs at normal pace
Class 4: Angina at any level of physical exertion
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Blood Pressure Measurements
Blood pressure was measured on the right arm by a cuff sphygmanometer. An
automated digital 'Omron' machine was used to keep measurements objective.
Measurements were taken in the supine position before venepuncture. A total of 3
measurements were taken during each visit and an average was used to represent the
blood pressure during that visit.
Anthropometric Measurements
Measurements of height and weight were taken to calculate body mass index during
each visit. Height was measured by a ruler scale fixed to a wall to avoid inter-visit
variation. Weight was measured by a 'Seca' digital scale, with footwear removed.
Body mass index was then calculated by the standard formula :
Weight in kg / (height in metres)2
Waist and hip circumference were measured manually by a standard tape
measurement. Waist circumference was taken at the level of the umbilicus. Hip





In all cases and controls blood tests were obtained in the fasting state after the
microvascular function tests were completed. This was to ensure that the minor stress
associated with venepuncture did not interfere with these other tests. In the cases of
women with 'Syndrome X', an 18-guage intravenous cannula (venflon) was inserted
into the right antecubital fossa to facilitate further blood sampling during the oral
glucose tolerance test. With the control subjects, blood was collected using the
'vacutainer' system. The venous blood was centrifuged immediately after collection
at 3000rpm for 10 minutes to separate out the serum and the serum was pipetted into
2ml alloquots for immediate freezing and storage at -80°C until batch analysis which
was undertaken at the of the study.
An oral glucose tolerance test (OGTT) was performed in the subjects with 'Syndrome
X'. After insertion on the intravenous cannula, and the extraction of a fasting blood
sample, the venflon was flushed with saline to keep it patent. At time 0' 75g of
glucose was administered orally. This took the form of 415ml of lucozade which was
drunk within a 2 minute period.
At time 60' and 120 minutes, blood was withdrawn from the indwelling venous
cannula for glucose, insulin and free fatty acids, after discarding the initial 5ml of
saline-contaminated blood. After the sample was obtained, the cannula was again
flushed with saline. The cannula was removed immediately after the last sample was
obtained. The samples obtained during the oral glucose tolerance test were treated in
the same way as the fasting blood samples.
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Blood Tests
• Insulin and Glucose
The plasma glucose measurement is presented in mmol/L.
Hyperinsulinaemia is used as a surrogate marker of insulin sensitivity. Data are
presented on fasting insulin in mu/L. These data are log transformed in order to
achieve a normal distribution and allow comparison by means of standard
statistical tests. The Quicki index is also presented. This is outlined as a measure
of insulin sensitivity in chapter 1. It incorporates both fasting glucose and fasting
insulin measures as well as a log and reciprocal transformation to restore
normality to the distribution. It is calculated thus:
Quicki index = (l/[(log insulin) + (log glucose)]
Although the gold-standard for measuring insulin resistance is the euglycaemic
clamp method as outlined in chapter 1, I made use of fasting insulin because
performing euglycaemic clamps on all subjects in a study of this size is very
labour intensive. Moreover, others have demonstrated good agreement between
fasting insulin and clamp-derived indices of insulin resistance, especially in obese
populations (11).
Non-esterified fatty acids (NEFA) are also presented and as these are normally
distributed, they are shown directly.
• Lipids
A full lipid profile is presented. Serum total cholesterol, low density lipoprotein
(LDL) cholesterol, high density lipoprotein (HDL) cholesterol and triglyceride are
all measured in mmol/L. The three cholesterol parameters are all normally
distributed and are therefore presented directly. However, serum triglyceride is not
normally distributed and these data are presented as a reciprocal transformation to
achieve normality.
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• Serum Endothelial Markers
Various measures are presented including tissue plasminogen activator (t-PA),
vascular cell adhesion molecule (V-CAM), intercellular adhesion molecule (I-
CAM), D-dimer and von Willebrand factor (vWF). All of these data require a log
transformation to achieve a normal distribution, except t-PA and are thus
presented as such. t-PA follows a normal distribution and is presented directly.
t-PA, I-CAM and V-CAM are measured in ng/L, vWF is expressed as a % and d-
dimer is measured in arbitrary units.
• C-reactive Protein
A high sensitivity C-reactive protein (CRP) was measured as a marker of
inflammation. These data are measured in mg/L and require a log transformation
in order to follow a normal distribution and are therefore presented as such.
• Leptin
This is a serum marker related to adiposity and is measured in ng/L. These data
follow a normal distribution and are therefore presented directly.
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Exercise Tolerance Test
This was done in the subjects with 'syndrome x' both during the baseline and the
follow-up visit. It was performed at the end of the visit and subjects were allowed to
have a light lunch before embarking on this test. A 'Marquette' treadmill was used
with a computerised controller. All patients were subjected to a full Bruce Protocol.
Exercise was symptom-limited. Standard measurements were recorded including:
• Limiting symptom and the occurrence of anginal chest pain
• Total exercise time
• Maximal ST-segment deviation (calculated manually using pencil and ruler from
hard copy ECG to nearest 0.5mm. This prevents artefactual interference which
would contaminate result if the automatically calculated, average computer-
generated ST-segment deviation were used)
• Duke Score
The Duke Score is a numerical score ranging from -25 to +10 reflecting the
performance of the patient during the treadmill test. It is calculated as following :-
Total Exercise 4 x Maximal ST
Time in " Segment Depression
Minutes in mm
It is a useful index to describe overall performance during the exercise tolerance test.
It has been used in patients with coronary disease as a prognostic indicator (12).
5 x Pain Index
Pain Index :
0 : no pain during exercise
1 : non-limiting pain during exercise
2 : limiting pain during exercise
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Assays
All blood samples were frozen in aliquots and stored at -80°C. They were all analysed
at the end of the study in batches before the randomisation codes for metformin and
placebo were broken.
Samples were analysed quantitatively for insulin using a Microparticle Enzyme
Immunoassay (MEIA) - IMx® from Abbott Laboratories. The coefficient of variation
as <8% and it had a sensitivity of 0.8mU/l.
Plasma glucose was measured using the standard glucose oxidase method in the
laboratories of Glasgow Royal Infirmary. (Glucose Reagent Kit - Olympus AU5200,
Olympus Optical Co Ltd)
Lipid profile was measured using established methods (Boehringer reagent kits, East
Sussex, UK) in a laboratory meeting CDC standardisation criteria.
Tissue plasminogen activator (t-PA), D-dimer and von Willebrand factor (vWF) were
measured by ELISA techniques. In the case of t-PA and D-dimer the ELISA was from
Biopool (Stockholm, Sweden) and for vWF the ELISA was from Dako
(Copenhagen, Denmark).
Vascular cell adhesion molecule (V-CAM) and intercellular adhesion molecule (I-
CAM) were assayed using commercially-available ELISAs quantification (R&D
systems Inc., Oxon UK)
C-reactive protein (CRP) was measured using a double antibody sandwich ELISA
with rabbit anti-human CRP and peroxidase conjugated rabbit anti-human CRP
(DAKO A/S, DK-2600 Glostrup, Denmark). Standard curves for CRP measurement
were linear up to 5mg/l and thereafter logarithmic. The inter-assay and intra-assay
coefficients of variation were less than 7% across the range of measured results. The
lower detection limit of this assay was 0.1mg/l.
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Leptin was measured by an in-house radioimmunoassay that has been validated
thoroughly against the commercially available Linco assay. The intra-assay and
interassay coefficients of variation were less that 7% and <10% respectively over the
sample concentration range. The detection limit for the assay was 0.5ng/ml.
Laser Doppler Imaging
Peripheral endothelium-dependent and endothelium-independent microvascular
function was assessed using laser Doppler imaging of the forearm cutaneous vascular
bed with the subject relaxed in the supine position in a quiet, temperature and light-
controlled environment. This was carried out before any blood tests were obtained.
The microvascular response to acetyl choline (ACh) and sodium nitroprusside (SNP)
was sought and these vasoactive drugs were delivered to the forearm cutaneous bed
non-invasively by iontophoresis.
Perspex iontophoresis chambers were applied to the extensor forearm surface. The
cathode chamber was filled with a 1% sodium nitroprusside (SNP) solution (dissolved
in 0.5% sodium chloride) and the anode chamber 1% acetyl choline (ACh) solution
(also dissolved in 0.5% sodium chloride). Incremental current was applied with
concurrent laser Doppler imaging to record the perfusion response. The laser Doppler
imager (Moor Instruments Ltd) made use of a red laser (wavelength 633nm, power
lmW, beam diameter 1mm). The voltages across the circuit were recorded to enable
calculation of the skin resistance as previously described. The perfusion response in
flux perfusion units was calculated using Moor Instruments software package and is
presented as both area under the curve for the scan and as a plot of flux perfusion
units against cumulative charge. The mean (± SD) between-day coefficient of
variation in healthy subjects for the ACh response was 6.4 ± 3.3% whilst the within-
day, between-site coefficient of variation, measured in both forearms was 8.9 ± 5.3%.
This novel method for assessing microvascular function will be the subject of chapter
5 and a more detailed description of the method employed will be given at this point.
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Statistics
The statistical methods employed to compare the differences in the measured
variables at various stages are described in detail in the relevant chapters. A brief
outline is given below:
• Variable distributions were tested for normality and where necessary
appropriate transformations were made so that parametric statistical
comparison tests could be employed.
• Continuous variables were compared by the unpaired t test for differences
between the Syndrome X group and control group at baseline
• Continuous variables were compared by the paired t test for differences
between the placebo and metformin groups (Syndrome X patients only)
• Dichotomous variables were compared by the chi-squared test where
appropriate
• The effects of differences (in age and BMI) between the Syndrome X group
and healthy controls were adjusted by regression analysis
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CHAPTER 4
Assessment at Baseline and Comparisons Between Healthy Controls
and Women with 'Syndrome X'
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Comparisons Between Healthy Female Controls and Women with Syndrome X
This chapter looks at the physical data collected at baseline in the cohort of 56 women
with cardiac 'Syndrome X'. Comparisons are made with the 25 healthy controls




Most of the variables within the 2 groups were normally distributed. This was tested
using frequency histogram plots as well as the more objective Shapiro-Wilk test.
Some variables did not quite meet the stringent normality criteria of this test. These
variables include diastolic blood pressure in the healthy controls, HDL-cholesterol in
the Syndrome X group, von Willebrand factor (vWF) in the Syndrome X group, non-
esterified fatty acids (NEFA) in the healthy control group, waist hip ratio and body
mass index in the Syndrome X group and leptin in the healthy control group. The
normality plots of these variables tended towards a gaussian distribution but failed to
satisfy the strict criteria of the Shapiro-Wilk. It is known, however, that these
variables are distributed normally in large scale populations and it is probable that
they did not satisfy the Shapiro-Wilk criteria due to the relatively small sample size
and the effect of outliers. For these variables a normal distribution was assumed as
this was suggested by the frequency histogram plot.
However, some other variables did not tend towards a normal distribution at all and
these include triglycerides, von Willebrand factor (vWF), d-dimers, I-CAM and V-




Table illustrating the distribution
pattern of the variables measured.
Normal Tending towards normality Not normally distributed
Age (both groups) Diastolic Bp (controls) Triglycerides (both groups)
Systolic Bp (both groups) HDL Choi (syndrome x) vWF (both groups)
Diastolic Bp (syndrome x) NEFA (controls) D-dimer (both groups)
Total Choi (both groups) W:H ratio (syndrome x) ICAM (both groups)
LDL Choi (both groups) BMI (syndrome x) VCAM (both groups)
HDL Choi (controls) Leptin (controls) Insulin (both groups)






In order for parametric tests to be applied, the variables which failed to satisfy tests
for normality underwent transformations. These are listed below. The transformed



















The groups of data collected in both the control subjects and those with Syndrome X
were compared against each other to test for equal variance using Levene's test. The
variance is a measure of how spread out a distribution is. It is computed as the
average squared deviation of each number from its mean. Variance was equal in all
groups of data and this is of importance when applying statistical tests looking for
differences between the groups.
Presentation ofData
Parametric statistical tests make the assumption that data are normally distributed.
This is not the case with all of the data collected. Therefore, the analysis was
undertaken on normally distributed variables and on the normally distributed
transformations of the non-normally distributed variables listed above.
The raw data for each set of variables is presented in tabular format with patients
being identified by an ID code to preserve confidentiality. The data sets are therefore
subsequently described in terms of the mean and standard deviation. The 2 sample t-
test has been used to look for differences between the data sets for each variable of
interest. Statistical analysis was done using a computer and the package Minitab®
Statistical Software.
The boxplots for each data set are shown with the central line representing the mean
and the box edges the standard deviation. The whiskers demonstrate the entire range
of the data with outliers being shown as a cross.
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1: Age
56 patients with Syndrome X and 25 healthy controls listed with DOB and age on 31/12/01





SX001 54 HC001 55
SX002 61 HC002 51
SX003 66 HC003 53
SX004 43 HC004 41
SX005 60 HC005 40
SX006 43 HC006 44
SX007 55 HC007 61
SX008 74 HC008 64
SX009 63 HC009 53
SX010 53 HC010 50
SX011 49 HC011 46
SX012 57 HC012 46
SX013 65 HC013 48
SX014 60 HC014 53
SX015 70 HC015 61
SX016 55 HC016 55
SX017 68 HC017 62
SX018 50 HC018 61
SX019 55 HC019 57
SX020 52 HC020 62
SX021 42 HC021 54
SX022 59 HC022 44
SX023 72 HC023 44
SX024 51 HC024 43
































Mean 56.7 Mean 51.3
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Boxplots of age SX and age HC


















Syndrome X 56 56.73 42-74 8.32
Controls 25 51.28 34-64 8.11
1.1
1.6
Mean Difference (years) 5.45
95% Confidence interval for difference lower higher
+1.50 +9.41
p value 0 . 008
There is therefore a significant difference between the ages of the subjects in the
2 groups. The subjects in the Syndrome X group are significantly older by an
average of almost 5.5 years.
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2: Body Mass Index
56 patients with Syndrome X listed with height and weight results at baseline along
with 25 healthy controls.













SX001 157 74 29.8 HC001 163 67 25.0
SX002 158 66 26.4 HC002 167 77 27.7
SX003 157 62 25.0 HC003 170 67 23.3
SX004 148 82 37.2 HC004 166 72 26.4
SX005 164 69 25.7 HC005 166 67 24.5
SX006 161 53 20.4 HC006 165 74 27.0
SX007 158 59 23.6 HC007 159 60 23.9
SX008 154 59 24.9 HC008 152 69 30.1
SX009 165 81 29.6 HC009 166 66 23.8
SX010 147 70 32.2 HC010 173 63 21.0
SX011 160 85 33.2 HC011 170 63 21.8
SX012 159 55 21.6 HC012 171 82 28.0
SX013 158 76 30.4 HC013 172 76 25.7
SX014 158 87 34.9 HC014 162 56 21.1
SX015 153 69 29.6 HC015 164 52 19.1
SX016 163 65 24.5 HC016 165 60 22.0
SX017 156 69 28.4 HC017 158 61 24.2
SX018 153 80 34.2 HC018 163 63 23.5
SX019 154 58 24.5 HC019 160 59 23.0
SX020 165 70 25.5 HC020 165 52 18.9
SX021 156 66 27.1 HC021 162 77 29.5
SX022 158 67 26.6 HC022 168 71 25.0
SX023 161 68 26.2 HC023 168 100 35.6
SX024 164 78 28.8 HC024 163 81 30.7
SX025 160 65 25.2 HC025 165 75 27.5
SX026 166 64 23.4
SX027 154 66 27.6
SX028 152 58 25.1
SX029 154 88 37.1
SX030 163 68 25.8
SX031 152 65 27.9
SX032 167 80 28.7
SX033 162 72 27.2
SX034 161 83 31.8
SX035 161 94 36.1
SX036 170 77 26.6
SX037 162 68 26.0
SX038 160 73 28.5
SX039 167 71 25.4
SX040 160 61 23.6
SX041 166 75 27.0
SX042 169 79 27.7
SX043 161 68 26.2
SX044 156 65 26.7
SX045 158 73 29.4
SX046 165 96 35.1
SX047 157 79 32.0
SX048 153 102 43.7
SX049 160 88 34.4
SX050 164 62 23.0
SX051 157 68 27.7
SX052 163 92 34.7
SX053 159 80 31.6
SX054 163 74 27.9
SX055 152 82 35.3
SX056 167 60 21.6
Mean 159 72 28.6 165 68 25.1
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Boxplots of BMI SX and BMI HC
(means are indicated by solid circles)
Boxplots of Height
(means are indicated by solid circles)
1
SX HC
















Standard Error of Mean
0.62
0.77
Mean Difference ( kg/m2) 3.445




Group n Mean Range Standard Standard Error of Mean
(cm) Deviation
Syndrome X 56 159.43 147-170 5.15 0.69
Controls 25 164.92 152-173 4 .72 0 . 94
Mean Difference (cm) -5.49
95% Confidence interval for difference lower higher
-7.84 -3.15
p value <0.001
There is a statistically significant difference in the body mass index (BMI) of the women between the 2 groups.
Women with syndrome x have a BMI which is higher by almost 3.5 kg/m2 compared to healthy female
controls. This is in part explained by the difference in height. Women in the Syndrome X group were over
5cm shorter on average than healthy controls.
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3 : Anthropometric Data
56 patients with Syndrome X listed with waist, hip, height and weight results at
baseline along with 25 healthy controls.
Syndrome X Healthy Controls
Patient Waist Hip W:H Patient Waist Hip W:H
ID (cm) (cm) ratio ID (cm) (cm) ratio
SX001 100 118 0.85 HC001 85 101 0.85
SX002 78 107 0.73 HC002 80 108 0.74
SX003 85 102 0.83 HC003 78 104 0.75
SX004 112 113 0.99 HC004 83 108 0.77
SX005 82 110 0.75 HC005 83 99 0.84
SX006 67 88 0.76 HC006 85 109 0.78
SX007 69 98 0.70 HC007 79 102 0.78
SX008 85 99 0.86 HC008 90 112 0.81
SX009 92 117 0.79 HC009 78 101 0.78
SX010 90 108 0.83 HC010 74 95 0.78
SX011 96 121 0.79 HC011 75 97 0.77
SX012 70 96 0.73 HC012 87 112 0.78
SX013 81 112 0.72 HC013 79 100 0.79
SX014 103 119 0.87 HC014 72 93 0.77
SX015 92 108 0.85 HC015 65 87 0.75
SX016 78 102 0.76 HC016 75 94 0.80
SX017 79 102 0.77 HC017 77 101 0.76
SX018 91 120 0.76 HC018 76 101 0.75
SX019 77 99 0.78 HC019 74 97 0.76
SX020 82 105 0.78 HC020 64 86 0.74
SX021 82 104 0.79 HC021 91 110 0.83
SX022 87 106 0.82 HC022 76 100 0.76
SX023 75 103 0.73 HC023 104 128 0.81
SX024 89 110 0.81 HC024 94 119 0.79
SX025 77 100 0.77 HC025 90 110 0.82
SX026 83 99 0.84
SX027 80 103 0.78
SX028 79 101 0.78
SX029 102 120 0.85
SX030 89 109 0.82
SX031 85 102 0.83
SX032 89 107 0.84
SX033 87 102 0.85
SX034 99 117 0.85
SX035 108 127 0.85
SX036 91 112 0.81
SX037 82 108 0.76
SX038 91 115 0.79
SX039 85 108 0.79
SX040 76 100 0.76
SX041 90 117 0.77
SX042 89 112 0.80
SX043 87 109 0.80
SX044 79 100 0.79
SX045 83 106 0.78
SX046 98 118 0.83
SX047 84 113 0.75
SX048 122 141 0.86
SX049 87 114 0.76
SX050 83 94 0.88
SX051 86 103 0.84
SX052 100 131 0.76
SX053 102 114 0.90
SX054 92 112 0.82
SX055 102 119 0.86
SX056 77 94 0.82
Mean 87.6 108.8 0.80 80.6 103.0 0.78
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Boxplots of Waist Measurements
(means are indicated by solid circles)
' p=0.003
Boxplots of Waist:Hip Ratio
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Two-Sample T-Test: W:H ratio
Group n Mean Range Standard Standard Error of Mean
(cm) Deviation
Syndrome X 56 0 . 804 0.70-0.99 0.051 0.007
Controls 25 0.782 0.74-0.85 0.031 0.006
Mean Difference 0.022
95% Confidence interval for difference lower higher
0.004 0.040
p value 0.020
There is a statistical difference in waist measurement between the 2 groups and




56 patients with Syndrome X listed with average systolic and diastolic blood pressure
at baseline along with 25 healthy controls.
Syndrome X Healthy Controls








SX001 135 86 HC001 127 82
SX002 99 67 HC002 110 72
SX003 126 75 HC003 112 66
SX004 139 67 HC004 133 87
SX005 111 73 HC005 107 68
SX006 118 74 HC006 107 70
SX007 128 79 HC007 125 79
SX008 132 68 HC008 148 92
SX009 156 85 HC009 121 81
SX010 151 87 HC010 109 71
SX011 135 97 HCOll 116 74
SX012 134 75 HC012 105 73
SX013 157 93 HC013 116 75
SX014 146 78 HC014 121 76
SX015 144 86 HC015 114 67
SX016 121 71 HC016 125 75
SX017 176 103 HC017 130 74
SX018 136 82 HC018 128 86
SX019 143 76 HC019 100 71
SX020 119 73 HC020 136 71
SX021 127 85 HC021 154 94
SX022 136 77 HC022 99 69
SX023 147 81 HC023 118 81
SX024 148 87 HC024 100 68
































Average 132 79 Average 119 76
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Boxplots of Blood Pressure
(means are indicated by solid circles)
SX HC SX HC
Two-Sample T-Test: Systolic Blood Pressure
Group n Mean Range Standard Standard Error of Mean
(mmHg) Deviation
Syndrome X 56 132.4 99-176 16.8 2.2
Controls 25 118.5 99-154 14.5 2.9
Mean Difference (mmHg) 13. 87
95% Confidence interval for difference lower higher
+ 6.51 +21.24
p value <0.001
Two-Sample T-Test: Diastolic Blood Pressure
Group n Mean Range Standard Standard Error of Mean
(mmHg) Deviation
Syndrome X 56 79.45 67-103 8 . 84 1.2
Controls 25 75.84 67-94 7. 65 1. 5
Mean Difference (itunHg) 3.61
95% Confidence interval for difference lower higher
-0.27 7.48
p value 0.068
There is a significant difference in the systolic blood pressure but not the
diastolic blood pressure between the 2 groups. Women in the syndrome x group









Daily Frequency of Chest Pain 0.66 -
Daily Frequency of GTN use 0.45 -
* Canadian Cardiovascular Society
Family History of Angina/Ml 37 (66%) 16 (64%)
Family History of Type 2 Diabetes 22 (39%) 9 (36%)
Gestational Diabetes 1 (2%) 1 (4%)
Hypertension During Pregnancy 14 (25%) 2 (8%)
Hysterectomy 16 (29%) 1 (4%)
Peri / postmenopausal 34(61%) 16(64%)
Smokers 8 (14%) 2 (8%)
Ex-smoker (given up >10 years) 9 (16%) 6 (24%)














Aspirin 41 (73%) 41 (73%)
Beta-Blockers 16(29%) 1 (2%)
Amlodipine 7 (13%) 1 (2%)
Diltiazem 19 (34%) 3 (5%)
Nitrates 14 (25%) 5 (9%)
Nicorandil 5 (9%) 3 (5%)















t comparison between Syndrome X during study and Control groups
HRT 14(25%) 14(25%) 6 (24%)
Syndrome X
(Assessment)
Number on at least one anti-anginal 39 (70%)
Number on at least two anti-anginals 14 (25%)
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Number on at least three anti-anginals 4 (7%)
Chest Pain andAnti-anginals
Patients with cardiac 'Syndrome X' have much morbidity and this is reflected by data
shown in the previous page. Amongst the 'Syndrome X' cohort, the average daily
chest pain index was 0.66 indicating an average of 2 episodes of chest pain every 3
days. The use of GTN is not insignificant with an average ofjust over 3
administrations every week, as calculated from the daily index of 0.45.
This ongoing burden of symptoms is reinforced by the data describing the use of anti¬
anginals. Over 70% of women with Syndrome X were taking at least 1 anti-anginal at
assessment with 25% taking at least 2 and 7% requiring 3 anti-anginal drugs.
However, for the study duration most anti-anginals were stopped in the 'Syndrome X'
group such that the rate of use of these drugs did not differ significantly with the
control cohort.
The use of HMG-CoA Reductase inhibitors was significantly higher in the 'Syndrome
X' group as compared with the control group. This difference is derived from the Chi-
Squared test (p=0.004). Data on lipid profile is presented in the next section.
Past Medical and Family History
From the above table it is clear that the women in these 2 groups are similar in terms
of the number with a family history of both ischaemic heart disease and type 2
diabetes. There are no significant differences in the smoking history between the
groups with a similar percentage of current smokers and a similar percentage of
previous smokers. These statistics were analysed by the 2x2 chi squared test.
146
b) Characteristics in terms of Menopause and Obstetric Data
Syndrome X Controls
Peri/Postmenopausal* 34 (61%) 16(64%) ns
On HRT 14 (25%) 6 (24%) ns
Oestrogen Deficient1 29 (52%) 9 (36%) ns
Hysterectomy 16 (29%) 1 (4%) * p=0.012
*amennorrhoeic for >12 months and FSH >30iU/L
t oestradiol <150 pmol/L
Hypertension during Pregnancy1 14 (25%) 2 (8%) ns
Gestational Diabetes* 1 (2%) 1 (4%) ns
J incidence reported by patient
Statistical p values obtained from the chi-squared test.
There is no statistically significant difference between the groups in terms of the
numbers of women who are peri or postmenopausal. This state was confirmed by an
oestradiol of less than 150micromol/L in conjunction with a raised FSH/LH (see
section 10). There is no statistical difference in the number of women talcing
hormone-replacement therapy between the 2 groups.
There is, however, a significant difference in the number of women who have
undergone hysterectomy in previous years between the 2 groups - 29% of the
'Syndrome X 'group compared with 4% of the controls. This finding has been
documented by previous groups.
Women in the 'Syndrome X' group tended towards having problems with
hypertension during pregnancy but the figure did not achieve statistical significance.
No observable difference in the numbers with gestational diabetes was seen. These
figures are based on self-reporting of gestational diabetes/hypertension, and as such
may potentially lack accuracy.
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6 : Insulin and Glucose
56 patients with Syndrome X listed with fasting insulin, glucose and non-esterified
fatty acid results at baseline along with 25 healthy controls.













SX001 5.0 8.3 0.6180 0.55 HC001 6.0 14.4 0.5164 0.42
SX002 4.4 4.3 0.7831 0.46 HC002 4.8 3.2 0.8429 0.39
SX003 5.2 15.2 0.5269 0.77 HC003 5.3 7.8 0.6187 0.54
SX004 4.7 33.6 0.4549 0.67 HC004 4.9 2.2 0.9684 0.71
SX005 4.5 3.7 0.8187 0.80 HC005 5.0 3.1 0.8401 0.48
SX006 4.7 5.6 0.7041 0.47 HC006 5.1 2.7 0.8780 0.26
SX007 4.6 3.3 0.8465 0.45 HC007 5.7 4.3 0.7198 0.51
SX008 4.4 5.0 0.7449 0.53 HC008 5.1 4.5 0.7349 0.68
SX009 4.4 5.7 0.7146 0.84 HC009 4.7 3.3 0.8399 0.44
SX010 4.4 4.3 0.7831 0.72 HC010 5.1 1.8 1.0386 0.22
SX011 4.4 8.2 0.6422 0 70 HC011 5.3 4.4 0.7311 0.38
SX012 5.3 5.6 0.6791 0.54 HC012 4.5 3.5 0.8352 0.46
SX013 4.8 3.7 0.8004 0.89 HC013 4.8 3.7 0.8004 0.44
SX014 4.6 5.5 0.7127 0.84 HC014 6.1 3.3 0.7670 0.38
SX015 5.2 5.7 0.6794 0.36 HC015 5.0 3.9 0.7752 0.15
SX016 4.5 7.0 0.6674 0.24 HC016 5.3 5.2 0.6943 0.55
SX017 5.3 5.4 0.6865 0.66 HC017 4.7 10.2 0.5950 1.08
SX018 4.2 4.5 0.7834 0.67 HC018 5.3 3.7 0.7737 0.19
SX019 4.5 14.2 0.5539 0.80 HC019 4.9 4.1 0.7675 0.53
SX020 5.4 7.0 0.6339 0.72 HC020 5.5 3.1 0.8119 0.71
SX021 4.6 9.2 0.6148 0.58 HC021 4.9 5.7 0.6915 0.47
SX022 4.7 9.4 0.6078 0.46 HC022 4.7 7.7 0.6416 0.27
SX023 5.0 7.9 0.6263 0.55 HC023 5.3 14.0 0.5346 0.49
SX024 4.3 7.6 0.6604 0.49 HC024 4.6 22.2 0.4977 0.32
SX025 4.7 3.6 0.8141 0.57 HC025 4.6 6.6 0.6746 0.38
SX026 4.7 4.2 0.7720 0.35
SX027 4.5 6.6 0.6790 0.42
SX028 5.0 11.7 0.5659 0.65
SX029 4.6 11.2 0.5841 0.82
SX030 4.9 7.1 0.6487 0.43
SX031 5.5 18.2 0.4999 0.59
SX032 4.9 8.0 0.6276 0.42
SX033 5.0 4.6 0.7344 0.42
SX034 5.5 13.9 0.5310 0.56
SX035 5.7 22.7 0.4735 0 51
SX036 5.0 7.7 0.6307 0.54
SX037 4.4 4.4 0.7771 0.43
SX038 5.0 6.9 0.6503 0.55
SX039 5.6 9.0 0.5874 0.52
SX040 5.6 6.5 0.6406 0.47
SX041 5.2 6.9 0.6431 0.40
SX042 4.8 14.7 0.5410 0.50
SX043 5.3 11.3 0.5626 0.62
SX044 5.3 7.9 0.6166 0.14
SX045 4.7 7.4 0.6488 0.34
SX046 5.0 26.6 0.4708 0.26
SX047 4.7 5.4 0.7120 0.41
SX048 5.5 7.3 0.6236 0.73
SX049 4.7 7.2 0.6538 0.51
SX050 5.1 8.2 0.6168 0.35
SX051 4.3 5.4 0.7321 0.37
SX052 4.9 9.7 0.5963 0.57
SX053 4.6 7.5 0.6503 0.53
SX054 5.1 18.0 0.5095 1.10
SX055 4.9 19.7 0.5039 0.51
SX056 5.5 13.8 0.5318 0.32
Mean 4.9 9.2 0.650 0.55 Mean 5.1 5.9 0.744 0.46
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Boxplots of Fasting Glucose
(means are indicated by solid circles)
Boxplots of Quicki Index
(means are indicated by solid circles)

























































Boxplots of log fasting insulin
(means are indicated by solid circles)
Boxplots of NEFA
(means are indicated by solid circles)





Standard Error of Mean
Syndrome X 56 0.896 3.3-33.6 0.228







































The fasting glucose is significantly lower in the Syndrome X group as compared to the healthy controls. This is
likely to be a statistical effect of the relatively small group sizes. The quicki index is lower and the fasting insulin
is higher in the Syndrome X group reflecting higher^Ievels of insulin resistance, despite a lower fasting plasma
glucose. There is, however, no significant difference in the fasting NEFAs between the groups.
7 : Lipids
56 patients with syndrome x listed with fasting lipid results at baseline along with 25
healthy controls.
Syndrome X Healthy Controls




















SX001 5.45 0.8333 0.25 3.75 1.45 HC001 6.45 0.2817 0.95 4.15 1.35
SX002 6.95 0.6250 0.4 5.1 1.45 HC002 4.50 1.2500 0.50 2.40 1.60
SX003 6.5 0.5405 0.7 4.6 1.2 HC003 4.15 0.6452 0.50 2.30 1.35
SX004 3.45 0.8000 0.3 2.1 1.05 HC004 5.00 1.1765 0.35 3.25 1.40
SX005 5.45 0.7692 0.35 2.85 2.25 HC005 5.80 1.1111 0.40 4.00 1.40
SX006 6.05 1.3333 0.35 3.85 1.85 HC006 5.15 1.0000 0.45 3.00 1.70
SX007 4.45 0.9524 0.3 2.85 1.3 HC007 4.80 1.4286 0.30 2.55 1.95
SX008 5.4 1.1111 0.35 3.25 1.8 HC008 5.15 1.8182 0.10 2.60 2.45
SX009 5.6 0.9091 0.25 3.3 1.6 HC009 4.10 1.6667 0.15 2.35 1.60
SX010 5.6 0.5263 0.35 3.5 1.75 HC010 4.25 1.4286 0.20 2.40 1.65
SX011 5.75 0.6061 0.45 4.15 1.15 HC011 3.75 1.8182 0.10 2.20 1.45
SX012 4.8 1.1111 0.4 2.9 1.5 HC012 5.60 0.8696 0.60 3.85 1.15
SX013 4.75 0.7692 0.05 3.3 1.4 HC013 4.45 0.8000 0.30 3.00 1.15
SX014 5.25 0.3448 1.15 3 1.1 HC014 5.00 1.0000 0.15 3.05 1.80
SX015 6.25 0.8000 0.25 4.25 1.75 HC015 5.70 1.2500 0.20 3.35 2.15
SX016 5.75 0.5128 0.7 4 1.05 HC016 5.00 1.1111 0.35 3.25 1.40
SX017 5.8 0.7143 0.35 3.65 1.2 HC017 5.05 1.8182 0.30 3.15 1.60
SX018 4.3 1.1765 0.25 2.5 1.55 HC018 5.95 1.1765 0.40 3.65 1.90
SX019 5.4 0.4545 0.85 3.25 1.3 HC019 5.80 1.0526 0.25 4.35 1.20
SX020 4.75 0.6897 0.25 3.2 1.3 HC020 3.50 1.1111 0.25 1.70 1.55
SX021 4.3 1.0000 0.2 2.55 1.55 HC021 6.15 0.7692 0.70 4.10 1.35
SX022 5.95 0.6452 0.45 3.8 1.7 HC022 3.15 2.5000 0.15 1.05 1.95
SX023 5.15 1.5385 0.25 2.7 2.2 HC023 5.50 0.6250 0.40 3.95 1.15
SX024 4.2 0.8333 0.2 2.8 1.2 HC024 4.25 0.6452 0.60 2.65 1.00
SX025 6.55 1.3333 0.55 4.15 1.85 HC025 4.80 0.3774 1.00 2.80 1.00
SX026 5.9 1.4286 0.3 4.15 1.45
SX027 4.15 0.9091 0.35 2.6 1.2
SX028 3.45 0.7143 0.3 1.35 1.8
SX029 6.3 0.7143 0.45 3.6 2.05
SX030 4.3 0.4651 0.8 2.7 0.8
SX031 4.55 1.1765 0.3 2.75 1.5
SX032 5.65 1.1765 0.5 3.95 1.2
SX033 5.8 0.6250 0.2 3.8 1.8
SX034 5.1 0.6250 0.65 3.4 1.05
SX035 4.25 0.3846 0.9 2.35 1
SX036 4.45 1.0526 0.25 2.7 1.5
SX037 5.45 1.0000 0.4 3.8 1.25
SX038 4.7 0.9524 0.35 3 1.35
SX039 3.5 0.5882 0.4 1.7 1.4
SX040 4.65 0.8000 0.35 2.95 1.35
SX041 3.9 0.8696 0.5 2.55 0.85
SX042 4.6 0.5882 0.4 3 1.2
SX043 5.2 0,3030 1.1 3.15 0.95
SX044 3.6 1.1111 0.15 2.3 1.15
SX045 3.65 0.8696 0.4 2.15 1.1
SX046 4.95 0.8696 0.45 3.7 0.8
SX047 3.9 1.2500 0.3 2.35 1.25
SX048 5.25 0.6452 0.4 2.45 2.4
SX049 4.2 1.0000 0.35 2.55 1.3
SX050 4.1 1.0000 0.3 2.65 1.15
SX051 4.55 0.9091 0.5 2.95 1.1
SX052 4.3 0.3704 0.7 2.25 1.35
SX053 6.2 0.8696 0.4 4.45 1.35
SX054 7.6 0.0565 5.55 1.3 0.75
SX055 3.7 0.7143 0.35 2.25 1.1
SX056 4.05 1.1765 0.45 2.2 1.4
Mean

















sx HC SX HC SX HC





Standard Error of Mean
Syndrome X 56 4.996 3.45-7.6 0.955













Group n Mean Range Standard Standard Error of Mean
(mmol/L) Deviation
Syndrome X 56 3.079 1.30-5.10 0.800 0.11
Controls 25 3.004 1.05-4.35 0. 816 0 .16
Mean Difference (mmol/L) 0.075
































Boxplots of Triglycerides (Reciprocal Transformation)
(means are indicated by solid circles)
SX HC





Standard Error of Mean
Syndrome X 56 0.824 0.30-1.25 0.301 0.040
Controls 25 1.149 0.28-2.5 0.506 0.10
Mean Difference (recip mmol/L) -0.325
95% Confidence interval for difference lower higher
-0.547 -0.103
p value 0.005
There is a significant difference in serum triglycerides between the two groups (women in
the Syndrome X group have significantly higher triglycerides). No difference in serum
total, LDL or HDL cholesterol is seen. This is despite more women in the syndrome x
group taking statins (39% Vs 8%)
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8 : Serum Endothelial Markers
56 patients with syndrome x listed with fasting endothelial marker results at baseline
along with 25 healthy controls.





























SX001 2.11 9.6 1.785 2.360 2.474 HC001 2.05 11.8 1.699 2.431 2.511
SX002 2.12 6.7 1.580 2.256 2.362 HC002 1.72 4.5 1.716 2.290 2.445
SX003 2.39 9.2 1.826 2.452 2.489 HC003 2.12 7.1 2.377 2.117 2.412
SX004 2.11 11.3 1.806 2.462 2.596 HC004 2.59 4.3 1.724 2.351 2.658
SX005 2.14 4.3 1.929 2.400 2.370 HC005 1.67 5.3 1.826 2.356 2.403
SX006 1.81 5.0 1.792 2.603 2.406 HC006 1.84 4.8 1.785 2.263 2.275
SX007 2.32 5.9 1.826 2.454 2.584 HC007 1.97 3.3 2.124 2.414 2.355
SX008 2.23 7.4 2.290 2.507 2.492 HC008 2.12 6.2 1.863 2.425 2.343
SX009 2.01 5.3 1.672 2.477 2.660 HC009 1.83 7.7 1.756 2.364 2.451
SX010 2.12 2.0 1.672 2.269 2.393 HC010 2.23 3.1 2.380 2.398 2.515
SX011 2.22 11.6 1.672 2.347 2.415 HC011 1.88 5.3 1.602 2.243 2.373
SX012 2.19 6.7 1.380 2.335 2.435 HC012 1.81 6.6 2.913 2.352 2.496
SX013 2.07 6.9 2.049 2.383 2.377 HC013 1.71 7.7 1.623 2.325 2.478
SX014 2.23 7.7 1.833 2.467 2.461 HC014 1.88 5.3 1.602 2.241 2.425
SX015 2.17 10.8 1.869 2.391 2.526 HC015 1.93 7.2 1.959 2.455 2.525
SX016 1.98 6.7 1.924 2.369 2.547 HC016 1.90 7.6 1.771 2.331 2.423
SX017 2.23 12.1 2.625 2.454 2.598 HC017 2.00 5.4 1.778 2.160 2.504
SX018 2.21 6.5 2.013 2.452 2.769 HC018 1.97 7.0 1.672 2.239 2.444
SX019 2.09 10.5 1.580 2.643 2.481 HC019 2.04 6.6 1.940 2.247 2.460
SX020 2.17 4.0 1.924 2.418 2.432 HC020 1.90 3.9 1.146 2.302 2.571
SX021 2.09 3.8 1.919 2.343 2.648 HC021 1.77 8.8 1.833 2.456 2.435
SX022 2.08 8.0 1.301 2.373 2.558 HC022 1.88 3.2 1.869 2.344 2.593
SX023 2.22 6.7 1.869 2.426 2.660 HC023 1.97 8.3 1.892 2.453 2.501
SX024 1.96 14.7 2.241 2.453 2.547 HC024 1.83 6.2 2.045 2.285 2.514
SX025 2.08 4.9 1.748 2.304 2.446 HC025 1.79 7.6 1.785 2.461 2.533
SX026 2.13 6.2 1.681 2.208 2.485
SX027 1.94 7.0 2.025 2.358 2.547
SX028 2.20 7.0 1.531 2.247 2.574
SX029 2.11 6.5 2.100 2.414 2.535
SX030 2.23 13.1 1.792 2.559 2.580
SX031 2.29 10.5 2.037 2.419 2.594
SX032 2.03 10.0 1.653 2.329 2.468
SX033 1.76 4.3 2.004 2.314 2.477
SX034 2.15 9.9 1.924 2.608 2,542
SX035 2.27 13.2 2.079 2.496 2.632
SX036 2.15 6.5 2.346 2.253 2.541
SX037 1.93 3.8 1.740 2.416 2.449
SX038 1,98 7.9 2.068 2.345 2.591
SX039 1.86 7.4 1.491 2.425 2.446
SX040 1.82 6.3 1.771 2.306 2.515
SX041 2.25 10.0 1.748 2.293 2.509
SX042 2.00 9.9 2.288 2.307 2.382
SX043 2.15 12.8 1.935 2.414 2.413
SX044 2.04 6.7 1.806 2.327 2.573
SX045 1.98 9.6 2.217 2.294 2.379
SX046 1.81 10.7 1.863 2.296 2.409
SX047 2.14 3.8 1.505 2.491 2.689
SX048 2.23 12.1 2.212 2.358 2.512
SX049 1.83 6.4 2.041 2.363 2.597
SX050 2.00 11.2 2.548 2.280 2.431
SX051 2.26 7.4 2.428 2.642 2.770
SX052 1.82 7.5 1.924 2.442 2.637
SX053 2.08 5.5 2.137 2.560 2.566
SX054 1.74 8.0 1.716 2.469 2.612
SX055 2.48 10.4 1.708 2.424 2.526
SX056 2.27 6.9 1.924 2.471 2.615
Mean 2.09 7.98 0.274 0.380 0.402 1.94 6.19 0.265 0.368 0.392
154
Boxplot of Endothelial Cell Marker Data
(log transformed)
~i 1 1 1 1 1 1 r
SX HC SX HC SX HC SX HC
Boxplots of tPA Data












Standard Error of Mean
Syndrome X 56 2.09 1.74-2.48 0.162
Controls 25 1.94 1.67-2.59 0.193
0 . 022
0.039
Mean Difference (log %)













Standard Error of Mean
Syndrome X 56 1.900 1.30-2.63 0.273
Controls 25 1.867 1.15-2.91 0.329
Mean Difference (log units)















Standard Error of Mean
Syndrome X 56 2.402 2.25-2.64 0.101
Controls 25 2.332 2.12-2.46 0.094
0.013
0 . 019
Mean Difference (log ng/ml)









Two-Sample T-Test: log V-CAM
Group n Mean Range Standard Standard Error of Mean
(log ng/ml) Deviation
Syndrome X 56 2.524 2.36-2.77 0.098 0.013
Controls 25 2.466 2.28-2.66 0.084 0. 017
Mean Difference (log ng/ml) 0.0579












Standard Error of Mean
Syndrome X 56 7 . 98 2.0-14.7 2. 84 0.38
Controls 25 6.19 3.1-11.8 2.02 0.40
Mean Difference (ng/ml) 1.787
95% Confidence interval for difference lower higher
+0.681 +2.892
p value 0.002
There is a significant difference in the endothelial cell factors - tPA, vWF, ICAM and VCAM
between the 2 groups. These factors are all higher in the Syndrome X group. However no significant
difference is seen in the D-dimers between the groups.
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9 : C-reactive Protein and Leptin
56 patients with syndrome x listed with CRP and leptin results at baseline along with
25 healthy controls.
Syndrome X Healthy Controls








SX001 -0.4815 58.4 HC001 0.5587 29.3
SX002 -0.3010 28.7 HC002 0 0607 12.0
SX003 04698 37.9 HC003 0.8420 19.9
SX004 1.1290 60.2 HC004 -0.1675 23.9
SX005 0.7543 28.8 HC005 0.0414 11.3
SX006 -0.2007 11.8 HC006 0.0374 18.5
SX007 0.4031 19.3 HC007 0.8370 19.9
SX008 0.3075 27.8 HC008 0 5441 36.5
SX009 0.3054 35.4 HC009 -0.8539 14.1
SX010 0.8938 40.8 HC010 0.1790 8.3
SX011 0 4378 49.9 HC011 -0.0177 18.8
SX012 0.0719 24.2 HC012 0.3784 27.2
SX013 1.0017 38.4 HC013 -0.0915 14.6
SX014 1.0073 38.0 HC014 -0.5376 17.1
SX015 -0.2757 33.0 HC015 -0.5229 CO CO
SX016 0.1673 23.4 HC016 -0.0269 7.9
SX017 -0.0362 23.7 HC017 0.3385 13.1
SX018 0.7649 44.8 HC018 0.1430 16.6
SX019 0.4472 24.8 HC0I9 0 4298 11.6
SX020 0.7332 37.0 HC020 -0 4089 2.4
SX021 0.5038 44.9 HC021 0.5428 33.6
SX022 0.0334 34.0 HC022 -0.2218 20.5
SX023 -0.3010 42.0 HC023 -0 1024 70.2
SX024 0 6785 44.3 HC024 0.2148 43.4

























SX050 0 0374 48.6






Mean 0.405 37.09 0.101 21.24
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Boxplots of CRP (log transformed)
(means are indicated by solid circles)
Boxplots of leptin
(means are indicated by solid circles)





Standard Error of Mean
Syndrome X 56 0 . 405 i 0 CO cn 1 t—' d* 00 0.466 0.062
Controls 25 0.101 1 0 CO 01 1 o CO 0.422 0 . 084
Mean Difference (log ng/ml) 0.304




Group n Mean Range Standard Standard Error of Mean
(ng/ml) Deviation
Syndrome X 56 37.1 11.2-79.2 14.1 1.9
Controls 25 21. 2 2 . 4-70.2 14.2 2.8
Mean Difference (ng/ml) 15. 86
95% Confidence interval for difference lower higher
+ 9. 00 + 22 .72
p value <0.001
There is a statistically significant difference in CRP and leptin between both groups. Both
parameters are significantly higher among the women in the Syndrome X group.
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10: Oestrogens
56 patients with syndrome x listed with sex
therapy (HRT) usage and oestrogen status a
Syndrome X
Patient ID FSH LH Oest HRT Oes
Status*
SX001 96.0 72.0 <50 0 0
SX002 2.1 1.4 1070 l 1
SX003 46.0 25.0 <50 0 0
SX004 5.6 8.6 360 0 1
SX005 57.0 55.0 120 0 0
SX006 12.0 9.5 630 0 1
SX007 110.0 56.0 <50 0 0
SX008 100.0 55.0 otoV 0 0
SX009 65.8 34.7 <50 0 0
SX010 5.8 4.4 530 1 1
SX011 17.0 27.2 328 0 1
SX012 118.5 53.8 <50 0 0
SX013 2.9 3.0 433 1 1
SX014 0.5 0.5 <50 1 0
SX015 57.8 23.4 <50 0 0
SX016 81.2 67.4 <50 0 0
SX017 65.3 30.2 <50 0 0
SX018 23.3 30.3 580 0 1
SX019 67.6 42.2 198 1 1
SX020 11.8 15.5 367 1 1
SX021 3.60 6.80 307 0 1
SX022 43.40 19.70 <50 0 0
SX023 85.80 30.40 <50 0 0
SX024 2.60 3.00 521 0 1
SX025 54.10 26.90 <50 0 0
SX026 10.00 9.20 201 0 1
SX027 67.50 26.80 <50 0 0
SX028 5.40 10.20 734 0 1
SX029 68.30 43.00 <50 0 0
SX030 59.7 107.6 <50 0 0
SX031 64.3 28.8 <50 0 0
SX032 52.6 26.9 <50 0 0
SX033 15.7 9.5 469 1 1
SX034 34.0 24.8 <50 0 0
SX035 74.3 38.0 <50 0 0
SX036 80.6 37.5 <50 0 0
SX037 7.9 7.8 641 0 I
SX038 10.0 7.4 123 1 0
SX039 45.3 41.0 434 1 1
SX040 90.7 17.9 <50 0 0
SX041 69.6 32.0 <50 0 0
SX042 17.2 16.7 563 0 1
SX043 53.5 31.4 <50 0 0
SX044 58.1 35.1 <50 0 0
SX045 8.3 4.6 176 0 1
SX046 7.8 5.6 154 0 I
SX047 20.0 30.0 373 . 0 I
SX048 9.3 14.1 304 1 I
SX049 3.4 3.8 441 1 1
SX050 11.8 8.3 296 I 1
SX051 85.6 48.8 <50 0 0
SX052 36.1 30.3 472 1 1
SX053 18.5 9.7 314 0 1
SX054 8.3 12.5 626 1 1
SX055 5.8 15.4 603 0 1
SX056 64.1 57.6 106 0 0
'Oestrogen status' - see explanatory note in
hormone profile result, hormone replace
t baseline along with 25 healthy controls.
Healthy Controls
Control ID FSH LH Oest HRT Oes
Status*
HC00I 4.6 6.6 671 1 1
HC002 24.5 6.9 <50 0 0
HC003 0.5 0.5 625 1 1
HC004 80.2 70.5 261 0 1
HC005 5.1 2.4 292 0 1
HC006 20.8 11.3 <50 0 0
HC007 33.1 19.1 249 1 1
HC008 71.9 19.0 <50 0 0
HC009 42.5 31.9 416 0 1
HC010 8.7 10.6 319 1 1
HC011 8.4 3.8 117 0 0
HC012 5.2 3.6 347 0 1
HC013 5.5 0.9 239 0 1
HC014 45.6 37.3 132 0 0
HC015 90.1 47.5 <50 0 0
HC016 7.5 6.2 494 0 1
HC0I7 79.8 33.0 <50 0 0
HC018 68.2 38.9 <50 0 0
HC0I9 63.2 19.1 156 1 1
HC020 0.9 0.5 607 1 1
HC021 97.8 40.9 <50 0 0
HC022 4.9 1.8 202 0 1
HC023 4.0 1.9 241 0 1
HC024 1.1 0.5 507 0 1




Peri/Postmenopausal 34 (61%) 16(64%)
On HRT 14 (25%) 6 (24%)
Oestrogen Deficient 29 (52%) 9 (36%)
Statistical p values obtained from the chi-squared test.
An oestrogen-deficient state was defined as <150micromol/L of oestradiol
irrespective of the gonadotroph ins or HRT status. An 'oestrogen status' of 0 denotes
an oestrogen deficient state whereas an 'oestrogen status of 1 denotes a non oestrogen
deficient state. There was no difference between the 2 groups. This has important
implications for the next section, as impaired vasomotor function has been
documented in postmenopausal oestrogen-deficient women.
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Correcting for Age and BMI
There were significant differences between the 2 groups in terms of age and body
mass index. Potentially, these could drive some of the differences between the other
variables presented in this chapter. Therefore, correction is required for age and body
mass index. One way of achieving this is by a technique termed regression analysis.
The other method would be to exclude women from the groups such that the BMI and
age of the 2 groups does match. Data from both these methods are presented.
1. Regression Analysis
Regression analysis is a statistical technique in whereby differences between the
variables are sought not only in relation to whether they belong to the 'Syndrome X'
or healthy control group, but also in relation to their age and BMI. The results of this
regression analysis are presented in the table below with variables corrected for age,
BMI then both age and BMI together. The goal of regression analysis is to obtain
estimates of an unknown parameters Beta_l,..., Beta_K which indicate how a change
in one of the independent variables (ie age/BMI) affects the values taken by the
dependent variable.
Results indicate that significant differences remain only between the groups for:
• Triglycerides
• Von Willebrand factor
• I-CAM
• Fasting glucose




Loss of significance occurs for :
• Systolic blood pressure
• Tissue plasminogen activator
• V-CAM
• Waist
• Waist: Hip ratio
• C-reactive protein
Adjustment for age and BMI results in some variables gaining significance for
difference between the groups:
• HDL-cholesterol
The unadjusted and adjusted results for the 'Syndrome X' patients and the controls
are summarised in tables 4.1 and 4.2.
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Corrected for age and BMI
(regression analysis)
Sys Blood Pressure p<0.001 * p=0.012 * p=0.004 * p=0.133 ns
reg coeff = 6.086 (SE 4.005}
T = 1.52
Recip Triglycerides p=0.005 * P<0.001 * P=0.01 * p=0.014 *
reg coeff =-0.2530 (SE 0.1007)
T = -2.51
HDL-Cholesterol p=0.095 ns p=0.014 * p=0.177 ns p=0.025 *
reg coeff=-0.21827 (SE 0.09577)
T = -2.28
tPA p=0.002 * p=0.014 * p=0.062 ns p=0.2 ns
reg coeff = 0 . 8935 . (SE 0.6919)
T = 1.29
log vWF p=0.001 * p=0.003 * p=0.001 * p= 0.015 *
reg coeff = 0.02538 (SE 0.00973)
T = 2.61
log I-CAM p=0.004 * p=0.003 * p=0.019 * p=0.018 *
reg coeff = 0.0119 (SE 0.00494)
T = 2.40
log V-CAM p=0.009 * p=0.017 * p=0.049 * p=0.083 ns
reg coeff = 0.00782 (SE 0.00445)
T = 1.76
Fasting glucose p=0.041 * p=0.006 * p=0.106 ns p=0.02 *
reg coeff = -0.2540 (SE 0.1071)
T = -2.37
log fasting insulin p=0.001 * p<0.001* p=0.013 * p=0.016*
reg coeff = 0.155 (SE 0.0626)
T = 2.47
quicki index p=0.002 * p<0.001 * p=0.007 * p=0.016 *
reg coeff = -0.0708 (SE 0.0289)
T = -2.45
waist p=0.003 * p=0.001 * p=0.979 ns p=0.887 ns
reg coeff = 0.184 (SE 1.293)
T = 0.14
waist:hip ratio p=0.02 * p=0.017 * p=0.519 ns p=0.349 ns
reg coeff = 0.01092 (SE 0.0116)
T = 0.94
log CRP p=0.005 * p=0.004 * p=0.115 ns p=0.129 ns
reg coeff = 0.1796 (SE 0.1171)
T = 1.53
Leptin p<0.001 * p<0.001 * p=0.003 * p=0.007 *
reg coeff = 7.608 (SE 2.754)
T = 2.76
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Table 4.2: Summary of results - differences between Syndrome X and Control








Indices of insulin resistance
fasting plasma glucose (mmol/L) 4.9(0.39) 5.1 (0.42) 0.041 0.02
log fasting insulin* (mu/L) 7.87 (1.69) 4.83 (1.84) 0.001 0.016
Quicki index ' 0.65 (0.096) 0.74 (0.132) 0.002 0.016
Blood Pressure
Systolic blood pressure (mmHg) 132.4(16.8) 118.5 (14.5) <0.001 0.133
Diastolic blood pressure (mmHg) 79.5 (8.8) 75.8 (7.7) 0.068 0.547
Lipids
Total cholesterol (mmol/L) 5.00 (0.96) 4.92 (0.85) 0.720 0.750
HDL-cholesterol (mmol/L) 1.38 (0.36) 1.53 (0.36) 0.095 0.025
Triglyceride* (mmol/L) 1.21(3.3) 0.87 (2.0) 0.005 0.014
Endothelial/inflammatory markers
Von Willebrand Factor* (%) 123.0 (1.45) 87.1 (1.56) 0.001 0.015
tPA (ng/ml) 7.91 (2.9) 6.13 (2.0) 0.002 0.2
ICAM-1* (ng/ml) 252.3 (1.26) 214.8 (1.24) 0.004 0.018
VCAM* (ng/ml) 334.2 (1.25) 292.4 (1.21) 0.009 0.083
C-reactive protein* (mg/L) 2.54 (2.9) 1.26 (2.6) 0.005 0.129
Adiposity measures
Waist (cm) 87.6 (10.6) 80.6 (8.9) 0.003 0.887
Waist:Hip ratio 0.80 (0.05) 0.78 (0.03) 0.02 0.349
Serum leptin (ng/ml) 37.1 (14.2) 21.2(14.2) <0.001 0.007
Geometric mean and standard deviation.^Quicki index = (l/[(log insulin) + (log glucose)]
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Analysis of Regression Analysis
Correcting for the differences in age and body mass index shows that significant
differences persist only for specific variables. These include
• Insulin and Glucose
Lower Quicki index of insulin sensitivity and higher fasting insulin for the
Syndrome X group, suggesting the Syndrome X group is more insulin
resistant. The lower fasting plasma glucose is difficult to explain in the light of
this increased insulin resistance compared to the controls, and is likely to be a
statistical consequence of relatively small sample sizes.
• Lipid Profile
Less favourable profile for the Syndrome X group with higher triglycerides
and lower HDL-cholesterol. This is despite significant number of the
'Syndrome X' group being on statin therapy.
• Serum Endothelial Cell Markers
Higher levels of vWF and I-CAM in the Syndrome X group compared with
control subjects. This suggests a potential difference in the function of
endothelial cells between the 2 groups.
• Leptin
Leptin is a serum marker associated with adiposity. The difference in leptin
between the groups remains very significant even after adjustment for the
differences in BMI and may hint that its effect is more wide ranging than just
reflecting obesity levels. The difference between the groups in waist:hip ratio
are rendered insignificant by BMI adjustment as would be expected. However,
the difference in CRP is also removed by BMI adjustment and this suggests
that inflammatory levels may be related to adiposity.
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2. Excluding Group Members
Eliminating the age differences between the groups can also be achieved by excluding
specific subjects from the analysis. The 2 groups are matched for age if the 4 oldest
members of the Syndrome X cohort are excluded along with the youngest control
group member. This involves excluding :





This generates the baseline demographics illustrated below in table 4.3
Table 4.3. Demographics of the patients with cardiac Syndrome X and healthy





Age* 55.6+/-2.07 52.0 +/- 3.04 NS
Body Mass Index* (kg/m2) 28.58 +/- 1.24 25.1 +/- 1.58 0.001
Fasting Glucose* (mmol/L) 4.9+/-0.1 5.1 +/- 0.2 0.022
Smokers 8 (15%) 1 (4%) NS
Gynaecological Factors
Hysterectomy 15 (29%) 1 (4%) 0.014
Peri/Postmenopausal 30 (58%) 16(67%) NS
On HRT 14 (27%) 6 (25%) NS
Hypertension in Pregnancy 14 (27%) 1 (4%) 0.021
Medication
Statin therapy 22 (42%) 2 (8%) 0.003
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Excluding these members on the basis of their age ensures that the 2 groups are
marched according to ages (see table 2). However, there does remain a significant
difference between the BMI of the 2 groups. Many more subjects would require
exclusion to make BMI comparable, and this would be at major expense of statistical
power. Therefore, adjustment for BMI is still required by regression analysis to
remove the direct effect of this variable on others measured.
The other variables are compared by an unpaired t test in a similar manner as earlier
in this chapter. The results are not fully presented by means of boxplots as before but
are merely summarised in table 4.4 below.
As can be seen, very similar findings are presented.
Significant differences are seen between the groups as before in :
• Insulin and Glucose
Fasting insulin and quicki index of insulin resistance. The differences in fasting
insulin and quicki index remain highly significant even after adjustment for body
mass index, suggesting that the Syndrome X group are insulin resistant compared
to the healthy controls. The lower fasting plasma glucose in the 'Syndrome X'
group remains difficult to explain.
• Blood Pressure
Systolic blood pressure between the groups is significantly different once the data




Differences in triglycerides and HDL-cholesterol are seen between the 2 groups
with the Syndrome X cohort having an unfavourable profile compared to the
healthy controls. Total and LDL-cholesterol are not significantly different between
the groups. The differences between HDL-cholesterol and triglycerides persist
after adjustment for BMI. Again the differences in the numbers of women taking
statin therapy is different, with significantly more women in the 'Syndrome X'
group taking a statin during the trial.
• Serum Endothelial Cell Markers
Higher levels of vWF, I-CAM, V-CAM and t-PA were seen in the Syndrome X
group compared with control subjects. With adjustment for BMI, significance was
lost in the V-CAM and t-PA differences leaving significance only in the vWF and
I-CAM differences, as seen with the prior method of analysis. This again suggests
a difference in the function of endothelial cells between the 2 groups.
• Leptin
The difference in leptin between the groups again remains very significant even
after adjustment for the differences in BMI and may hint that its effect is more
wide ranging than just influencing obesity levels. The CRP difference is lost as
before once adjustment for BMI is made.
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Table 4.4. Classical and novel risk factor parameters in cases and controls
Syndrome X Controls p value -
n=52 n=24 p value BMI adj.
Indices of insulin resistance
log fasting insulin* (mu/L) 7.86 (1.70) 4.77(1.86) 0.001 0.016
Quicki index t 0.65 (0.096) 0.75 (0.134) 0.001 0.009
Blood Pressure
Systolic blood pressure (mmHg) 131.6(17.1) 119.2 (14.4) 0.002 0.017
Diastolic blood pressure (mmHg) 79.6 (9.0) 75.9 (7.8) 0.078 0.547
Lipids
Total cholesterol (mmol/L) 4.97 (0.97) 4.93 (0.86) 0.839 0.838
HDL-cholesterol (mmol/L) 1.35 (0.35) 1.55 (0.35) 0.023 0.042
Triglycerides* (mmol/L) 1.37(1.7) 0.93 (1.6) 0.002 0.018
Endothelial/inflammatory markers
Von Willebrand Factor* (%) 121.3 (1.46) 87.5 (1.56) 0.004 0.005
tPA (ng/ml) 7.91 (2.9) 6.13 (2.0) 0.003 0.082
ICAM-1* (ng/ml) 251.2(1.3) 212.3 (1.2) 0.003 0.021
VCAM* (ng/ml) 331.3 (1.3) 290.3 (1.2) 0.012 0.067
C-reactive protein* (mg/L) 2.71 (2.9) 1.24 (2.7) 0.003 0.071
Adiposity measures
Waist (cm) 87.9(10.9) 80.2 (8.9) 0.002 0.855
Serum leptin (ng/ml) 36.9(14.3) 20.8 (14.3) <0.001 0.005
Geometric mean and standard deviation. Quicki index = (1 /[(log insulin) + (log glucose)]
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Correlations Between Indices of Insulin Resistance and Other
Features of the Metabolic Syndrome
Resistance to the metabolic effects of insulin is thought to be the central factor in the
metabolic syndrome, which was discussed in chapter 1. Briefly, it is a inter-related
cluster of metabolic derangements which are known to pre-dispose to cardiovascular
disease. This is represented schematically below.
As discussed already in this chapter, the population of 56 women with cardiac
'Syndrome X' enrolled into the MIRS Study exhibited many features of the metabolic
syndrome as compared with the 25 healthy controls. The following section sets out to
describe the correlations seen between indices of insulin resistance (log transformed
fasting insulin was found to be the best) and the other metabolic variables measured.
Most of these relationships are well-described.
The correlations were made using data that was collected at baseline and after
treatment with either placebo or metformin in the 'Syndrome X 'group. The data on
the healthy controls were also included to give a total of 127 data points. Using all the
available data ought to provide information on a more complete spectrum of insulin
sensitivity.
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1 : Anthropometric Variables
Plot of BMI against Fasting Insulin
r = 0.456
r- squ = 21%
p < 0.001
Plot of Weight against Fasting Insulin
r = 0.358
r- squ = 13%
p < 0.001
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Plot of Waist against Fasting Insulin
r = 0.523
r - squ = 27%
p < 0.001
r = 0.370
r - squ = 14%
p < 0.001
Plot of Waist: Flip ratio against Fasting Insulin
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Plot of Weight Against Leptin Plot of Waist Against Leptin
r = 0.648
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All of the anthropometric variables exhibit a significant relationship to insulin
sensitivity. This tends to suggest that insulin resistance is related not only to body
mass (total fat mass) but also waist diameter and, therefore, central adiposity. Serum
leptin (thought to reflect fat mass) is strongly correlated to both total weight and waist
diameter and, therefore, as expected has a robust association itself with insulin
sensitivity.
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2 : Lipid Profde
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Significant correlations exist between both triglycerides and HDL-cholesterol and this
index of insulin resistance. No relationship was observed for total cholesterol nor LDL-
cholesterol.
3 : Serum Endothelial Markers
Plot of tPA against Fasting Insulin
r = 0.535
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There is a relatively strong correlation between tPA and insulin sensitivity
and a much weaker association for the cellular adhesion molecules. No
correlation was seen for D-dimers nor von Willebrand factor.
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Plot of CRP against Fasting Insulin
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A fairly weak correlation exists between this index of insulin sensitivity and
sensitive CRP. Many now regard inflammation as part of the metabolic syndrome
and this relationship would tend to support this position.
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Summary
Subjects within the cardiac 'Syndrome X' group exhibit a variety of metabolic
differences compared to the cohort of healthy controls. Chance sampling resulted in
the healthy controls being approximately 5 years younger than the 'Syndrome X'
group. The body mass index of the 'Syndrome X' group was slightly but significantly
greater than controls. Much of this effect was due to the average height of the control
subjects being over 5cm greater than that of the subjects in the 'Syndrome X' cohort.
This, in itself, is difficult to explain other than as a result of chance. However, the
higher body mass index points to a greater proportion of body fat in the 'Syndrome X'
group, also reflected by the higher leptin levels in this group.
The significant differences in fasting insulin and quicki index between the groups
indicates higher levels of insulin resistance in the 'Syndrome X 'cohort, even when
adjusted for the differences in BMI between the groups. This insulin resistance is sub¬
clinical and one would not expect any difference in fasting glucose between the
groups (elevated fasting glucose was actually used as an exclusion criterion for the
study). However, although fasting glucose for all subjects was 'normal', the mean
fasting glucose was statistically lower in the subjects with 'Syndrome X'. This result
is difficult to explain metabolically, and again is likely a chance finding given the
relatively small sample sizes studied. Higher levels of insulin resistance would be
expected in relation to the higher fat mass within the 'Syndrome X' group and indeed
a modest correlation was seen between body mass index and fasting insulin (r2 =
21%). My data on higher fasting insulin levels concur with considerable previous
data in subjects with cardiac syndrome X (1-8).
The 'Syndrome X' cohort also show other features of the metabolic syndrome which
go along with the insulin resistance. These include lipid perturbances namely relative
hypertriglyceridaemia and lower levels of HDL-cholesterol. Higher systolic blood
pressure was seen in the 'Syndrome X' when analysed such that subjects were
excluded to facilitate age-matching between the groups. Higher CRP levels were also
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seen in the 'Syndrome X' group, suggesting an inflammatory response, but these
differences lost significance when BMI was taken into account.
Serum markers of endothelial dysfunction were elevated in the 'Syndrome X' group.
These include von Willebrand factor and I-CAM but the differences in t-PA and V-
CAM lost significance when corrected for age and BMI.
These data demonstrate that despite glucose concentrations within normal ranges,
women with cardiac 'Syndrome X' have biochemical indices reflecting relative
insulin resistance. They also demonstrate BMI-independent elevations in a number of
novel parameters linked to insulin resistance and endothelial function namely Ieptin,
vWF and ICAM-1, which have been shown to predict incident CHD. CRP was also
higher in absolute terms but BMI adjustment reduced the difference in accordance
with considerable evidence for an effect of adiposity on inflammatory status
These data are important and in some respects unique in that I have now extended the
spectrum of risk factor abnormalities in women with Cardiac Syndrome X to include
vWF, ICAM-1, leptin and potentially t-PA and CRP. The elevation in leptin is of
particular interest since a recent report has linked leptin to vascular dysfunction
independently of other pathways (9). These observations are relevant since many of
these parameters are recent additions to the spectrum of perturbances linked to
'metabolic' syndrome X, and thus, in turn, to insulin resistance.
Correlations with insulin sensitivity were seen in several metabolic variables known
to be associated with the metabolic syndrome. Although blood pressure did not
exhibit correlation, associations of various strength with fasting insulin were seen
with lipids, inflammatory markers, anthropometric data reflecting fat mass and central
adiposity and some serum markers of endothelial function. Most of these correlations
were fairly modest with relatively small correlation co-efficients. This reflects the
fact that overall, insulin resistance per se probably plays a minor role in influencing
these variables independently and that many other contributory factors are at work.
178
Interestingly, I noted that 27% of the cases (vs 4% of controls) reported problems
with hypertension during pregnancy. This finding suggests that impaired peripheral
microvascular function is associated with hypertensive complications during
pregnancy. Recent data from our group and others have confirmed that women with a
history of pre-eclampsia have impaired microvascular function by the techniques of
flow-mediated dilatation (10) and laser Doppler imaging (11).
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Assessing Peripheral Microvascular Response
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Assessing Vascular Function
Vascular function has been assessed in various different groups using several different
techniques in recent years. Impaired vasomotor function has been demonstrated in
patients with hypertension (1), diabetes (2), sub-clinical insulin resistance (3) and
coronary artery disease (4). Several techniques with varying degrees of invasiveness
have been employed and some of these are listed in table 5.1 below.
Table 5.1:
Various methods of measuring vascular function listed with important characteristics
Method Location Measurement Vessel Size Invasive








coronary Intra-coronary Macro/micro Invasive: intra- coronary
temperature catheters




























Non-invasive if used with
reactive hyperaemia but
may involve arterial or
venous cannulation








Techniques listed above measure changes in vascular properties in relation to specific
provocations which can be either endothelium-dependent or endothelium-
independent. Examples of typical provocations include:
Acetylcholine normally produces endothelium-dependent vasodilation
and subsequent increase in vascular flow.
Nitrate normally produces endothelium-independent
vasodilation and subsequent increase in vascular flow.
Adenosine induces coronary vasodilatation in an endothelium-
dependent and independent way.
Dipyridamole induces coronary vasodilatation in an endothelium
dependent way.
• Cold Pressor Test normally produces sympathetic-driven coronary
vasodilatation.
• Reactive Hyperaemia normally produces endothelium-dependent vasodilation
after transient vascular occlusion.
The methods listed in the table above measure vascular function in different vascular
beds as well as in vessels of varying calibre, from conduit arteries to capillary
microcirculation. Many groups have discriminated between endothelium-dependent
and independent mechanisms using different vasoactive drugs which act through
different pathways. Nitrate donors such as sodium nitroprusside (SNP) can affect
vascular smooth muscle vasodilation directly, whereas drugs such as acetylcholine
(ACh) rely on an intact endothelial layer to couple their effects to the production of
endothelial-derived vasodilators including endogenous nitric oxide (NO).
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Vasomotor Dysfunction in Microvascular Angina
It has been postulated that reduced vasodilator reserve due to microvascular
dysfunction is responsible for the generation of myocardial ischaemia in some
patients with anginal chest pain and normal coronary arteries. This has been dealt with
in more detail in chapter 2. Briefly, coronary vasomotor abnormalities have been
documented in subsets of patients with cardiac 'Syndrome X' in response to pacing
and intra-coronary drugs using direct coronary ultrasound, thermodilution, calculated
coronary resistance and great cardiac vein catheterisation and flow measurements (5-
9). Additionally, there is evidence of more widespread vascular dysfunction, with
abnormalities being demonstrated in the forearm cutaneous vascular beds in response
to relative ischaemia. Modalities used include plethysmography and brachial artery
ultrasound (10-12).
There are data that demonstrate correlations between the behaviour of coronary and
peripheral (brachial) arteries in patients undergoing coronary angiography. Anderson
et al looked at the coronary vasomotor response to intra-coronary acetyl choline
(ACh) and found that those subjects who exhibited a coronary vasoconstrictor
response, had attenuated brachial artery flow-mediated vasodilatation, as assessed by
high resolution brachial artery ultrasound (13).
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Measurement of Vascular Function using Laser Doppler Imaging
The measures of cutaneous vascular function performed as part of the MIRS study in
both women with cardiac 'Syndrome X' and healthy controls were done using this
non-invasive technique. Essentially, the imager detects changes in forearm cutaneous
sub-dermal microvascular blood flow during iontophoresis of topically applied
vasoactive drugs. The protocol employed for each patient is identical and is described
below.
Iontophoresis
This is a non-invasive technique facilitating the delivery of relatively small charged
ions into local tissue. In the protocol, sodium nitroprusside (SNP) was used to
measure the endothelium-independent response and acetylcholine (ACh) the
endothelium-dependent response. 1% solutions of these drugs were made up by
dissolving O.lg of solute in 10ml of 0.5%saline solution. These solutions were than
placed into a specially designed perspex chambers, which were applied to the forearm
extensor surface using adhesive tape. Care was taken in the placement of these
chambers to avoid hair, broken skin and superficial veins. A thin platinum wire on the
Forearm
Chamber filled with SNP cathode anode Chamber filled with ACh
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inside surface of these plastic chambers was connected by means of an external wire
to a source of constant current. SNP, containing the negatively charged nitroprusside
ions, was placed in the cathodal chamber. The ACh solution, containing the positively
charged ACh ions, was placed in the anodal chamber.
When the battery-operated constant current source is activated, the positive charge at
the anode repels the positively charged ACh ions into the superficial layers of the
skin, thereby effecting delivery of this vasoactive drug to the subdermal capillaries.
The same process occurs at the cathode for the negatively charged SNP ions.
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The Principle ofLaser Doppler Imaging
The Doppler principle implies that the wavelength of a reflected electromagnetic
waveform is shifted if it is reflected off a moving object. Furthermore, this shift is
proportional to the velocity of this moving object. This is the principle used by the
laser Doppler imager to record changes in forearm cutaneous perfusion during
iontophoresis. The laser Doppler imager used (Moor Instruments Ltd) made use of a
red laser (wavelength 633nm, power lmW, beam diameter 1mm).
A laser beam is directed towards a point on the skin. Subdermal capillary recruitment
occurring during iontophoresis results in increasing numbers of mainly red blood cells
in the superficial layers of the skin. A laser beam that reflects off one of these moving
blood cells will exhibit a Doppler shift which is picked up by the detector section of
the imager. The presence and magnitude of this shift therefore reflects a perfusion
response to the vasoactive chemicals applied. This response can be monitored at a
single point - this is the method applied by single point laser Doppler fluximetry.
Laser Doppler imaging, however, scans thousands of individual points over a given
area (which corresponds to the area over which iontophoresis takes place). The area of
interest (over the iontophoresis chambers) is defined manually and the laser Doppler
imager scans over this preset area in a linear fashion. The Doppler shift at each point
is recorded, and as several thousand points are scanned, this method averages the
perfusion changes over an area. This, therefore, takes into account the heterogeneous
nature of these perfusion changes over an area. Each scan takes approximately 50
seconds to scan over the area of skin on which the iontophoresis chambers are
attached.
The tissue thickness penetrated by the laser is typically 1mm. Flow is measured in
capillaries with diameters in the order of 10 microns with flow velocities ranging
from typically 0.01 to lOmm/s. This is shown in Figure 1 below.
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Figure 5.1:
Schematic of superficial skin layer
demonstrating blood vessels scanned by LD1.
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The laser Doppler imager derives the perfusion change at each point from the Doppler
shift recorded at this point - this is recorded as an arbitrary unit. The average change
in perfusion is calculated by taking each point lying in the area beneath the anode or
cathode chambers and calculating the median for this area. This gives a single number
as an arbitrary unit to describe the perfusion in the area of interest during each scan.
The median is used because the Doppler shifts recorded at each point within the area
of interest are not normally distributed.
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The Iontophoresis Protocol
This works in conjunction with the laser Doppler imager. A total of 20 scans are made
by the imager and the current is varied for each of these scans as shown in the table
below. An incremental current regime is used to increase drug delivery throughout the
20 scans reaching a peak at scan 15, after which the current is withdrawn, drug
delivery is stopped and perfusion changes regress. Each scan takes approximately 50
seconds to complete.
A baseline scan is performed before any current is applied. After this the current is
increased to 5pAmp for the next 4 scans. A further increase to lOpAmp for 4 scans
and then 15pAmp for a further 4 scans is followed by the maximum current of
20pAmp for the next 2 scans. After this the current is discontinued and another 5






















At the anode, the ACh response is usually maximal at scan 16 following the maximal
current. The SNP response at the cathode can be more sustained with increases in
perfusion sometimes continuing even after the current has been stopped. Voltage is
recorded during each scan to facilitate the calculation of the resistance time integral.
The median perfusion value is calculated for each of the 20 scans for the area of
interest. This can be plotted as a graph and the total perfusion response can be derived
for the area under the curve (AUC) for this graph.
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The Hyperaemic Response
It has been noted that Laser Doppler imaging during iontophoresis sometimes
produces an artefact known as the hyperaemic response, which may over-estimate the
perfusion response. This usually occurs at the cathode especially in subjects with high
skin resistance, reflected by high measured voltages in the circuit. This artefact
consists of a vasodilating response picked up by the laser Doppler imager under these
circumstances. If it does occur, it can hamper the interpretation of the SNP response,
as vasodilation that occurs is not a direct effect of iontophoresis of SNP ions.
It is thought that the hyperaemic response is a local neurally-mediated response which
occurs as a result of the high voltages needed to sustain the current under conditions
of high skin resistance. Several factors are thought to be important in determining
whether a hyperaemic response is elicited. These include:
• Solution vehicle used
• Area of iontophoresis chamber
• Cumulative charge used
We used iontophoresis chambers with a large surface area and a low resistance
vehicle solution, which is known to minimise this artefact (14). In order to identify
which scans were subject to this artefact, laser Doppler imaging was undertaken
during saline solution (0.75%) iontophoresis, so that no vasoactive drugs were being
delivered. 0.75% saline was chosen in order to mimic the ionic concentration of the
drug solutions. In fact, the ionic concentration of the drug solutions used is 1.5% so a
control solution of 0.75% is conservative. This figure of 0.75% was chosen because it
was recognised from previous work that this concentration of saline produces
resistance values similar to that of the drug solution used during iontophoresis. In
practice, one is more likely to encounter artefact responses with a lower concentration
solution and so using a control solution of 0.75% ought to provide an over-estimate of
the artefact response produced.
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It had been thought, anecdotally, that subjects in whom a hyperaemic response was
noted, had high cutaneous resistance thereby necessitating larger voltages in order to
keep the current delivered at the level shown in the iontophoresis protocol. Because
skin resistance is dynamic throughout a scan, the resistance-time integral (RTI) was
calculated for each of these scans using recorded voltages. The RTI is therefore a
reflection of the resistance for the duration of each scan.
The chart below shows the perfusion response during iontophoresis of 0.75% saline at
the anode and the cathode against the RTI. It is evident that in the 84 vehicle scans
performed there is generally a low response with the vast majority being less than 300
units. Only 7% of control scan perfusion responses exceeded this value. Generally
there is a higher response to the control solution at the cathode. The exact reason for
this is unclear. There is no clear correlation between the RTI and the perfusion
response at either the anode or the cathode. Those scans with the highest RTI did not
produce the highest perfusion responses and conversely, the subjects in which the
biggest perfusion responses were seen, did not have the largest RTI. No clear pattern
has emerged linking perfusion responses to the magnitude of the RTI, and it is likely
that other factors, as yet unknown, play a role in producing this artefact. However, all
recognised variables that produce this artefact were adjusted to keep it to a minimum
(14).
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Calculating the Perfusion Response from Laser Doppler Imaging
The data obtained from the laser Doppler imager consists of 20 images of the area
scanned (one image corresponding to one scan at each of the incremental
iontophoresis points). Each pixel within the scans corresponds to one point at which
the flux in the wavelength of the reflected laser beam is measured.
Using a software package from Moor instruments, supplied with the laser Doppler
imager, the area of interest (AOI) is marked for each of these scans. The AOI is the
circular area within the ACh or SNP chambers, depending on which response is being
analysed. Each pixel within the AOI is assigned a number (arbitary unit) depending
on the wavelength flux at this point. All the values within the AOI are collected in this
way and a median value is assigned to represent the perfusion response. In this
manner, 20 values are obtained for the ACh and SNP response for each scan. These
numbers can be represented graphically with the cumulative perfusion response being
calculated by the area under the curve (AUC).
The values derived from the LDI to reflect microvascular responsiveness can be
presented in several ways. Here the data for each scan are presented in 4 different
ways :
• Raw AUC value (AUC)
• AUC value corrected for RTI (AUC-r)
• Raw AUC value - baseline (AUC-b)
• Raw AUC value - baseline corrected for RTI (AUC-br)
It is not known which measure of perfusion response is most valid and the data on the




The amount of drug delivered during iontophoresis depends on :
• The magnitude of the current applied to the circuit by the power source
• The resistance of the skin (higher skin resistance leads to reduced drug delivery
for a given current)
The current is increased incrementally from 5pAmp to 20pAmp over a 15 minute
period during which the laser Doppler imager scans over the area of the skin to record
changes in perfusion. The voltage within the circuit is monitored during the scan and
the resistance calculated using Ohm's Law :
Voltage = current x resistance
However, the skin resistance is dynamic and starts off relatively high at the start,
reducing constantly during iontophoresis. Resistance within the circuit is therefore
measured at regular intervals and the graph of resistance against time is plotted for
each scan. The area under this curve (AUC) serves as an index of the skin resistance
for this period and is referred to as the resistance time integral (RTI). The changes in
perfusion measured by the Laser Doppler imager during iontophoresis can be
corrected for by the RTI to allow for the differences in drug delivery caused by
variation in skin resistance (15).
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Subtracting the Baseline Value
The AUC response derived from the LDI gives the raw-AUC value. The baseline
value at the first scan (OpAmp) can be deducted from each subsequent scan so that
each of the 19 subsequent scans reflect the perfusion response to iontophoresis. This
will ensure that an artificially high response is not derived as a result of a high
baseline result. However, it is not known whether this approach is valid or whether
the total AUC response is a better guide to the vascular response.
Graph showing raw-AUC response Graph showing AUC-baseline response
The line graph represents the perfusion response against time. The
shaded area represents the area under the curve. The graph on the right
shows the AUC correctedfor the baseline (i.e. the entire graph is shifted
downwards so that the initialperfusion value is 0)
If this approach is adopted this AUC-baseline response may still be multiplied by the
resistance time integral (RTI) to correct for skin resistance and differences in drug
delivery.
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Reproducibility of the Perfusion Response using LDI
Inter-arm Variation
Little information exists about the reproducibility of LDI results on different parts of
the body. Most investigators use the forearm as a relatively flat accessible and easy to
use region. However, it is unknown how even opposite arms differ in their superficial
cutaneous perfusion response to the iontophoresis of vasoactive drugs. In an attempt
to characterise this, iontophoresis and laser Doppler imaging was performed on both
arms consecutively using ACh and SNP. This was done on 24 healthy control subjects
and 4 'Syndrome X' patients at baseline and 12 'Syndrome X' patients after treatment
with either placebo or metformin, giving a total of 40 subjects in whom data on
perfusion response in both arms on the same session are available.
ACh
Right Arm Left Arm
AUC AUC-r AUC-b AUC-br
1848 8760 1044 4949
3805 25912 3148 21438
1643 10417 839 5319
2479 12469 1714 8621
3480 19349 2872 15968
1137 8641 656 4986
1366 9234 729 4928
2650 8878 2062 6908
2971 13162 2186 9684
2896 19345 2180 14562
1722 19235 957 10690
4485 24623 3606 19797
2011 10759 1060 5671
2426 13222 1583 8627
1938 11066 1213 6926
760 5715 221 1662
2139 15144 1384 9799
1325 8599 688 4465
2508 17054 1547 10520
1600 9152 923 5280
1545 7431 849 4084
2307 14649 1582 10046
2525 10959 1770 7682
3210 19132 2240 13350
1380 8416 752 4586
973 6568 296 1998
1881 10816 1126 6475
1242 6819 642 3525
1464 7071 719 3473
1767 12298 924 6391
2934 16636 2326 13188
1390 8590 537 3319
1476 6539 858 3801
1363 5779 520 2205
2624 10207 1908 7422
1485 6074 534 2184
1459 9119 871 5444
1624 8494 927 4848
1419 6939 645 3154
857 4928 73 420
AUC AUC-r AUC-b AUC-br
1775 8698 1010 4949
3189 17571 2621 14442
1412 8881 677 4258
1680 7375 964 4232
3445 18086 2769 14537
1078 7956 411 3033
2050 11583 1432 8091
3438 9833 2448 7001
4870 23766 4007 19554
2829 16550 2065 12080
2115 17533 1281 10619
4357 23484 3484 18779
2213 14871 1292 8682
3531 17196 2364 11513
2320 11855 1535 7844
954 7365 376 2903
3003 16727 2081 11591
1261 9470 644 4836
4467 22648 3232 16386
1506 13810 741 6795
1627 10022 872 5372
2148 15100 1256 8830
2723 14895 1968 10765
2722 15216 2055 11487
1607 11088 882 6086
971 7749 167 1333
1579 6032 814 3109
1302 12239 702 6599
1063 11587 259 2823
1384 10851 629 4931
1122 4825 504 2167
1492 9250 521 3230
1183 6270 428 2268
1010 7373 118 861
2762 10496 1850 7030
1258 7171 591 3369
1756 14926 1168 9928
1317 7507 532 3032
1173 6686 614 3500
1124 7531 290 1943
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SNP
Right Arm Left Arm
AUC AUC-r AUC-b AUC-br
2566 12163 1821 8632
3416 23263 2652 18060
1534 9726 857 5433
2225 11192 1353 6806
2144 11921 1536 8540
1519 11544 989 7516
1802 12182 978 6611
2816 9434 2150 7203
3555 15749 2790 12360
1078 7201 352 2351
2193 24496 1252 13985
2922 16042 2078 11408
2761 14771 1790 9577
1405 7657 543 2959
2532 14458 1846 10541
1190 8949 631 4745
1492 10563 816 5777
2116 13733 1498 9722
2371 16123 1351 9187
1137 6504 373 2134
782 3761 105 505
1926 12230 1132 7188
1122 4869 524 2274
1376 8201 532 3171
858 5233 201 1226
951 6419 246 1661
1298 7464 602 3462
1122 6160 605 3321
1374 6636 746 3603
1322 9201 518 3605
2129 12071 1433 8125
1211 7484 476 2942
1009 4470 431 1909
2425 10282 1690 7166
2341 9106 1508 5866
1359 5558 457 1869
1418 8863 820 5125
1936 10125 1240 6485
732 3579 -13 -64
1113 6400 260 1495
AUC AUC-r AUC-b AUC-br
2201 10785 1455 7130
3089 17020 2481 13670
1770 11133 1083 6812
1766 7753 1079 4737
2009 10547 1391 7303
1750 12915 1014 7483
1839 10390 1172 6622
2396 6853 1513 4327
3464 16904 2660 12981
991 5797 246 1439
2106 17459 1263 10470
3949 21285 3057 16477
2889 19414 1938 13023
3018 14698 1890 9204
2369 12106 1604 8196
681 5257 152 1173
2010 11196 1196 6662
1703 12790 1017 7638
2764 14013 1754 8893
2740 25126 1877 17212
1770 10903 1113 6856
3081 21659 2424 17041
1340 7330 654 3577
1414 7904 806 4506
1273 8784 518 3574
1711 13654 887 7078
863 3297 20 76
1243 11684 727 6834
924 10072 189 2060
772 6052 7 55
2463 10591 1580 6794
1375 8525 425 2635
806 4272 81 429
1062 7753 288 2102
2369 9002 1497 5689
1017 5797 321 1830
2263 19236 1684 14314
1144 6521 448 2554
816 4651 130 741
1305 8744 590 3953
The distribution of the LDI perfusion units is non-parametric. Logarithmically
transforming the data produces normality and allows comparison using the paired t-
test. Boxplots of these data are shown below.
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Boxplot of Inter-arm Variability of LDI response to ACh
(Log Transformed)
rt It rt It rt It






































%diff ach-r %diff ach-b %diff ach-br








































-1.96 standard deviation (-0.23)
-0.3 H
-0.4





Bland Altman Plot of log ACh-r Perfusion Response
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Boxplot of Inter-arm % Difference of LDI response to SNP
Log Perfusion Units
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Analysis of Inter-arm Variation
Boxplots above show that there is no significant difference between the measurements
of LDI perfusion measurements taken from the left and right arms using the unpaired
t-test for both the ACh and SNP response. This applies to all 4 methods of analysis
including the raw area under the curve value (AUC), the value adjusted for the
baseline value (AUC-b), the value adjusted for the resistance-time integral (AUC-r)
and the value adjusted for both (AUC-br). However, it is clear looking at the boxplots,
that the AUC and the AUC-r values have a smaller range than AUC-b and AUC-br
reflecting less variation in the inter-arm measurements.
This is supported by the data looking at the mean % difference in the inter-arm
results. AUC and AUC-r have a much lower % difference between arms. For the ACh
response this is 2.7% and for the SNP response it is a little higher at 3.9% and 3.8%
respectively.
The Bland-Altman graphs are used to look at the repeatability of the LDI
measurements for both arms. Here the difference between the arm measurements are
plotted against the average of both arms value. These are plotted for both the raw
AUC and the AUC-r data for both the ACh and SNP response.
The mean difference for all 4 of the plots is approximately 0 as would be expected if
the inter-arm measurements are approximately the same. The standard deviation of
the differences is also calculated and shown in the plots as a dashed line. If good
statistical repeatability is present then at least 95% of the differences ought to lie
between 2 standard deviations (16).
For the ACh AUC measurement 2 data points out of 40 (5%) lie outside the 95%
range suggesting that the technique meets the standard for repeatability. The ACh
AUC-r measurement is better, however, with only 1 out of 40 difference (2.5%) lying
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outside the 2 standard deviations of difference. The SNP repeatability is less good
with 92.5% of the differences lying with 2 standard deviations of difference.
Looking at the spread of the data points on the Bland-Altman graph, magnitude of the
ACh and SNP response analysed as both the raw AUC data and the AUC-r, has no
bearing on the difference seen between the arms.
All of this would tend to suggest that some of the correction of the raw AUC data
for the baseline has a detrimental effect on the repeatability between arms, of
laser Doppler imaging in measuring the microvascular response to both ACh
and SNP. The most robust analysis to ensure good repeatability between arms
would seem to be using the raw AUC data or correcting for resistance-time
integral (AUC-r). The latter appears to be slightly better than just using the raw
AUC data. The SNP measurements are less good in terms of repeatability than
ACh and just fall outside the Bland-Altman criteria for good statistical
repeatability. This short-fall may reflect the relatively small sample size of 40
subjects. The superior repeatability of the ACh data is reflected in the smaller
standard deviation of differences seen in the Bland-Altman plots.
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Temporal Variation
Many different factors affect the iontophoresis and laser Doppler perfusion response
and although I have attempted to correct for and standardise as many of these as
possible, there are likely to be additional factors as yet unknown and others for which
one can only partly correct - such as the emotional state of the subject. It is not known
how reproducible over time the perfusion response measured by LDI is.
In order to address this question, the LDI perfusion response was assessed in the 22
women with cardiac 'Syndrome X' who received placebo treatment, at baseline and
again after 8 weeks. The raw data is shown in the table below:
Baseline 8 Weeks
AUC AUC-r AUC-b AUC-br
1400 11194 850 6796
1105 15135 405 5547
2586 14264 1703 9394
1388 7123 972 4988
1136 8889 319 2496
1351 6285 763 3550
1808 7503 1014 4208
1647 8543 990 5135
1341 14179 469 4959
526 4651 134 1185
2699 20008 2121 15723
815 5467 197 1321
776 5631 325 2358
864 4809 296 1648
2462 18926 1707 13122
1359 7366 673 3634
1212 12666 673 7033
1051 10362 424 4180
764 3078 107 431
1533 13939 1003 9117
1380 8416 752 4586
973 6568 296 1998
954 7628 471 3766
1028 14080 294 4027
1340 7391 490 2703
886 4547 436 2237
1482 11596 598 4679
761 3540 359 1670
2244 9312 1303 5407
1672 8673 1015 5265
1008 10658 28 296
646 5712 263 2326
1674 12410 1203 8918
692 4642 152 1020
1484 10769 729 5290
940 5232 410 2282
1541 11846 1022 7856
2749 14845 1729 9337
1004 10492 446 4661
1370 13507 732 7217
1117 4500 587 2365
1091 9917 502 4563
858 5233 201 1226
951 6419 246 1661
AUC AUC-r AUC-b AUC-br
2291 12005 1874 9820
1094 13938 461 5873
2538 12995 1872 9585
1538 8597 654 3656
1213 9668 513 4089
759 3909 142 731
1672 13493 1064 8586
1672 10918 878 5733
1464 7071 719 3473
1463 7169 757 3709
1529 11330 1068 7914
1353 10188 735 5535
1036 7107 242 1660
1982 4995 1365 3440
2485 18911 1760 13394
1173 5114 526 2293
2934 16636 2326 13188
734 6980 195 1854
1363 5779 520 2205
1459 9119 871 5444
1419 6939 645 3154
857 4928 73 420
1362 7137 978 5125
1035 13186 585 7453
1614 8264 914 4680
1543 8625 659 3684
895 7133 295 2351
1169 6020 444 2287
1649 13307 992 8005
939 6132 380 2481
1374 6636 746 3603
1649 8080 1022 5008
1258 9322 856 6343
871 6559 312 2349
893 6126 285 1955
769 1938 93 234
1208 9193 600 4566
1464 6383 925 4033
2129 12071 1433 8125
573 5449 63 599
2425 10282 1690 7166
1418 8863 820 5125
732 3579 -13 -64
1113 6400 260 1495
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Paired T-Test Results (log transformed)
AUC T-Value = -1.48 P-Value = 0.155
AUC-r T-Value = 0.10 P-Value = 0.923
AUC-b T-Value = -0.81 P-Value = 0.428
AUC-br T-Value = -0.09 P-Value = 0.931









Boxplot of Temporal % Difference of LDI Response to ACh
Log Perfusion Units
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Bland Altman Plot of log SNP Perfusion Response 8 Weeks Apart
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Analysis of Temporal Variation
Boxplots above show that there is no significant difference between the measurements
of LDI perfusion measurements taken 8 weeks apart without any intervention, using
the unpaired t-test for both the ACh and SNP response. This, in a similar fashion to
the inter-arm variation, applies to all 4 methods of analysis including the raw area
under the curve value (AUC), the value adjusted for the baseline value (AUC-b), the
value adjusted for the resistance-time integral (AUC-r) and the value adjusted for both
(AUC-br). However, as with the inter-arm variation data, it seems that the AUC and
the AUC-r values have a smaller range than AUC-b and AUC-br reflecting less
variation in the in the measurements taken 8 weeks apart.
Once again, this is supported by the data looking at the mean % difference in the
results 8 weeks apart. AUC and AUC-r have a much lower % difference. For the ACh
response this is 4.3% and 3.5% respectively and for the SNP response it is a little
higher at 5.9% and 4.7% respectively.
As before, the Bland-Altman graphs are used to look at the repeatability of the LDI
measurements taken 8 weeks apart.
For the ACh AUC measurement 1 data point out of 22 (4.5%) lies outside the 95%
range suggesting that the technique meets the standard for repeatability. The ACh
AUC-r measurement is better, however, with only no data points lying outside the 2
standard deviations of difference. The SNP repeatability is better with no data points
lying outside the 2 standard deviations for both AUC and AUC-r.
Again, it appears that the magnitude of the ACh and SNP response analysed as both
the raw AUC data and the AUC-r, has no bearing on the difference seen between
measurements
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All of this would tend to suggest that, as with the inter-arm measurement,
correction of the raw AUC data for the baseline has a detrimental effect on the
repeatability of laser Doppler imaging in measuring the microvascular response
to both ACh and SNP. The most robust analysis to ensure good repeatability
between scan performed at different time intervals would seem to be using the
raw AUC data or correcting for resistance-time integral (AUC-r). The latter
appears to be slightly better than just using the raw AUC data. Better
reproducibility is seen with the ACh data compared with SNP, reflected by the
smaller standard deviation of the differences in the Bland-Altman plots.
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Summary
There are several modes of presenting LDI perfusion data in response to iontophoresis
of vasoactive drugs. The raw value obtained from the area under the curve (AUC) and
the raw value corrected for skin resistance tend to give the least variability between
arms and between repeat scans.
Using the log of (AUC corrected for the RTI) gives the most consistent results with an
average inter-arm variability of 2.7% for ACh and 3.8% for SNP. Temporal variation
is also minimal with 3.5% variability for the ACh response and 4.7% for the SNP
response. Fairly good correlations between arms and between scans 8 weeks apart are
also seen with the raw AUC value. Bland-Altman plots confirm that inter-arm and
temporal repeat scans give reproducible data with minimal difference in mean values.
Much wider fluctuations in reproducibility are seen when the baseline values are
subtracted, although there still remains no statistical difference between the data sets.
The greater variability seen between scans when the baseline perfusion is subtracted
may suggest that this baseline value in itself may be of some relevance. This baseline
value may be a measure of vascular responsiveness or subjects starting with a high
baseline value may subsequently exhibit a lower response as a result of a higher
starting value. Whatever the mechanism, it seems that subtracting this baseline is not
a useful exercise and the data suggest that only correction for the RTI should be made
for the perfusion response.
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CHAPTER 6
Examining the Difference in Microvascular Function Between
Women with 'Syndrome X' at Baseline, and Healthy Controls.
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Introduction
Chapter 5 dealt with the methodology behind assessment of microvascular function
using iontophoresis of topically applied ACh and SNP in conjunction with laser
Doppler imaging, and the reproducibility of these results.
In this chapter the differences in microvascular function between subjects recruited
with cardiac 'Syndrome X' and healthy controls is examined. These data are baseline
data, before any intervention. The data presented in this chapter are for both the
endothelium-dependent (ACh) response and the endothelium-independent (SNP)
response.
Boxplots are shown for area under the curve (AUC) data analysed by the 4 methods
described in the chapter 5, although it has been shown that raw AUC and AUC
corrected for resistance time integral (RTI) are the most reproducible.
Average 'dose-response' curves are also presented for response to ACh and SNP by
the cardiac 'Syndrome X' group and the healthy controls. The data used in these
curves are the raw values (uncorrected for RTI) but as can be seen from chapter 5, this
is a good reproducible method of presenting microvascular response to ACh and SNP.
Finally in this chapter correlations are looked at between insulin resistance and
microvascular function and endothelial cell markers.
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1. Acetyl Choline (Endothelium-dependent) Response
The magnitude of the perfusion response to ACh is listed in the table below for the 56
'Syndrome X' patients and the 25 healthy controls (left arm data). The values have
been log transformed in order to conform to normality for the purposes of box plot
presentation and t-test comparison.
Patient id ACh ACh-r ACh-b ACh-br
SX001 1400 11194 850 6796
SX002 1105 15135 405 5547
SX003 5322 18008 3955 13382
SX004 2586 14264 1703 9394
SX005 961 7200 -39 -292
SX006 2430 19208 1547 12228
SX007 1128 6830 462 2797
SX008 853 5501 103 664
SX009 2032 8766 1398 6031
SX010 3243 4809 2643 3919
SX011 1388 7123 972 4988
SX012 1136 8889 319 2496
SX013 1351 6285 763 3550
SX014 1808 7503 1014 4208
SX015 1433 7833 717 3919
SX016 1265 7825 665 4114
SX017 1866 7013 1016 3818
SX018 1406 8929 896 5690
SX019 910 3444 498 1885
SX020 1647 8543 990 5135
SX021 1327 8651 720 4694
SX022 1149 7425 766 4950
SX023 1704 16668 1234 12071
SX024 1341 14179 469 4959
SX025 4180 26312 3641 22919
SX026 526 4651 134 1185
SX027 2699 20008 2121 15723
SX028 815 5467 197 1321
SX029 1087 8600 538 4256
SX030 1767 12298 924 6431
SX031 1544 8760 857 4862
SX032 776 5631 325 2358
SX033 1061 3630 355 1215
SX034 1106 4026 429 1562
SX035 1732 11331 1114 7288
SX036 864 4809 296 1648
SX037 864 5789 50 335
SX038 2462 18926 1707 13122
SX039 1848 13229 1014 7259
SX040 986 3836 496 1930
SX041 817 6364 250 1947
SX042 1359 7366 673 3634
SX043 1212 12666 673 7033
SX044 1051 10362 424 4180
SX045 1192 5850 584 2866
SX046 1611 9402 964 5626
SX047 1404 7813 825 4591
SX048 764 3078 107 431
SX049 1185 8479 577 4129
SX050 754 8167 97 1051
SX051 1533 13939 1003 9117
SX052 1024 10942 338 3612
SX053 2213 7716 1477 5150
SX054 1380 8416 752 4586
SX055 973 6568 296 1998
SX056 1881 10816 1126 6475
Control id ACh ACh-r ACh-b ACh-br
HC001 1775 8698 1010 4949
HC002 1770 14744 2405 11472
HC003 3189 17571 2621 14442
HC004 1412 8881 677 4258
HC005 1680 7375 964 4232
HC006 3445 18086 2769 14537
HC007 1078 7956 411 3033
HC008 2050 11583 1432 8091
HC009 3438 9833 2448 7001
HC010 4870 23766 4007 19554
HC011 2829 16550 2065 12080
HC012 2115 17533 1281 10619
HC013 4357 23484 3484 18779
HC014 2213 14871 1292 8682
HC015 3531 17196 2364 11513
HC016 2320 11855 1535 7844
HC017 954 7365 376 2903
HC018 3003 16727 2081 11591
HC019 1261 9470 644 4836
HC020 4467 22648 3232 16386
HC021 1506 13810 741 6795
HC022 1627 10022 872 5372
HC023 2148 15100 1256 8830
HC024 2723 14895 1968 10765
HC025 2722 15216 2055 11487
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SX HC SX HC SX HC SX HC
Two-Sample T-Test and CI : log ACh
Two-sample T for log ACh
Two-Sample T-Test and CI: log ACh-r




N Mean StDev SE Mean group N Mean StDev SE Mean
25 3.368 0.193 0.039 AUC-r HC 25 4 .127 0.155 0.031
56 3.146 0.190 0.025 AUC-r SX 56 3.945 0.208 0.028
Difference = mu (0) - mu (1)
Estimate for difference: 0.2216
95% CI for difference: (0.1287, 0.3145)
T-Test of difference = 0 (vs not =):
P-Value < 0.001
Difference = mu (0) - mu (1)
Estimate for difference: 0.1821
95% CI for difference: (0.0989, 0.2654)
T-Test of difference = 0 (vs not =):
P-Value < 0.001
Two-Sample T-Test and CI : log ACh-b
Two-sample T for log ACh-b
group N Mean StDev SE Mean
AUC-b HC 25 3.167 0.283 0.057
AUC-b SX 55 2.830 0.355 0.048
Two-Sample T-Test and C I: log ACh-br
Two-sample T for log ACh-br
group N Mean StDev SE Mean
AUC-br HC 25 3.926 0.235 0.047
AUC-br SX 55 3. 627 0.343 0.046
Difference = mu (0) - mu (1)
Estimate for difference: 0.3372
95% CI for difference: (0.1890, 0.4855)
T-Test of difference = 0 (vs not =):
P-Value < 0.001
Difference = mu (0) - mu (1)
Estimate for difference: 0.2992
95% CI for difference: (0.1676, 0.4308)
T-Test of difference = 0 (vs not =):
P-Value < 0.001
Highly significant differences in the peripheral microvascular ACh response are evident
between the 'Syndrome X' group and the healthy controls with healthy controls exhibiting a
significantly increased vasodilating response to ACh compared to the 'Syndrome X' group.
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Line Chart Showing Perfusion Response to ACh for Syndrome X
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The above chart shows the mean perfusion response as measured by laser Doppler
imaging over the 20 scans for the entire groups with cardiac 'Syndrome X' and
healthy controls for ACh. As with the box charts, it can be seen that the average
response differs significantly between the 2 groups. The vertical bars represent the
Standard error of the mean (SEM), and the SEM for each data point do not overlap
suggesting a significant difference at each data point.
These curves are analogous to a dose-response curve as the dose of ACh increases to
a maximum at scan 15 with maximum current applied iontophoretically. No current is
applied for the last 5 scans which is why the curves tail downwards after this point.
The group with cardiac 'Syndrome X' have a significantly lower vasodilating
response compared to the healthy controls, suggesting impaired endothelium-
dependant microvascular function.
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2.Sodium Nitroprusside (Endothelium-independent) Response
The magnitude of perfusion response to SNP is listed in the table below for the 56
'Syndrome X' patients and the 25 healthy controls (left arm data). The values have
again been log transformed in order to conform to normality for the purposes of
boxplot presentation and t-test comparison.
Patient id SNP SNP-r SNP-b SNP-br
SX001 954 7628 471 3766
SX002 1028 14080 294 4027
SX003 3487 11799 2570 8696
SX004 1340 7391 490 2703
SX005 1228 9200 262 1963
SX006 1080 8537 347 2743
SX007 1598 9676 1114 6745
SX008 808 5211 208 1341
SX009 1019 4396 453 1954
SX010 1378 2043 678 1005
SX011 886 4547 436 2237
SX012 1482 11596 598 4679
SX013 761 3540 359 1670
SX014 2244 9312 1303 5407
SX015 1816 9927 1150 6286
SX016 872 5394 238 1472
SX017 2154 8095 1488 5592
SX018 1380 8764 959 6090
SX019 1195 4523 655 2479
SX020 1672 8673 1015 5265
SX021 1593 10385 936 6102
SX022 500 3231 166 1073
SX023 1027 10046 616 6026
SX024 1008 10658 28 296
SX025 1243 7824 704 4431
SX026 646 5712 263 2326
SX027 1674 12410 1203 8918
SX028 692 4642 152 1020
SX029 928 7342 507 4011
SX030 1322 9201 518 3605
SX031 1539 8732 598 3393
SX032 1484 10769 729 5290
SX033 1484 5077 768 2628
SX034 1260 4586 456 1660
SX035 1110 7262 473 3094
SX036 940 5232 410 2282
SX037 803 5380 146 978
SX038 1541 11846 1022 7856
SX039 1487 10645 674 4825
SX040 710 2762 63 245
SX041 574 4471 34 265
SX042 2749 14845 1729 9337
SX043 1004 10492 446 4661
SX044 1370 13507 732 7217
SX045 775 3803 187 918
SX046 1769 10324 1250 7295
SX047 884 4919 354 1970
SX048 1117 4500 587 2365
SX049 1260 9016 731 5231
SX050 793 8589 146 1581
SX051 1091 9917 502 4563
SX052 912 9745 294 3142
SX053 1896 6611 1239 4320
SX054 858 5233 201 1226
SX055 951 6419 246 1661
SX056 1298 7464 602 3462
Control id SNP SNP-r SNP-b SNP-br
HC001 2201 10785 1455 7130
HC002 1969 9392 1253 5977
HC003 3089 17020 2481 13670
HC004 1770 11133 1083 6812
HC005 1766 7753 1079 4737
HC006 2009 10547 1391 7303
HC007 1750 12915 1014 7483
HC008 1839 10390 1172 6622
HC009 2396 6853 1513 4327
HC010 3464 16904 2660 12981
HC011 991 5797 246 1439
HC012 2106 17459 1263 10470
HC013 3949 21285 3057 16477
HC014 2889 19414 1938 13023
HC015 3018 14698 1890 9204
HC016 2369 12106 1604 8196
HC017 681 5257 152 1173
HC018 2010 11196 1196 6662
HC019 1703 12790 1017 7638
HC020 2764 14013 1754 8893
HC021 2740 25126 1877 17212
HC022 1770 10903 1113 6856
HC023 3081 21659 2424 17041
HC024 1340 7330 654 3577
HC025 1414 7904 806 4506
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Two-Sample T-Test and CI : log SNP
Two-sample T for log SNP raw
Two-Sample T-Test and CI : log SNP-r
Two-sample T for log SNP-r
group N Mean StDev SE Mean group N Mean StDev SE Mean
AUC HC 25 3.314 0.171 0.034 AUC-r HC 25 4 .073 0.181 0.036
AUC SX 56 3.071 0.163 0.022 AUC-r SX 56 3.869 0.194 0.026
Difference = mu (0) - mu (1)
Estimate for difference: 0.2430
95% CI for difference: (0.1612, 0.3249)
T-Test of difference = 0 (vs not =):
P-Value < 0.001
Difference = mu (0) - mu (1)
Estimate for difference: 0.2036
95% CI for difference: (0.1141, 0.2931)
T-Test of difference = 0 (vs not =):
P-Value < 0.001
Two-Sample T-Test and CI : log SNP-b
Two-sample T for log SNP-b
group N Mean StDev SE Mean
AUC-b HC 25 3.089 0.293 0.059
AUC-b SX 56 2 . 667 0.382 0.051
Difference = mu (0) - mu (1)
Estimate for difference: 0.4226
95% CI for difference: (0.2673, 0.5780)
T-Test of difference = 0 (vs not =):
P-Value < 0.001
Two-Sample T-Test and CI : log SNP-br
Two-sample T for log SNP-br
group N Mean StDev SE Mean
AUC-br HC 25 3.848 0.289 0.058
AUC-br SX 56 3.465 0.365 0.049
Difference = mu (0) - mu (1)
Estimate for difference: 0.3832
95% CI for difference: (0.2317, 0.5346)
T-Test of difference = 0 (vs not =):
P-Value < 0.001
Highly significant differences in the peripheral microvascular SNP response are evident
between the 'Syndrome X' group and the healthy controls with healthy controls exhibiting a
significantly increased vasodilating response to ACh compared to the 'Syndrome X' group.
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Line Chart Showing Perfusion Response to SNP for Syndrome X
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The above chart shows the mean perfusion response as measured by laser Doppler
imaging over the 20 scans for the entire groups with cardiac 'Syndrome X' and
healthy controls for SNP. As with the box charts, it can be seen that the average
response differs significantly between the 2 groups. The vertical bars represent the
Standard error of the mean (SEM), and the SEM for each data point do not overlap
suggesting a significant difference at each data point.
These curves are analogous to a dose-response curve as the dose of SNP increases to a
maximum at scan 15 with maximum current applied iontophoretically. No current is
applied for the last 5 scans which is why the curves flatten out after this point. A
downturn at the tail-end of the curve is not observed as for ACh, presumably due to
SNP having a longer duration of action before breakdown.
The group with cardiac 'Syndrome X' have a significantly lower vasodilating
response compared to the healthy controls, suggesting impaired endothelium-
independent microvascular function. This suggests that this group may have
more generalised vascular smooth muscle dysfunction.
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Correcting for Age and BMI
Although significant differences are seen between all of the vascular responses in the
2 groups, there are also significant differences in the ages and BMI of the 2 groups. In
order to ensure that age and BMI are playing no part in the differences between the









ACh response p<0.001 * p<0.001* p<0.001 *
ACh response
Corrected for RTI
p<0.001 * p<0.001 * p=0.002 *
ACh response
- baseline
p<0.001 * p<0.001 * p<0.001 *
ACh response
-baseline, cor RTI
p<0.001 * p<0.001 * p=0.001 *
SNP response p<0.001 * p<0.001 * p<0.001 *
SNP response
Corrected for RTI
p<0.001 * p<0.001 * p<0.001 *
SNP response
- baseline
p<0.001 * p<0.001 * p<0.001*
SNP response
-baseline, cor RTI
p<0.001 * p<0.001 * p<0.001 *


































Even after correction for age and BMI, highly significant differences remain between
the cardiac 'Syndrome X' group and the healthy controls for both endothelium-
dependent and independent microvascular function.
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Plot of ACh against SNP LDI Response
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The above graph shows the relationship between the SNP and ACh response for the
'Syndrome X' patients and the healthy controls as one group. It is clear that there is a
robust correlation between the endothelium-dependent ACh response and the
endothelium-independent SNP response.
This would tend to suggest that the microvascular response is dependent not only on
an intact endothelial monolayer but also on normally functioning vascular smooth
muscle and that blunting of these two systems may occur in tandem in patients with
cardiac 'Syndrome X'. It also suggests that the magnitudes of the endothelium-
dependent impairment and endothelium-independent impairment are correlated.
223
Correlating Microvascular Function to Insulin Sensitivity
A very weak relationship exists between LDI-measured endothelium-dependant and
independent microvascular function and the Quicki index of insulin sensitivity at
baseline. Considering the group of healthy controls and subjects with 'Syndrome X'
together ensures that the whole spectrum of measured insulin sensitivity and
microvascular function are taken into account. Considering the large numbers of other
variables inter-acting in a complex biological system, even a weak statistically
significant association is likely to hold some relevance.
Plot of Endothelium-Dependant Microvascular
Function Against Quicki Index
Fasting Quicki Index
Plot of Endothelium-lndependent
Microvascular Function Against Quicki Index
0.45 0.55 0.65 0.75 0.85 0.95 1.05
Fasting Quicki Index
Correlating Microvascular Function to Serum Endothelial Markers
The plot below shows the relationship between the ACh perfusion response as
measured by laser Doppler imaging and von Willebrand factor (a complex
polypeptide produced by the endothelium and often used as a serum marker to reflect
its function). The plot is for all the women at baseline ('Syndrome X' and control
group) with a total of 81 data points. Again this ensures that the whole spectrum of
data is considered, not just the 'Syndrome X' data, which will be at one end of the
range of these variables.
A very weak but, none-the-less, significant correlation is seen between these 2
variables. This is not surprising as both are deemed to be measures of endothelial
function but the correlation is weak suggesting that there are many other factors
affecting these measures in-vivo. No significant association was seen with any of the
other serum endothelial markers measured during the study.
Plot of Von Willebrand Factor Against
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Summary
There are highly significant differences between both the ACh and SNP responses of
the subjects in the 2 groups and this persists even after correction for age and BMI by
regression analysis. The vascular responses of the 'Syndrome X' group are attenuated
compared to the controls and this suggests microvascular dysfunction at the level of
the vascular smooth muscle and the endothelium (endothelium-dependent and
independent responses).
There is a significant correlation between the ACh and SNP responses in all of the
subjects and this suggests that those subjects with a good ACh response also have a
good SNP response with the converse also being true. This may suggest a common
factor being involved in the generation of both vascular responses.
Weak correlations exist between insulin sensitivity and both endothelium-dependant
and independent measures of microvascular function as assessed by LDI. The r-
squared values are small (7% and 6% respectively) suggesting that the interaction
between these two variables is relatively small and that it is likely many other factors
are at work. Interpreting this correlation data is of course difficult due to the relatively
small numbers of patients and controls studied.
Although no causal role can be established from this correlation, many suggest that
insulin resistance may impact upon microvascular function as discussed in chapter 2
(see figure 2 in chapter 2) A causal relationship can only be ascertained by modifying
insulin resistance and looking at the effect on vascular function. Chapter 7 discusses
the impact of insulin-sensitisation with metformin on microvascular function.
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CHAPTER 7




It has been shown that women with 'Syndrome X' exhibit insulin resistance compared
to healthy controls as well as several features of the metabolic syndrome and impaired
peripheral microvascular function. The rationale for this double-blinded placebo-
controlled trial was to determine whether metformin, as an insulin-sensitising
modality, would have any effect on:
• Indices of insulin resistance
• Other features of the metabolic syndrome
• Serum markers of endothelial function.
• Anthropometric data
Bisuanides
This class of drug has been used for almost 50 years in clinical practice for the
treatment of type 2 diabetes. They reduce hyperglycaemia without causing weight
gain or hypoglycaemia. Metformin is widely prescribed and phenformin is still used
in some countries, although it has a higher association with lactic acidosis.
Metformin has been looked at mainly in the context of type 2 diabetes where its
principal effect is on hepatic insulin sensitivity. It reduces hepatic glucose output by a
reduction in hepatic gluconeogenesis with a possible effect on glycogenolysis also (1).
There is also evidence that metformin increases hepatic glucose uptake and glycogen
synthesis, via a pathway involving glucose-derived 3-carbon units. Less significant
end-products of these 3-carbon units include lactate and pyruvate, both of which are
seen to increase in subjects treated with metformin (1 ;2).
Metformin also has an effect on peripheral tissue insulin-sensitivity, primarily in
skeletal muscle. In vitro studies of rat muscle have shown that samples treated with
metformin have an increased rate of insulin-mediated glucose uptake and glycogensis
(3). There is also evidence to imply that this effect extends to human tissues - muscle
samples obtained both from insulin-resistant subjects and grown from cell-culture,
show improved insulin-mediated glucose uptake when treated with metformin (3).
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There is emerging evidence that metformin may influence the secretory function of
islet cells directly, from rat models. Rat islet cells whose insulin-secretory capacity
had been impaired by long-term exposure to elevated free fatty acid and glucose
concentrations in vitro, showed improvements in normal secretory function when
treated with metformin (4). Whether or not these data will have any relevance to
human physiology is yet to be determined.
As well as direct effects on glucose metabolism, metformin also has appreciable
effects on other features of the insulin resistance syndrome. The BIGPRO trial was a
prospective study designed to look at these parameters and included 324 non-diabetic
individuals with central obesity (5;6). Significant reductions in fasting insulin levels
were seen after one year of metformin compared with placebo as would be expected.
However, significant weight loss also occurred together with a reduction in total and
LDL-cholesterol. The fibrinolytic system also showed differences with a reduction in
the level of tissue-type plasminogen activator antigen, although plasminogen activator
inhibitor levels were not significantly changed. No significant effect was seen on
blood pressure or plasma triglyceride levels.
A similar trial in subjects with type 2 diabetes did show a significant reduction in
triglyceride levels and plasminogen activator inhibitor-1 after 12 weeks of metformin
treatment compared with 12 weeks of placebo in a cross-over fashion. As with the
BIGPRO data, blood pressure was unaffected (7).
Clear benefits were seen with metformin in the UK Prospective Diabetes Study
(UKPDS). Overweight patients with type 2 diabetes treated with metformin, showed a
clear reduction in all cause mortality (36%), myocardial infarction (39%) and total
macrovascular disease (30%) encompassing stoke, angina, myocardial infarction,
sudden death and peripheral vascular disease, compared to dietary treatment alone.
More importantly, when compared to patients assigned to intensive therapy with
sulphonylureas or insulin, the metformin group had a significantly greater reduction in
all-cause mortality. Smaller reductions in the incidence of myocardial infarction and
stroke were seen in the metformin group, compared with the sulphonylureas/insulin
group, but these reductions were not statistically significant (8).
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This observation would suggest that the benefit in all-cause mortality seen with
metformin can not in full be attributed to better glycaemic control alone. In fact,
median glycated haemoglobin levels were similar between the group assigned
metformin and the group assigned sulphonylureas or insulin. The improvements in
insulin sensitivity and the other features of the insulin resistance syndrome are the
likely mediators of this benefit.
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Tolerability and Side-effects of Metformin
56 women were enrolled in the MIRS Study initially. 27 women were randomised to
metformin and 29 received placebo. The flowchart below outlines the incidence and









• 1 stopped due to UTRI






• 1 admitted with chest pain
• 3 GI s/e
















14 with mild short-lived GI upset
1 with more prolonged GI upset
3 with other side-effects
All 7 with mild transient GI upset
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Serum Lactate
Lactic acidosis has always been a concern during treatment of patients with
metformin, especially high risk groups with renal impairment or cardiac failure. I
measured serum lactate before and after treatment in the 'Syndrome X' cohort as well
as in the healthy controls. Log transformation of the raw data was required to
establish a normal distribution. Results are shown below in table form and boxplots.
In one subject in the Syndrome X group no serum sample was obtained.
Syndrome X at baseline Healthy Controls
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Boxplot of Lactate at Baseline
(Log Transformed)
Controls Syndrome X
Two-Sample T-Test and CI: log Lactate at Baseline
Two-sample T for log lactate (Syndrome X Vs Controls)
group N Mean StDev SE Mean
Controls 25 -0.048 0.126 0.025
Syndrome X 55 -0.030 0.128 0.017
Difference = mu (0) - mu (1)
Estimate for difference: -0.0178
95% CI for difference: (-0.0791, 0.0435)
T-Test of difference = 0 (vs not =):
P-Value = 0.563
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Boxplot of Lactate in Syndrome X
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Baseline Treatment Baseline Treatment
Paired T-Test and CI: log lactate (Metformin)
Paired T for log lactate before and after metformin
Paired T-Test and CI: log lactate (Placebo)




















95% CI for mean difference: (-0.1045, -0.0053)
T-Test of mean difference = 0 (vs not = 0):
N Mean StDev SE Mean
Baseline 22 -0.0431 0.1386 0.0296
Placebo 22 0.0097 0.1496 0.0319
Difference 22 -0.0527 0.1108 0.0236
95% CI for mean difference: (-0.1018, -0.0036)
T-Test of mean difference = 0 (vs not = 0) :
P-Value = 0.032 P-Value = 0.037
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Analysis of Lactate Data
75% of women treated with metformin had side-effects on treatment with the vast
majority being mild transient gastro-intestinal (GI) upset. This compares with 32% on
placebo complaining of gastro-intestinal side-effects. Only 1 woman who completed
the study had more prolonged and sustained GI side-effects with metformin.
Despite this higher rate of side-effects only 3 dropouts were seen in the metformin
arm (13%) as compared to 7 women (32%) with placebo.
Serum lactate was not significantly different between the 'Syndrome X' group and the
controls at baseline. After 8 weeks both the 'Syndrome X 'group treated with
metformin and the group treated with placebo, showed a very small increase in serum
lactate.
The average lactate level rose from 0.97 mmol/L to 1.13 mmol/L in the metformin
group ( an average rise of 17%). This is a similar increment to that seen in the
placebo-treated group (0.95 mmol/L to 1.09 mmol/L - an average rise of 17% also)
In summary, although the incidence of GI side-effects was relatively high with
metformin (75%), in most cases it took the form of a very mild transient GI
upset. Overall, metformin was well-tolerated with fewer dropouts than seen with
placebo. Although a minor increase in serum lactate was seen during metformin
treatment, it was statistically significant. However, a comparable rise was
observed in the placebo group. The cause for this increase in the placebo group is
not clear but it does suggest that the small increase in lactate observed during
treatment with metformin may not be related to metformin treatment per se.
Lactic acidosis was not a significant problem.
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Baseline Characteristics
Table 7.1 illustrates the baseline characteristics of the 2 groups of women with cardiac
'Syndrome X'. There were similar numbers of smokers and postmenopausal women
in both groups. Rates of drug-use were similar between the groups with the exception
that slightly more women in the metformin-treated group took statins and calcium-
channel blockers for the duration of the study. The difference for calcium channel
blockers just reached statistical significance.
As can be seen from table 7.2, the metformin and placebo groups of women with
cardiac 'Syndrome X' were well matched at baseline in terms of most of the clinical,
metabolic, anthropometric and vascular variables measured. The only statistically
significant difference seen between the groups was with respect to GTN usage. The
placebo-treated group used less GTN than the metformin-treated group at baseline
and this may therefore make any conclusions about the change in GTN usage
following treatment difficult to interpret.
Table7. 1 Baseline characteristics ofstudy population in terms ofsmoking, menopause and drug use
Metformin Placebo
group group p value*
n=24 n=22
Smoker 8 9 ns
Postmenopausal 17 14 ns
HRT use 7 7 ns
Aspirin 18 16 ns
Statin use 13 7 ns
Beta blockers 0 1 ns
Nitrate 3 2 ns
Calcium channel blockers 4 0 0.045
Other antihypertensive 2 2 ns
ACE inhibitor 2 3 ns
Angiotensin receptor blocker 1 0 ns
*
p value calculated by 2x2 chi-squared test
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Characteristics of Metformin-treated Group and Placebo-treated Group
Table 7.2. Clinical characteristics of the metformin and placebo group at baseline.
1






Systolic blood pressure (mmHg)
Diastolic blood pressure (mmHg)
56.6 +/- 7.83 *
131.3 +/-19.5*
79.5 +/- 8.4f












































130.32 +/- 1.40* NS
8.69 +/- 2.62 NS
78.3 +/- 1.92* NS






















C-reactive protein 2.85 +/- 1.97* 3.17 +/-4.02* NS
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Presentation of Results
The results for the measured metabolic, clinical and anthropometric variables before
and after metformin and placebo are presented in the following pages.
The raw data are shown in a table for both the metformin and placebo groups. Data
presented are on the women who completed the trial follow-up, therefore data on 24
women in the metformin group and 22 in the placebo group are shown. Some samples
were unsuitable for analysis which leads to missing data points in some tables.
Subsequently, the outcomes are first shown in tabular form with the mean and
standard error of mean (SEM) shown at baseline and after the 8 weeks of intervention
with either metformin or placebo. The statistical significance of the change is shown
next to each set of measurements. Statistical non-significance is represented by 'ns'
whereas the p valve for any significant change is shown.
Additionally, the change for each variable, before and after intervention, was
calculated for all of the women in both groups, and the difference between this change
in both groups was looked at. The difference was compared statistically between the
groups, using a 2-sample t-test, and this result is shown in the last column of each
table. Again 'ns' is simply used to imply that the difference in the mean change
between the groups is not statistically significant, with a p valve being presented only
when the difference achieved statistical significance.
Finally a boxplot is shown for the important variables measured with the central bar
representing the mean and the box representing the standard deviation of the data set.
Data are presented as a boxplot for each time point on the oral glucose tolerance test
for the insulin/glucose metabolism data in section 1. Metformin-treated subjects are
displayed adjacent to their placebo-treated counterparts. This is shown to more
graphically illustrate the change in variables measured before and after intervention.
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1 : Effects of Metformin on Indices of Glucose/Insulin Metabolism
The raw data are shown in the tables below for the metformin and placebo groups at
baseline and then post intervention.
Metformin Group at Baseline
glue glue glue ins ins ins quicki quicki quicki NEFA NEFA NEFA
0 60 120 0 60 120 0 60 120 0 60 120
in mo 1/1 minol/1 m mo 1/1 mu/1 mu/1 mu/1 units units units mmol/1 mmol/1 mmol/1
5.2 11.6 9.2 15.2 90.5 107.2 0.53 0.33 0.33 0.77 0.3 0.09
4.5 10.2 8.7 3.7 63.4 47.2 0.82 0.36 0.38 0.8 0.24 0.1
4.6 3.6 5.9 3.3 20.7 33.9 0.85 0.53 0.43 0.45 0.05 0.05
4.4 8.5 5.7 108.2 70.6 0.71 0.34 0.84 0.04 0.02
4.4 9.4 7.8 4.3 116.6 68.9 0.78 0.33 0.37 0.72 0.13 0.12
4.5 7.6 6.7 7.0 73.3 39.8 0.67 0.36 0.41 0.24 0.04 0.03
5.3 14.2 5.4 65.3 32.8 0.69 0.34 0.66 0.07 0.05
4.2 6.7 5.7 4.5 36.9 32.9 0.78 0.42 0.44 0.67 0.22 0.02
4.5 6.4 9.6 14.2 90.7 185.4 0.55 0.36 0.31 0.8 0.16 0.06
4.6 9.5 6.9 9.2 139.7 82.9 0.61 0.32 0.36 0.58 0.08 0.04
4.7 7.7 5.7 3.6 83.1 47.6 0.81 0.36 0.41 0.57 0.07 0.03
4.9 7.9 4.5 7.1 71.4 42.8 0.65 0.36 0.44 0.43 0.06 0.05
5.5 13.9 8.4 18.2 169.5 106.8 0.50 0.30 0.34 0.59 0.07 0.03
5.0 10.4 5.1 4.6 95.7 26.8 0.73 0.33 0.47 0.42 0.12 0.05
5.5 18.6 14.1 13.9 198 289.7 0.53 0.28 0.28 0.56 0.26 0.07
5.6 11.3 7.8 9.0 29.6 32.6 0.59 0.40 0.42 0.52 0.17 0.05
5.6 6.7 7.2 6.5 37.4 51 0.64 0.42 0.39 0.47 0.14 0.07
5.2 5.3 6.1 6.9 59.7 47.4 0.64 0.40 0.41 0.4 0.11 0.03
4.7 9 6.5 7.4 100.5 56.8 0.65 0.34 0.39 0.34 0.11 0.04
4.7 6.7 6.5 5.4 50.5 65.7 0.71 0.40 0.38 0.41 0.04 0.02
4.7 6.7 5.8 7.2 64.9 45.3 0.65 0.38 0.41 0.51 0.04 0.03
5.1 7.4 5.5 8.2 172.4 109.1 0.62 0.32 0.36 0.35 0.13 0.08
4.9 7.1 8.7 9.7 147.8 97.3 0.60 0.33 0.34 0.57 0.09 0.05
Metformin Group post intervention
glue glue glue ins ins ins quicki quicki quicki NEFA NEFA NEFA
0 60 120 0 60 120 0 60 120 0 60 120
mmol/1 mmol/1 mmol/1 mu/1 mu/1 mu/1 units units units mmol/1 mmol/1 mmol/1
5.7 15.2 11.5 15.7 107.6 65.1 0.51 0.31 0.35 0.76 0.35 0.05
4.6 11.8 9.6 3.7 71 56.7 0.81 0.34 0.37 0.77 0.18 0.05
4.4 7.9 4.8 2.9 68.3 22.5 0.90 0.37 0.49 0.59 0.08 0.02
4.7 7.1 7.2 0.7 44.5 38.7 1.93 0.40 0.41 0.75 0.18 0.06
4.3 9.9 8.0 4.0 125.8 96.1 0.81 0.32 0.35 0.76 0.15 0.12
4.5 5.2 5.1 8.8 55.9 28.5 0.63 0.41 0.46 0.32 0.12 0.14
5.1 14.1 14.4 5.7 36.6 40.5 0.68 0.37 0.36 1.01 0.16 0.06
4.9 8.6 5.0 30.9 0.72 0.41 0.79 0.47
4.4 8.6 7.0 7.1 49.2 90.4 0.67 0.38 0.36 0.58 0.08 0.04
4.5 12.0 8.0 6.6 117.5 64.1 0.68 0.32 0.37 0.69 0.08 0.05
4.6 9.8 7.4 5.1 70.2 57.2 0.73 0.35 0.38 0.72 0.19 0.04
4.8 7.5 4.2 5.9 65.4 35.3 0.69 0.37 0.46 0.34 0.12 0.06
4.7 8.6 9.1 7.3 51.2 49.8 0.65 0.38 0.38 0.63 0.32 0.09
5.7 10.7 2.9 3.3 106 7.8 0.78 0.33 0.74 0.33 0.06 0.04
4.6 15.2 11.0 13.0 142.3 165.4 0.56 0.30 0.31 0.55 0.28 0.09
4.9 9.9 10.0 6.6 21.9 42 0.66 0.43 0.38 0.62 0.18 0.07
5.0 6.5 6.4 6.8 14.4 33.6 0.65 0.51 0.43 0.35 0.12 0.08
5.1 6.0 5.8 10.9 97.1 52.3 0.57 0.36 0.40 0.14 0.08 0.05
4.7 9.6 8.5 7.7 64.5 81.7 0.64 0.36 0.35 0.39 0.15 0.04
4.5 6.4 6.8 6.1 66.5 58.5 0.70 0.38 0.38 0.47 0.09 0.03
4.7 6.5 6.4 6 41.4 45.2 0.69 0.41 0.41 0.46 0.04 0.02
5.2 8.5 4.7 7.4 423.6 94.7 0.63 0.28 0.38 0.39 0.11 0.07
5.1 8.0 6.8 10.1 92.5 72.2 0.58 0.35 0.37 0.56 0.14 0.08
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Placebo Group at Baseline
glue glue glue ins ins ins quicki quicki quicki NEFA NEFA NEFA
0 60 120 0 60 120 0 60 120 0 60 120
mmol/1 m mo I/I m mo I/I mu/I mu/1 mu/I units units units mmol/1 mmol/1 mmol/1
5.0 13.3 9.0 8.3 79.0 153.3 0.62 0.33 2.19 0.55 0.08 0.03
4.4 8.4 8.2 4.3 54.9 57.4 0.78 0.38 1.76 0.46 0.08 0.06
4.7 11.8 7.2 33.6 1005.6 562.8 0.45 0.25 2.75 0.67 0.09 0.07
4.4 10.5 8.2 8.2 112.1 182.0 0.64 0.33 2.26 . 0.7 0.23 0.04
5.3 7.3 7.2 5.6 76.4 50.0 0.68 0.36 1.70 0.54 0.05 0.04
4.8 10.2 8.6 3.7 45.2 45.5 0.80 0.38 1.66 0.89 0.17 0.07
4.6 9.4 5.2 5.5 63.3 16.4 0.71 0.36 1.21 0.84 0.09 0.05
5.4 12.1 8.9 7.0 96.7 93.5 0.63 0.33 1.97 0.72 0.21 0.04
4.3 9.9 10.6 7.6 62.5 93.7 0.66 0.36 1.97 0.49 0.21 0.07
4.7 4.7 4.7 4.2 42.6 33.2 0.77 0.43 1.52 0.35 0.12 0.05
4.5 9.4 8.7 6.6 64.2 87.6 0.68 0.36 1.94 0.42 0.18 0.05
5.0 16.0 7.3 11.7 590.4 273.2 0.57 0.25 2.44 0.65 0.17 0.08
4.9 11.7 8.1 8.0 69.3 95.6 0.63 0.34 1.98 0.42 0.25 0.06
5.0 4.3 5.5 7.7 88.0 71.9 0.63 0.39 1.86 0.54 0.12 0.05
5.0 7.8 7.2 6.9 24.3 31.2 0.65 0.44 1.49 0.55 0.17 0.07
4.8 11.2 6.6 14.7 103.4 129.5 0.54 0.33 2.11 0.5 0.29 0.09
5.3 10.9 8.8 11.3 248.4 156.1 0.56 0.29 2.19 0.62 0.18 0.08
5.3 9.0 8.6 7.9 133.4 130.7 0.62 0.32 2.12 0.14 0.09 0.03
5.5 12.1 12.5 7.3 30.6 46.9 0.62 0.39 1.67 0.73 0.34 0.11
4.3 9.0 7.0 5.4 48.2 37.1 0.73 0.38 1.57 0.37 0.11 0.04
5.1 8.5 7.7 18.0 483.2 297.6 0.51 0.28 2.47 1.1 0.61 0.45
4.9 10.7 7.3 19.7 292.4 149.1 0.50 0.29 2.17 0.51 0.08 0.04
Placebo Group post intervention
glue glue glue ins ins ins quicki quicki quicki NEFA NEFA NEFA
0 60 120 0 60 120 0 60 120 0 60 120
mmol/1 mmol/1 mmol/1 mu/1 mu/1 mu/I units units units mmol/1 mmol/1 mmol/1
4.9 8.1 6.5 10.4 44.2 55.2 0.59 0.39 0.39 0.43 0.05 0.02
4.4 7.9 8.2 4.0 44.8 120.9 0.80 0.39 0.33 0.71 0.12 0.09
4.8 10.7 8.0 35.1 906.4 705.2 0.45 0.25 0.27 0.49 0.08 0.04
4.9 u 8.5 7.6 8.7 70.4 136.0 0.61 0.36 0.33 0.52 0.22 0.06
4.9 7.8 7.0 4.0 140.0 80.3 0.77 0.33 0.36 0.48 0.10 0.05
5.2 9.9 11.5 3.1 39.8 43.5 0.83 0.39 0.37 0.59 0.16 0.04
3.9 10.3 6.6 6.9 79.4 33.4 0.70 0.34 0.43 0.72 0.17 0.07
5.5 11.7 9.5 6.5 58.0 88.0 0.64 0.35 0.34 0.74 0.31 0.04
5.1 9.6 7.2 11.0 69.2 32.3 0.57 0.35 0.42 0.37 0.18 0.13
4.8 3.2 4.8 6.5 25.1 75.4 0.67 0.52 0.39 0.4 0.04 0.04
4.8 8.1 6.7 10.7 60.0 56.6 0.58 0.37 0.39 0.42 0.16 0.10
5.0 14.8 4.6 9.2 768.4 72.2 0.60 0.25 0.40 0.78 0.12 0.07
4.3 7.3 5.7 13.4 79.3 34.9 0.57 0.36 0.44 0.14 0.05 0.05
5.1 5.7 6.4 6.5 166.9 41.5 0.66 0.34 0.41 0.44 0.16 0.05
5.0 9.5 6.8 7.8 72.6 65.2 0.63 0.35 0.38 0.37 0.14 0.03
4.5 11.6 10.1 10.2 87.7 179.8 0.60 0.33 0.31 0.37 0.23 0.09
5.3 11.9 10.7 12.6 172.0 181.8 0.55 0.30 0.30 0.66 0.27 0.07
5.1 10.1 8.0 6.4 107.8 169.7 0.66 0.33 0.32 0.46 0.12 0.03
5.4 10.9 6.6 29.7 132.0 73.3 0.45 0.32 0.37 0.46 0.09 0.05
4.4 7.6 10.1 10.2 38.0 56.1 0.61 0.41 0.36 0.23 0.10 0.05
5.0 10.7 9.8 12.0 242.7 403.6 0.56 0.29 0.28 0.87 0.41 0.18
5.1 11.5 6.3 26.8 698.8 186.1 0.47 0.26 0.33 0.38 0.08 0.06
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a) Glucose results
Results of the glucose values obtained from the oral glucose tolerance test are
summarised in table 7.3 below.
Table 7.3: showing mean change in glucose data before and after intervention
'Mean +/- standard error ofmean
Metformin Metformin Mean Placebo Placebo Mean Difference
group at group after p change group at group after p change between
baseline' treatment' baseline' treatment' mean change
Fasting glucose 4.88 +/- 0.088 4.81 +/-0.078 ns -0.067 +/- 0.084 4.87 +/- 0.077 4.88 +/- 0.082 ns +0.009 +/- 0.068 ns
(mmol/L)
60 min glucose 8.97 +/- 0.69 9.29 +/- 0.59 ns +0.3 +/- 0.443 9.92 +/- 0.56 9.43 +/- 0.52 ns -0.491 +/-0.367 ns
(mmol/L)
120 min glucose 7.34 +/- 0.48 7.20 +/- 0.52 ns +0.55 +/- 0.795 7.87 +/- 0.36 7.67 +/- 0.40 ns -0.2 +/- 0.467 ns
(mmol/L)
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b) Insulin results
Results of the insulin (log transformed) values obtained from the oral glucose
tolerance test are summarised in table 7.4 below.
Table 7.4: showing mean change in insulin data before and after intervention






















Fasting 0.845 +/- 0.043 0.771 +/-0.056 ns -0.075 +/- 0.047 0.917+/-0.050 0.974 +/- 0.057 ns +0.057 +/- 0.039 0.036
log (insulin)
60 min 1.894+/-0.053 1.822+/-0.063 ns -0.071 +/-0.050 2.002 +/- 0.089 2.025 +/-0.091 ns +0.023 +/- 0.053 ns
log (insulin)
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c) Results for Quicki Index of Insulin Resistance
Results of Quicki index obtained from the oral glucose tolerance test are summarised
in table 7.5 below.
Table 7.5: showing mean change in quicki index data before and after intervention






















Fasting quicki 0.666 +/- .020 0.735 +/- 0.058 ns +0.068 +/- 0.054 0.636+/-0.019 0.617+/-0.021 ns -0.019 +/-0.014 ns
(units)
60 min quicki 0.361 +/-0.011 0.367+/-0.010 ns +0.006+/-0.011 0.343 +/-0.011 0.345 +/-0.013 ns +0.002 +/- 0.009 ns
(units)
120 min quicki 0.384 +/- 0.010 0.404+/-0.018 ns +0.035 +/- 0.034 0.360 +/-0.012 0.360 +/-0.010 ns +0.001 +/-0.011 ns
(units)
Boxplot of Fasting quicki Index
0.55 -f
Boxplot of 60' quicki Index
ns *
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d) Non-esterified fatty acid (NEFA) results
Results of NEFA obtained from the oral glucose tolerance test are summarised in
table 7.6 below.
Table 7.6: showing mean change in NEFA data before and after intervention






















Fasting NEFA -0.271 +/-0.029 -0.0283 +/- 0.039 ns -0.004 +/- 0.027 -0.267 +/-0.038 -0.331 +/-0.038 ns -0.064 +/- 0.039 ns
(log units)
60 min NEFA -1.006+/-0.057 -0.863 +/- 0.053 0.019 +0.143 +/-0.056 -0.824 +/- 0.054 -0.887 +/- 0.055 ns -0.062 +/- 0.055 0.012
(log units)
120 min NEFA -1.344+/-0.046 -1.261 +/-0.046 ns +0.066 +/- 0.055 -1.220 +/-0.053 -1.249 +/-0.047 ns -0.028 +/- 0.043 ns
(log units)
























Boxplot of 120' NEFA
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Analysis of Glucose/Insulin Metabolism Data
The only index of insulin resistance which showed significant change after metformin
treatment compared to placebo was the 2 hour post-glucose load insulin level which
was reduced on average just over 5% (p=0.019) after metformin compared to a
negligible change with placebo. There was also a significant difference in the change
in fasting insulin, between metformin and placebo treated groups. There was an
almost 9% decrease in log (fasting insulin) with the metformin group compared to a
6% increase in the placebo group, giving a statistically significant difference
(p=0.036).
A similar trend was seen with the 1 hour-post glucose insulin levels with a decrease of
almost 4%. This is as compared to placebo in which there was little appreciable
change at the 1-hour post-glucose insulin point. This trend at the 1-hour post-glucose
insulin level failed to achieve statistical significance.
The glucose levels were relatively unaffected after metformin treatment with an
approximate reduction in the fasting glucose of 1.5%. Although this trend was in a
favourable direction, statistical significance was not reached.
Looking at the quicki index of insulin sensitivity, a 10% increase at the fasting state
was seen after metformin compared to a slight reduction in those taking placebo.
However, this missed out on statistical significance (p—0.215). A 9% increase at the
2-our post glucose point was also seen compared to a negligible change for placebo
but again this insufficient to obtain significance (p=0.115).
These patterns point to very modest improvements in insulin resistance in this
group after metformin treatment with most parameters moving in a favourable
direction but only 2-hour post glucose load insulin reaching significant levels of
amelioration.
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2 : Effects of Metformin on Lipid Profile
The raw data are shown in the tables below for the metformin and placebo groups at
baseline and then post intervention.
Metformin group at baseline Metformin group post intervention
total chol trig LDL-C HDL-C
mmol/I mmol/I mmol/l mmoI/L
6.50 1.85 4.60 1.20
5.45 1.30 2.85 2.25
4.45 1.05 2.85 1.30
5.60 1.10 3.30 1.60
5.60 1.90 3.50 1.75
5.75 1.95 4.00 1.05
5.80 1.40 3.65 1.20
4.30 0.85 2.50 1.55
5.40 2.20 3.25 1.30
4.30 1.00 2.55 1.55
6.55 0.75 4.15 1.85
6.30 1.40 3.60 2.05
4.30 2.15 2.70 0.80
4.55 0.85 2.75 1.50
5.80 1.60 3.80 1.80
5.10 1.60 3.40 1.05
3.50 1.70 1.70 1.40
4.65 1.25 2.95 1.35
3.90 1.15 2.55 0.85
3.65 1.15 2.15 1.10
3.90 0.80 2.35 1.25
4.20 1.00 2.55 1.30
4.10 1.00 2.65 1.15
4.30 2.70 2.25 1.35
total chol trig LDL-C HDL-C
mmol/l mmol/l mmol/l mmol/L
5.70 1.60 4.05 1.25
4.75 1.55 2.40 2.20
4.15 0.85 2.30 1.50
4.75 0.70 2.80 1.80
6.05 2.20 3.35 1.90
6.85 1.95 4.85 1.25
5.50 0.90 3.45 1.90
4.80 0.85 2.75 1.90
4.90 1.20 3.35 1.45
4.85 0.75 2.95 1.55
6.50 0.90 4.45 2.00
5.40 1.00 2.80 2.25
3.55 1.35 2.20 0.95
3.50 0.90 1.95 1.30
5.50 1.35 3.20 1.90
5.30 1.85 3.55 1.10
4.95 2.10 2.90 1.35
5.70 1.25 3.65 1.35
4.30 1.25 3.00 0.90
4.90 1.70 3.00 1.35
3.40 0.80 1.98 1.05
3.85 0.85 2.15 1.20
4.30 1.25 2.60 1.25
4.35 2.00 2.45 1.50
Placebo group at baseline Placebo group post intervention
total chol trig LDL-C HDL-C
mmol/l mmol/l mmol/l mmol/L
5.45 1.20 3.75 1.45
6.95 1.60 5.10 1.45
3.45 1.25 2.10 1.05
5.75 1.65 4.15 1.15
4.80 0.90 2.90 1.50
4.75 1.30 3.30 1.40
5.25 2.90 3.00 1.10
4.75 1.45 3.20 1.30
4.20 1.20 2.80 1.20
5.90 0.70 4.15 1.45
4.15 1.10 2.60 1.20
3.45 1.40 1.35 1.80
5.65 0.85 3.95 1.20
4.45 0.95 2.70 1.50
4.70 1.05 3.00 1.35
4.60 1.70 3.00 1.20
5.20 3.30 3.15 0.95
3.60 0.90 2.30 1.15
5.25 1.55 2.45 2.40
4.55 1.10 2.95 1.10
7.60 17.70 1.30 0.75
3.70 1.40 2.25 1.10
total chol trig LDL-C HDL-C
mmol/l mmol/l mmol/l mmol/L
4.55 0.90 3.05 1.35
6.30 1.15 4.60 1.40
3.40 1.05 2.00 1.05
4.10 1.25 2.55 1.00
4.70 0.80 3.10 1.50
4.80 1.15 3.40 1.20
5.70 2.70 3.60 1.20
4.55 1.95 2.70 1.20
5.40 2.00 3.25 1.25
5.40 0.85 3.90 1.30
4.40 0.95 2.75 1.20
4.00 1.60 1.65 2.05
5.40 1.00 3.75 1.15
4.70 0.90 2.95 1.55
4.90 1.25 3.10 1.55
4.95 2.45 2.95 1.20
5.40 2.80 3.15 1.05
3.50 1.00 2.05 1.15
5.20 0.90 3.15 2.20
3.70 1.15 2.35 1.10
6.20 10.20 1.75 1.00
4.15 1.30 2.55 1.35
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Beta-quant analysis was undertaken in the fasting state pre and post treatment with
placebo and metformin. Before and after data are shown for these with respect to
placebo and metformin in table 7.7 below and in the boxplots following.
As described earlier, triglyceride values required log transformation to achieve
normality but the other lipid variables did not.
Table 7.7: showing mean change in lipid data before and after intervention
fMean +/- standard error ofmean











Total cholesterol 4.91 +/-0.19 4.91 +/-0.18 ns -0.006+/- 0.15 4.92 +/- 0.22 4.79+/-0.17 ns -0.125+/-0.14 ns
(mmol/L)
Triglycerides 0.121 +/-0.03 0.086 +/- 0.03 ns -0.036 +/- 0.02 0.166+/-0.062 0.148+/-0.054 ns -0.02 +/- 0.025 ns
(log mmol/L)
LDL-cholesterol 3.03 +/-0.14 3.01 +/-0.15 ns -0.020+/-0.11 2.98+/-0.19 2.92+/-0.15 ns -0.05+/-0.11 ns
(mmol/L)
HDL-cholesterol 1.40 +/- 0.07 1.51 +/-0.08 0.009 +0.11 +/-0.04 1.31 +/-0.07 1.32 +/- 0.07 ns +0.01 +/-0.03 0.049
(mmol/L)
Boxplot of Total Cholesterol Boxplot of Triglycerides
fLoa Transformed')





















i I i i
Baseline Treatment Baseline Treatment
Analysis of Lipid Data
No appreciable difference was seen in either total or LDL-cholesterol after metformin
treatment. However, HDL-cholesterol did increase significantly on average by almost
8% (p=0.009) compared to an average increase of less than 1% in those taking
placebo. The difference in change between the 2 groups also just achieved statistical
significance for HDL-cholesterol (p=0.049). A favourable trend also emerged from
log-transformed triglyceride analysis with an average reduction ofjust over 29% in
those receiving metformin compared to a reduction of approximately 11% in those
taking placebo. These reductions were not statistically significant.
From the women treated with metformin, 13 out of 24 (54%) were on a statin prior to
and during the trial. This compares with 7 out of 22 (32%) for the placebo-treated
women. These differences as judged by 2x2 chi-squared test are not significant
(p=0.127).
From these data significant increases in HDL-cholesterol were seen in the
metformin-treated group with a favourable trend emerging from the triglyceride
data. No appreciable change is seen in total or LDL-cholesterol. This is despite
no significant difference in statin usage between the groups.
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3 : Effects of Metformin on Serum Endothelial Markers
The raw data are shown in the tables below for the metformin and placebo groups at
baseline and then post intervention.
letformin group at baseline Metformin group post intervention
vWF tPA ICAM VCAM D-dimer
% ng/L ng/ml ng/l units
247 9.2 283.4 308.7 67
138 4.3 250.9 234.7 85
210 5.9 284.3 383.7 67
103 5.3 300.2 456.9 47
131 2.0 185.8 247.2 47
95 6.7 233.6 352.2 84
171 12.1 284.7 396.4 422
163 6.5 283.4 587.6 103
124 10.5 439.8 302.5 38
123 3.8 220.1 444.6 83
121 4.9 201.3 279.2 56
128 6.5 126
168 13.1 362.0 380.6 62
196 10.5 262.2 392.9 109
57 4.3 206.0 300.1 101
141 9.9 405.7 348.2 84
73 7.4 266.1 279.2 31
66 6.3 202.1 327.5 59
178 10.0 196.5 323.1 56
95 9.6 196.8 239.5 165
137 3.8 309.9 488.9 32
67 6.4 230.6 395.6 110
100 11.2 190.4 269.6 353











240 6.6 237.9 400.5 80
132 2.8 209.4 271.8 63
194 4.6 263.2 341.4 86
110 5.8 308.9 412.9 43
134 2.7 187.9 273.2 37
89 5.2 231.7 332.3 75
194 9.5 245.6 408.6 335
144 4.8 211.6 320.3 1019
94 6.0 491.3 347.2 45
116 3.9 197.0 429.4 108
110 3.8 205.9 270.2 46
148 7.1 315.6 415.2 82
167 7.1 263.9 265.2 100
51 2.2 204.5 211.5 63
118 8.2 416.9 423.5 99
73 7.4 257.2 310.0 28
74 5.6 178.4 398.3 34
173 9.8 219.9 264.6 60
98 5.8 206.6 207.0 183
123 4.1 257.8 432.5 41
83 6.1 213.4 392.3 102
111 11.1 284.8 546.3 302
65 7.7 251.1 420.5 90
lacebo group at baseline Placebo group post intervention
vWF tPA ICAM VCAM D-dimer vWF tPA ICAM VCAM D-dimer
% ng/L ng/ml ng/I units % ng/L ng/ml ng/l units
130 9.6 229.2 298.2 61 120 8.7 211.1 291.1 57
131 6.7 180.4 230.4 38 110 6.0 186.7 280.5 30
128 11.3 289.8 394.9 64 98 10.1 263.1 380.5 57
165 11.6 222.3 259.8 47 141 7.5 208.5 359.2 52
156 6.7 216.1 272.2 24 147 6.1 214.3 303.3 27
117 6.9 241.3 238.4 112 92 8.5 231.3 261.5 126
170 7.7 293.3 288.8 68 205 8.7 251.1 315.9 59
148 4.0 261.5 270.6 84 158 5.7 246.8 285.2 108
91 14.7 284.0 352.1 174 110 21.7 277.8 349.1 121
136 6.2 161.6 305.7 48 136 3.1 176.7 248.9 61
88 7.0 228.2 352.2 106 85 8.9 264.2 353.6 60
158 7.0 176.4 374.9 34 143 7.7 185.4 359.8 48
107 10.0 213.1 293.7 45 111 5.6 287.8 280.4 78
141 6.5 179.1 347.2 222 148 6.6 172.8 315.6 167
96 7.9 221.5 390.3 117 104 4.2 213.8 365.2 45
101 9.9 202.9 240.9 194 70 6.5 218.6 249.6 130
140 12.8 259.3 258.6 86 117 13.8 262.6 289.5 71
109 6.7 212.4 374.4 64 108 7.4 195.0 318.5 54
171 12.1 228.1 325.3 163 121 15.0 243.3 351.2 86
184 7.4 438.4 589.0 268 140 7.6 404.7 471.5 62
55 8.0 294.7 408.8 52 53 9.5 281.1 363.6 45
301 10.4 265.2 335.4 51 99 11.0 302.9 315.0 55
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Venous samples were obtained in the fasting state pre and post treatment with placebo
and metformin. Before and after data are shown in table 7.8 for these with respect to
placebo and metformin with boxplots thereafter. As described in the methods section,
all endothelial markers except tPA required log transformation to become normally
distributed.
Table 7.8: showing mean change in serum endothelial cell marker data before and after intervention
fMean +/- standard error ofmean











vWF 2.078 +/- 0.037 2.062 +/- 0.034 ns -0.016+/-0.01 2.115+/-0.031 2.059 +/- 0.027 0.036 -0.056 +/- 0.025 ns
dog units)
tPA 7.404 +/- 0.60 5.996 +/- 0.48 0.001 -1.448 +/-0.36 8.686 +/- 0.56 8.632+/-0.86 ns -0.055 +/- 0.562 0.045
(units)
I-CAM 2.409+/-0.022 2.392 +/- 0.022 ns -0.017 +/-0.01 2.371 +/- 0.020 2.373+/- 0.019 ns + 0.002+/-0.01 ns
(log units)
V-CAM 2.538 +/- 0.022 2.534 +/- 0.023 ns -0.005 +/- 0.02 2.504+/-0.021 2.504+/-0.014 ns +0.000+/-0.01 ns
(log units)
D-dimer 1.910+/-0.057 1.930 +/- 0.075 ns +0.028 +/- 0.05 1.894 +/- 0.060 1.816+/-0.043 ns -0.078 +/- 0.042 ns
(log units)
















































Analysis of Serum Endothelial Marker Data
Only tPA showed a significant change after treatment with metformin - a reduction of
19% compared to little appreciable change in the placebo-treated group. Although
tPA also showed a non-significant decrease in the placebo group, the difference
between the change in the 2 groups for tPA also achieved statistical significance
(p=0.045). Weak trends towards reduction were seen with log-transformed vWF and
I-CAM although for some of these parameters similar trends towards a decrease were
observed in the placebo-treated group.
Of note, there was a significant decrease in vWF of approximately 3% after placebo
(p=0.036). The reason for this is unclear but likely reflects statistical variability due to
the relatively small group sizes.
Only tPA showed a significant downward difference after treatment with
metformin.
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4 : Effects of Metformin on Blood Pressure
The raw data for the averaged blood pressures are shown in the tables below for the
metformin and placebo groups at baseline and then post intervention.
Metformin group
Systolic Systolic Diastolic Diastolic
BP BP BP BP
Baseline Post Baseline Post
mmHg inmllg mmllg nimHg
126 139 75 77
111 116 73 69
128 118 79 71
156 145 85 79
151 134 87 69
121 138 71 78
176 183 103 106
136 114 82 74
143 134 76 78
127 123 85 85
133 143 74 97
137 141 92 87
110 95 67 55
148 141 77 80
153 155 83 87
129 117 82 64
92 101 70 77
152 149 85 82
121 127 72 70
142 126 90 90
112 107 71 83
103 95 75 59
111 117 73 72
133 118 82 74
Placebo group
Systolic Systolic Diastolic Diastolic
BP BP BP BP
Baseline Post Baseline Post
mmHg mmHg mmHg mmHg
135 126 86 82
99 121 67 70
139 105 67 63
135 125 97 80
134 119 75 64
157 253 93 86
146 138 78 75
119 114 73 73
148 119 87 78
149 151 85 82
140 135 87 79
160 153 85 83
108 104 69 65
123 116 76 69
125 138 70 74
144 137 87 84
141 137 72 78
119 133 75 88
144 135 98 91
141 126 73 84
146 151 91 94
115 107 70 73
252
Averaged systolic and diastolic measurements made before and after administration of
metformin or placebo. Before and after data are shown in table 7.9 with boxplots
thereafter.
Table 7.9: showing mean change in blood pressure before and after intervention
'Mean +/- standard error ofmean











Systolic BP 131.3+/-4.0 128.2 +/-4.1 ns -3.1 +1-22 134.9+/-3.3 133.8+/-6.4 ns -1.1 +/- 5.3 ns
(mmHg)
Diastolic BP 79.5 +/-1.7 77.6 +/- 2.3 ns -1.9+/- 1.9 80.0+/-2.1 78.0+/- 1.8 ns -2.1 +/- 1.5 ns
(mmHg)














Boxplot of Diastolic Blood Pressure
Baseline Treatment Baseline Treatment
Analysis of Blood Pressure Data
Small downward trends are observed for both systolic and diastolic blood pressure in
those treated with metformin and placebo. No difference achieved statistical
significance, nor did the difference between the changes in respective groups. In
summary, no significant effect on blood pressure was observed with metformin
treatment.
253
5 : Effects of Metformin on C-Reactive Protein
The raw data are shown in the tables below for the metformin and placebo groups at
baseline and then post intervention.






















































Venous samples were obtained in the fasting state before and after treatment with
metformin/placebo and analysed for high sensitivity C-reactive protein, as a measure
of levels of inflammation. Before and after data are shown in table 7.10 with boxplots
thereafter. CRP data required log transformation in order to be distributed normally.
Table 7.10: showing mean change in C-reactive protein before and after intervention























0.445+/-0.061 0.425 +/- 0.090 ns -0.013 +/-0.05 0.501 +/-0.13 0.463+/-0.12 ns -0.038 +/- 0.05 ns








Baseline Treatment Baseline Treatment
Analysis of CRP data
There appears to be no significant effect of metformin on CRP with a small average
fall (3%) in the log-transformed values compared to an almost 8% reduction after
placebo. There is no significant difference between the changes seen in both groups.
In summary metformin appears to have no significant effect on CRP after 8
weeks of treatment.
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6 : Effect of Metformin on Anthropometric Variables
The raw data are shown in the tables below for the metformin and placebo groups at
baseline and then post intervention.
Metformin group at baseline Metformin group post intervention
Waist W:H Weight BMI Leptin
(cm) ratio (kg) (Kg/m2) (ng/ml)
85.0 0.83 62.0 25.00 37.9
82.0 0.75 69.0 25.70 28.8
69.0 0.7 59.0 23.60 19.3
92.0 0.79 81.0 29.60 35.4
90.0 0.83 70.0 32.20 40.8
78.0 0.76 65.0 24.50 23.4
79.0 0.77 69.0 28.40 23.7
91.0 0.76 80.0 34.20 44.8
77.0 0.78 58.0 24.50 24.8
82.0 0.79 66.0 27.10 44.9
77.0 0.77 65.0 25.20 31.9
102.0 0.85 88.0 37.10 36.4
89.0 0.82 68.0 25.80 16.9
85.0 0.83 65.0 27.90 57.7
87.0 0.85 72.0 27.20 29.7
99.0 0.85 83.0 31.80 41.6
85.0 0.79 71.0 25.40 29.4
76.0 0.76 61.0 23.60 11.2
90.0 0.77 75.0 27.00 38.2
83.0 0.78 73.0 29.40 28.5
84.0 0.75 79.0 32.00 50.9
87.0 0.76 88.0 34.40 52.5
83.0 0.88 62.0 23.00 48.6
100.0 0.76 92.0 34.70 60.6
Waist W:H ratio Weight BMI Leptin
(cm) (kg) (Kg/m2) (ng/ml)
82.0 0.83 65.0 27.06 25.5
79.0 0.72 70.0 25.71 25.6
69.0 0.8 57.0 22.55 14.8
93.0 0.81 79.0 28.33 35.4
84.0 0.8 70.0 31.11 33.4
81.0 0.78 66.0 24.84 25.5
83.0 0.78 67.5 27.38 11.8
92.0 0.75 81.5 33.06 59.8
83.0 0.85 59.0 23.94 26.8
84.0 0.8 67.0 27.53 55.2
80.0 0.79 65.5 25.27 40.1
109.0 0.89 87.0 37.41
85.0 0.79 67.0 24.91 20.4
80.5 0.82 63.0 27.27 26.5
84.0 0.84 69.0 26.29 18.6
91.0 0.8 80.5 31.06 34.4
85.0 0.79 72.5 26.63 28.4
74.0 0.76 62.5 24.57 9.9
86.0 0.79 72.5 26.63 29.2
81.0 0.76 71.5 28.82 33
89.5 0.84 80.0 31.25 53.7
86.0 0.74 85.5 33.19 57.5
82.0 0.87 60.5 22.63 39.4
97.0 0.74 90.5 34.70 61.8
Placebo group at baseline Placebo group post intervention
Waist W:H Weight BMI Leptin Waist W:H ratio Weight BMI Leptin
(cm) ratio (kg) (Kg/m2) (ng/ml) (cm) (kg) (Kg/m2) (ng/ml)
100.0 0.85 74.0 29.80 58.4 97.0 0.83 77.0 31.64 62.7
78.0 0.73 66.0 26.40 28.7 89.0 0.83 67.5 27.74 31.6
112.0 0.99 82.0 37.20 60.2 115.0 0.96 85.0 39.34 69.6
96.0 0.79 85.0 33.20 49.9 100.0 0.83 83.0 33.67 33.3
70.0 0.73 55.0 21.60 24.2 75.0 0.77 56.0 22.15 25.9
81.0 0.72 76.0 30.40 38.4 81.0 0.73 76.5 29.51 25.6
103.0 0.87 87.0 34.90 38.0 97.0 0.82 88.0 34.81 46.5
82.0 0.78 70.0 25.50 37.0 79.0 0.77 69.0 25.34 32.4
89.0 0.81 78.0 28.80 44.3 91.0 0.84 77.0 29.34 51.3
83.0 0.84 64.0 23.40 15.3 83.0 0.84 65.5 24.06 17.3
80.0 0.78 66.0 27.60 30.7 82.0 0.80 65.5 27.26 38.1
79.0 0.78 58.0 25.10 41.3 82.0 0.80 59.5 25.42 39.8
89.0 0.84 80.0 28.70 47.7 92.0 0.86 79.0 29.02 42.1
91.0 0.81 77.0 26.60 36.9 87.0 0.81 78.5 27.16 32.6
91.0 0.79 73.0 28.50 21.3 90.0 0.79 75.0 28.93 32.6
89.0 0.80 79.0 27.70 21.9 87.0 0.80 80.0 28.18 16.5
87.0 0.80 68.0 26.20 51.0 85.0 0.79 67.0 25.85 46.6
79.0 0.79 65.0 26.70 46.4 80.0 0.81 65.5 26.57 43.7
122.0 0.86 102.0 43.70 49.8 120.5 0.84 104.0 43.85 57.9
86.0 0.84 68.0 27.70 26.8 94.0 0.87 70.0 29.14 38.9
92.0 0.82 74.0 27.90 32.6 92.0 0.82 75.0 27.89 34.6
102.0 0.86 82.0 35.30 52.2 101.0 0.86 82.5 35.71 46.4
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Venous samples were obtained in the fasting state pre and post treatment with placebo
and metformin and analysed for leptin. Anthropometric measurements were also
made pre and post metformin/placebo. Before and after data are shown in table 7.11
for these with respect to placebo and metformin with boxplots thereafter.
Table 7.11: showing mean change in anthropometric data and serum leptin before and after intervention
fMean +/- standard error ofmean











Waist 85.5 +/- 1.62 85.0 +/- 1.60 ns -0.5+/-0.79 90.05 +/- 2.58 90.89 +/- 2.39 ns +0.84+/-0.84 ns
lem)
Waist:Hip Ratio 0.79 +/- 0.009 0.80 +/- 0.009 ns +0.007+/-0.008 0.81 +/-0.012 0.82+/-0.010 ns +0.009 +/- 0.006 ns
lunits)
Weight 71.71 +/- 1.97 71.23 +/- 1.87 ns -0.48 +/- 0.35 74.05 +/- 2.23 74.82+/-2.25 0.015 +0.77 +/- 0.29 0.008
Kg)
3ody Mass Index 28.30+/-0.83 28.01 +/- 0.79 ns -0.30+/-0.17 29.22 +/- 1.06 29.66 +/- 1.09 0.01 +0.44+/-0.15 0.003
Kg/m2)
^eptin 35.75+/-2.64 33.33 +/-3.18 ns -2.38+/-2.01 38.77 +/- 2.67 39.36+/-2.86 ns +0.59+/- 1.64 ns
ng/ml)
Boxplot of Waist Measurements
i.o -r















Baseline Treatment Baseline Treatment
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Analysis of Anthropometric Data and Leptin
There is no statistically significant change in any of the anthropometric data after
treatment with metformin. However, several non-significant trends have emerged.
Waist circumference was reduced by an average of 0.5cm approximately in both the
placebo and metformin-treated groups and W:H ratio fell slightly in both groups also.
Treatment with metformin reduced body mass by an average of approximately 0.5kg
over 8 weeks compared to an average increase of approximately 0.8kg in the placebo-
treated group. This increase in weight in the placebo group was actually statistically
significant and was the driving factor behind the difference in mean change in weight
being statistically significant between the groups (p=0.008). This change in body
mass affected the BMI with a small non-significant fall for the metformin group
compared to a statistically significant increase in the placebo-treated group (p=0.01).
Again this increase in the placebo group drove the difference in change between the
groups to statistical significance (p=0.003).
The reasons behind the significant weight gain and increase in BMI in the placebo-
group are unclear.
Leptin was reduced by almost 7% in the metformin group (non-significant) compared
to a increase of 1.5% in the placebo group. These trends in leptin are not surprising as
serum leptin is known to be correlated to body fat mass.
These figures suggest favourable trends with metformin treatment. Modest reductions
occurred in total body mass and leptin (related to fat mass) although it is likely that
our sample sizes were insufficiently powered to prove these trends statistically
significant.
In summary, metformin treatment was not associated with any significant
changes in weight, waist, BMI or leptin but favourable trends towards a
reduction in total body and fat mass were seen.
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Summary
Metformin is an insulin sensitiser that had a number of actions primarily on the liver.
It is fairly well tolerated and of the 27 women randomised to metformin, 24
completed the 8 week trial, compared to 22 of the 29 women randomised to placebo.
The main side-effect was mild gastro-intestinal upset. There was a small increase in
lactate in both groups and the magnitude of this rise was similar between the
metformin and placebo groups. The reason for the increase in lactate in the placebo
group is not clear.
The 22 women in the placebo group were well matched to the 24 women in the
metformin group in terms of baseline characteristics and baseline measured variables.
The only statistically significant difference was that more women in the metformin
group were taking calcium-channel blockers during the trial compared to the placebo
group (4 out of 24 compared to 0 out of 22). The effect of this on the results is unclear
but there is no data to show that calcium channel antagonism affects any of the
variables measured.
The insulin/glucose data did point to some modest increases in insulin sensitivity.
Although there were not any differences in glucose tolerance, there were important
changes in the insulin levels. There were downward trends in measured insulin levels
at all 3 points in the oral glucose tolerance test (OGTT), suggesting improved insulin
sensitivity. The reduction in insulin became significant at the 120min point of the
OGTT but there was a significant difference in the change between the metformin and
placebo groups at the fasting sample. No trends emerged within the quicki index,
which likely reflects that glucose is taken into account when calculating this index.
The lipid data did show a highly significant increase in HDL-cholesterol in the
metformin group with no discernable trend seen in the other lipid variables measured.
Looking at the serum endothelial markers, there was a trend towards lower vWF after
metformin (as in the placebo group also) but there was a highly significant reduction
in tPA. No trends of any importance were seen with I-CAM, V-CAM or d-dimer.
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There was a small trend towards lower blood pressure after metformin, which was
most evident in the systolic pressure but no statistical significance was reached.
Similarly, there was a minor trend towards lower C-reactive protein with metformin
(and also in the placebo group) but statistical significance was not achieved. In terms
of the anthropometric data, there was a reduction in weight of approx 0.5kg in the
metformin group leading to a reduction in BMI of approximately 0.3 kg/m2. Although
these changes did not reach statistical significance in themselves, there was a highly
significant difference when the change in weight and BMI were compared between
the metformin and placebo groups. There was a reduction in serum leptin within the
metformin group but again, the magnitude was not quite large enough to reach
statistical significance.
These data are summarised in table 7.12 overleaf. Modest amelioration of insulin
resistance was seen with metformin along with some weight reduction and small
improvements in some other features of the metabolic syndrome (HDL-cholesterol
and trends for blood pressure) as well as some serum markers of endothelial function
(tPA and trends for vWF).
Chapter eight goes on to look at the effects of metformin on measures of peripheral
microvascular function and clinical measures of ischaemic burden.
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Table 7.12 : Summary of changes seen in variables measured in the metformin and placebo
groups over the course of the trial (p values shown).
Difference
Variable Metformin Placebo between
n=24 n=22 change
fasting glucose ns ns ns
60 min glucose ns ns ns
120 min glucose ns ns ns
fasting insulin ns ns 0.036
60 min insulin ns ns ns
120 min insulin 0.019 ns ns
fasting quicki index ns ns ns
60 min quicki index ns ns ns
120 min quicki index ns ns ns
fasting NEFA ns ns ns
60 min NEFA 0.019 ns 0.012
120 min NEFA ns ns ns
Total Cholesterol (mmol/L) ns ns ns
Triglycerides (mmol/L) ns ns ns
LDL-cholesterol (mmol/L) ns ns ns
HDL-cholesterol (mmol/L) 0.009 ns 0.049
Von Willebrand Factor ns 0.036 ns
Tissue plasminogen activator 0.001 ns 0.045
D-Dimer ns ns ns
I-CAM ns ns ns
V-CAM ns ns ns
Systolic blood pressure (mmHg) ns ns ns
Diastolic blood pressure (mmHg) ns ns ns
Waist (cm) ns ns ns
Waist: Hip ratio ns ns ns
Weight (kg) ns 0.015 0.008
Body Mass Index (kg/m2) ns 0.01 0.003
Leptin ns ns ns
C-reactive protein ns ns ns
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Effects of Metformin on Peripheral Microvascular Function and




It has been demonstrated that women with cardiac 'Syndrome X' have impaired
peripheral microvascular function compared to healthy controls. Furthermore, in the last
chapter the effects of metformin on various metabolic and anthropometric measures were
compared to placebo. The rationale for this part of the double-blinded placebo-controlled
trial was to determine whether metformin, as an insulin-sensitising modality, would have
any effect on:
• Peripheral microvascular function (endothelium-dependent and independent)
• Measures of ischaemic burden
Chest pain episodes and GTN use
Indices of ischaemia derived from exercise tolerance testing
The theoretical background and the mechanisms of metformin action have been dealt
with in chapter 7 along with the tolerability data and the effects on lactate.
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Baseline Results
The baseline characteristics of the subjects who completed the trial in both the metformin
group (n=24) and the placebo group (n=22) were well-matched at baseline and these data
are presented in chapter 7. The only statistical difference was that 4 women in the
metformin group were taking calcium channel blockers compared to none within the
placebo group, despite attempts to minimise anti-anginal use.
Characteristics of Metformin-treated Group and Placebo-treated Group
Table 1. Clinical characteristics of the metformin andplacebo group at baseline.
'
mean +/- standard deviation.
Metformin Placebo
n=24 n=22 P value
Chest pain index (episodes/day) 0.45 +/- 0.57^ 0.58 +/- 0.91 ^ NS
GTN use index (usage/day) 0.26 +/- 0.06+/-0.11' 0.045
Treadmill exercise time (mins) 6.08 +/- 1.55^ 6.17+/-2.08^ NS
Maximal ST depression (mm) 1.5 +/- 1.2^ 1.2 +/- l.C NS
Duke Score -5.42+/-7.6^ -1.86+/-6.6f NS
The above table illustrates that the group randomised to receive metformin were well
matched with the group randomised to receive placebo. This is with the exception that the
metformin group had a statistically significantly higher frequency of GTN use at




The results for microvascular function and ischaemic measures before and after
metformin and placebo are presented in the following pages.
The raw data are shown in a table for both the metformin and placebo groups.
Subsequently, the outcomes are first shown in tabular form with the mean and standard
error of mean (SEM) shown at baseline and after the 8 weeks of intervention with either
metformin or placebo. The statistical significance of the change is shown next to each set
of measurements. Statistical non-significance is represented by 'ns' whereas the p valve
for any significant change is shown.
Additionally, the change for each variable, before and after intervention, was calculated
for all of the women in both groups, and the difference between this change was looked
at. The difference was compared statistically between the groups, using a 2-sample t-test,
and this result is shown in the last column of each table. Again 'ns' is simply used to
imply that the difference in the mean change between the groups is not statistically
significant, with a p valve being presented only when the difference achieved statistical
significance.
Finally a boxplot is shown for the important variables measured with the central bar
representing the mean and the box representing the standard deviation of the data set.
Metformin-treated subjects are displayed adjacent to their placebo-treated counterparts.
This is shown to more graphically illustrate the change in variables measured before and
after intervention. Bar charts and line charts are used to illustrate any additional data.
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1 : Effect of Metformin on LDI Microvascular Function
The raw data are shown in the tables below for the metformin and placebo groups at
baseline and then post intervention.





5322 18008 3487 11799
961 7200 1228 9200
1128 6830 1598 9676
2032 8766 1019 4396
3243 4809 1378 2043
1265 7825 872 5394
1866 7013 2154 8095
1406 8929 1380 8764
910 3444 1195 4523
1327 8651 1593 10385
4180 26312 1243 7824
1087 8600 928 7342
1767 10885 1322 8144
1544 8760 1539 8732
1061 3630 1484 5077
1106 4026 1260 4586
1848 13229 1487 10645
986 3836 710 2762
817 6364 574 4471
1192 5850 775 3803
1404 7813 884 4919
1185 8479 1260 9016
754 8167 793 8589





4240 12593 3124 9278
1255 7806 1659 10319
2482 11442 2049 9446
2224 10520 1302 6158
3612 19252 1343 7158
1242 6819 1122 6160
1127 4948 1133 4974
2031 8307 1464 5988
3466 15042 1599 6940
1590 12831 1121 9046
3994 22047 1822 10057
1957 10353 819 4333
1914 19092 1455 14514
1277 8224 695 4476
880 3238 974 3584
2162 13540 1101 6895
2124 18479 1017 8848
1418 9330 938 6172
1082 10084 954 8891
1390 8590 1211 7484
1476 6539 1009 4470
2624 10207 2341 9106
1485 6074 1359 5558
1624 8494 1936 10125









1400 11194 954 7628 2291 12005 1362 7137
1105 15135 1028 14080 1094 13938 1035 13186
2586 14264 1340 7391 2538 12995 1614 8264
1388 7123 886 4547 1538 8597 1543 8625
1136 8889 1482 11596 1213 9668 895 7133
1351 6285 761 3540 759 3909 1169 6020
1808 7503 2244 9312 1672 13493 1649 13307
1647 8543 1672 8673 1672 10918 939 6132
1341 14179 1008 10658 1464 7071 1374 6636
526 4651 646 5712 1463 7169 1649 8080
2699 20008 1674 12410 1529 11330 1258 9322
815 5467 692 4642 1353 10188 871 6559
776 5631 1484 10769 1036 7107 893 6126
864 4809 940 5232 1982 4995 769 1938
2462 18926 1541 11846 2485 18911 1208 9193
1359 7366 2749 14845 1173 5114 1464 6383
1212 12666 1004 10492 2934 16636 2129 12071
1051 10362 1370 13507 734 6980 573 5449
764 3078 1117 4500 1363 5779 2425 10282
1533 13939 1091 9917 1459 9119 1418 8863
1380 8416 858 5233 1419 6939 732 3579
973 6568 951 6419 857 4928 1113 6400
:i - resistance time integral (see chapter 5)
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The peripheral microvascular perfusion response data 'area under the curve' (AUC) for
ACh and SNP are shown below in table 8.1, both in its raw form and corrected for the
skin resistance. These were the 2 most consistent and reproducible ways of representing
this data, as demonstrated in chapter 5. Log transformation was required so that the data
are normally distributed.
Table 8.1: showing mean change in LDI* microvascular response to ACh and SNP before and after intervention
























3.15+/- 0.044 3.27+/-0.038 0.005 +0.113+/-0.036 3.10+/-0.038 3.16+/-0.034 ns +0.059+/-0.040 ns
ACh (RTI)
erfusion units)
3.89 +/- 0.043 4.00+/-0.040 0.025 +0.113+/-0.047 3.94 +/- 0.045 3.94 +/- 0.039 ns -0.004+/-0.036 ns
SNP (raw)
erfusion units)
3.07+/- 0.034 3.12+/-0.031 ns +0.039+/-0.035 3.07+/-0.034 3.08+/-0.033 ns +0.013+/-0.046 ns
SNP (RTI)
erfusion units)
3.81 +/-0.041 3.85+/-0.030 ns +0.040+/-0.043 3.91 +/-0.040 3.86+/-0.039 ns -0.049+/-0.046 ns
* LDI - laser Doppler imaging
Following the boxplots, there are line charts showing mean ACh and SNP perfusion
response for the entire group. Value at each data point is a mean of each data point within
the group and Standard Error of the Mean (SEM) is shown by the vertical bars. The
values shown are corrected for resistance-time integral as detailed in chapter 5, as this
corrects for differences in cutaneous drug delivery and serves to make the results more
reproducible.
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Figure 1 : Line chart showing mean perfusion response
—♦— ACh pre
—ACh post
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Figure 2 : Line chart showing mean perfusion response
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Figure 3 : Line chart showing mean perfusion response
—♦— SNP pre
—■— SNP post
Chart showing Perfusion Response to SNP Before and After Metformin
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Analysis of Microvascular Function Data
After treatment with metformin for 8 weeks, significant improvements in endothelial-
dependent indices of peripheral microvascular function were seen. This is demonstrated
by the increased LDI perfusion response to ACh manifested in both the raw data
(p=0.005) and in the data corrected for the skin resistance (p=0.025). The difference
before and after treatment was attenuated after correction for skin resistance (as reflected
in the higher p value), but none-the-less remained statistically significant.
No difference before and after placebo was observed with a tendency towards
improvement seen in the raw data, but virtually no difference after correction for skin
resistance (p=0.924). These data were presented in chapter 5 where the temporal
reproducibility of the laser Doppler imaging technique has been discussed.
The line charts in figures 1 and 2 mirror these results. The lines representing perfusion
response to ACh before and after metformin (figure 1) are widely separated and the bars
representing the standard error of the mean (SEM) are also separated by the time the
current reaches lOmamp, and remain separated until the current is switched off. In
contrast, the placebo curves (figure 2) are almost superimposed and certainly there is no
trend for the separation of the SEM bars, suggesting no difference in mean perfusion
response before and after metformin.
Statistically, no differences emerged in the SNP laser Doppler response after metformin
treatment with changes seen comparable to the placebo group. Again, this is borne out by
figures 3 and 4. Figure 3 shows the perfusion response to SNP before and after metformin
and the curves are almost identical with no separation of the SEM bars. After placebo the
curves are more widely apart, but this seems to reflect the difference in the resting
perfusion response (the baseline data points in figure 4 are separated). During the phase
of the curve when the iontophoresis current is active, the SEM bars are not separated and
they are only apart during the-phase of the curve at which no iontophoresis current is
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applied. This would tend to suggest that metformin had no appreciable effect on the
endothelium-independent pathways of microvascular vasodilatation - the vascular
smooth muscle response.
This is in agreement with the hypothesis that improvements in insulin resistance will
effect improvements in endothelial-dependent vasodilatory capacity via enhanced NO
production (amongst other intermediaries). It is interesting to note that the very modest
improvements in the indices of insulin resistance were seen in association with
improvements in endothelial-dependant microvascular function which were themselves
fairly modest.
In summary, improvements in ACh-mediated microvascular vasodilatation were
seen after 8 weeks of metformin therapy. No differences were seen in the SNP
(endothelium-independent) response.
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2 : Effects of Metformin on Measures of Ischaemic Burden
a) Chest Pain Frequency and GTN use
The raw data are shown in the tables below for the metformin and placebo groups at
baseline and then post intervention.
tformin pre Metformin post
est Pain GTN use Chest Pain GTN use
index Index Index Index
0.38 0.16 0.17 0.079
0.88 0 0.52 0
1.14 0 1.61 0
0.107 0.571 0 0
0.14 0 0.05 0.011
0 0 0 0
0 0 0.068 0.017
0.22 0.11 0.18 0.017
0.83 1.96 0.13 0.2
0.54 0.54 0.41 0.59
0.207 0 0.057 0.038
0.031 0 0 0
0.171 0.086 0.056 0
0 0 0.097 0.016
0.48 0.43 0.25 0.25
0 0 0.071 0
2.64 1.14 1.19 0.43
0.25 0.25 0.14 0.14
0.188 0 0.184 0
0.33 0.148 0.048 0.032
0.25 0 0.071 0.036
0.76 0.112 0.75 0.107
1 0.82 0.34 0.0714
0.312 0 0.0635 0
Placebo pre Placebo post
Chest Pain GTN use Chest Pain GTN use
Index Index Index Index
0.32 0 0.28










0 0 0.018 0.01
0.23 0.17 0.22 0.1
0.29 0.18 0.35 0.
0.86 0 0.21
0.071 0.071 0.054 0.03
0.303 0 0.412
0.93 0 1
0.24 0.12 0.161 0.10
0 0 0.21
0.0588 0 0.0794 0.079
0.2 0 0.109
The chest pain index, as discussed in the methods chapter, is a guide to the frequency of
chest pain and is essentially the number of episodes of anginal chest pain per day as
calculated by the total number of chest pain episodes recorded divided by the number of
days over which the diary was kept. A similar index for GTN usage is calculated in the
same way. Data are presented below in boxplot form before and after treatment with both
metformin and placebo.
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The data pertaining to the chest pain index and GTN use for the women in the metformin
and placebo groups are summarised below in table 8.2.
Table 8.2: showing mean change in chest pain index and GTN use before and after intervention
fMean +/- standard error ofmean













0.45+/-0.12 0.27 +/- 0.08 0.02 -0.18+/-0.07 0.58+/-0.19 0.41 +/-0.15 ns -0.17+/-0.09 ns
use Index
GTN/day)
0.26+/-0.10 0.08 +/- 0.30 0.042 -0.18+/-0.08 0.06 +/- 0.02 0.05 +/- 0.03 ns -0.002 +/- 0.008 0.045































b) Treadmill Test Performance
The raw data for total exercise time on the treadmill and maximal ST-segment depression
are shown in the tables below for the metformin and placebo groups at baseline and then
post intervention.
tformin pre Metformin post Placebo pre Placebo post
tl exercise ST-segment Total exercise ST-segment
time depression time depression
mins) (mm) (mins) (mm)
6.18 0 4.3 0
4.2 3.5 2.5 3.5
9.4 0 9.17 0
6.73 2.5 6.93 2
6.72 1 6.62 2
7.35 0.5 7.27 0
2.83 0.5 3.65 0
6.55 3 7.48 1.5
4.22 2.5 4.32 2
6.73 2.5 6.85 2
6.8 0.5 7.38 1
4.1 0 3.68 0
6.67 2.5 9.02 0
8.48 3 7.77 0.5
4.35 3.5 5.02 0
6.27 1.5 4.72 0.5
6.25 1.5 5.5 1.5
5.75 2.5 9.35 2.5
6.42 0 6.72 0
8.15 0.5 9.15 0
4.32 1 4.67 0.5
5.75 2 6.18 1
6.93 1 7.13 0.5
4.87 0.5 4.05 0.5
Total exercise ST-segment Total exercise ST-segment
time depression time depression
(mins) (mm) (mins) (mm)
3.77 1.5 3.77 1.5
5.05 0 5.13 0.5
9.22 0.5 9.22 0.5
7.25 1.5 8.4 1.5
9.48 2.5 9.17 3
6 1.5 6.58 1.5
1.77 0.5 2.22 0.5
6.33 3.5 6.17 2.5
7.5 1.5 9.92 0.5
6.42 3 7.47 3.5
9.75 0.5 9.58 1.5
5.88 0 3.95 0
5.5 0.5 4.12 0.5
6.98 1 4.78 1
6.57 0 6 0
8.73 3 9.2 3
4.6 1 6.3 1
2.87 0.5 3.73 1.5
4.93 0 4.8 0
5.07 3 5.05 3
4.53 1 1.72 2
7.43 0 7.5 0.5
All patients underwent treadmill testing before and after treatment with either metformin
or placebo. The total treadmill exercise time and the ST-segment depression were the
principle measures recorded. These results are summarised below in table 8.3 with
boxplots thereafter.
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Table 8.3: showing mean change in exercise time and ST-segment depression before and after intervention
























6.08 +/- 0.32 6.23 +/- 0.40 ns +0.14+/-0.24 6.17+/-0.44 6.13+/-0.52 ns -0.04 +/- 0.26 ns
ST-segment
ssion (mm)
1.50+/-0.24 0.90 +/- 0.20 0.008 1.21 +/-0.24 1.21 +/-0.24 1.34+/- 0.23 ns +0.14+/-0.11 0.003
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c) Duke Score
As described in the methods section, the Duke Score is a widely used scoring method
which is used to reflect the overall treadmill performance. It has been shown that the
Duke Score is correlated to mortality in patients with obstructive coronary disease.
These boxplots represent the Duke Score data. The Index is derived from :
• 0 - no chest pan on treadmill
• 1 - non-limiting chest pain on the treadmill
• 2 - Chest pain which limits exercise
The Duke score which reflects overall treadmill performance is then calculated by:
(Exercise time in mins) - (5 x Max ST-segment deviation) - (4 x index)
Raw data for the Duke Score are shown below for both groups
tin pre Metformin post Placebo pre Placebo post
X Duke Score Index Duke Score
2 -1.82 0 4.3
1 -17.3 I -19
1 5.4 0 9.17
0 -5.77 0 -3.07
1 -2.28 1 -7.38
0 4.85 0 7.27
1 -3.67 0 3.65
1 -12.45 1 -4.02
1 -12.28 0 -5.68
2 -13.77 2 -11.15
0 4.3 1 -1.62
1 0.1 0 3.68
1 -9.83 0 9.02
1 -10.52 0 5.27
2 -21.15 1 1.02
1 -5.23 1 -1.78
2 -9.25 0 -2
1 -10.75 1 -7.15
0 6.42 1 2.72
0 5.65 0 9.15
2 -8.68 1 -1.83
1 -8.25 1 -2.82
1 -2.07 1 0.63
1 -1.63 1 -2.45
Index Duke Score Index Duke Score
l -7.73 2 -11.73
0 5.05 1 -1.37
l 2.72 1 2.72
0 -0.25 0 0,9
0 -3.02 0 -5 83
1 -5.5 1 -4.92
0 -0.73 0 -0.28
1 -15.17 2 -14.33
2 -8 0 7.42
0 -8.58 1 -14.03
0 7.25 0 2.08
0 5.88 0 3.95
0 3 0 1.62
2 -6.02 2 -8.22
0 6.57 2 -2
0 -6.27 0 -5.8
1 -4.4 1 -2.7
0 0.37 1 -7.77
0 4.93 0 4,8
0 -9.93 0 -9.95
2 -8.47 1 -12.28
0 7.43 1 1
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This generally gives a score of between -18 and 12 with a more positive score correlating
with a better overall treadmill performance.
Worse Performance Better Performance
-18 0 +12
The data pertaining to the Duke Score for the women in the metformin and placebo
groups are summarised below in table 8.4 and thereafter represented in the boxplots and
bar charts below.
Table 8.4: showing mean change in Duke Score index and total Duke Score before and after intervention
fMean +/- standard error ofmean
Metformin Metformin Mean Placebo Placebo Mean Difference
group at group after P change group at group after P change between
baseline^ treatment^ baseline^ treatment'' mean chang
Score Index 1.0+/- 0.14 0.58+/-0.12 0.015 -0.42+/-0.16 0.50+/-0.16 0.73+/-0.16 ns +0.23+/-0.17 0.009
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Analysis of Angina/Treadmill Data
Significant changes are seen in the episodes of chest pain and GTN-use logged in the
patients diaries before and during treatment with metformin but not with placebo.
However a downward trend in the frequency of chest pain with placebo also occurs, just
missing out on statistical significance. This could mean at least part of the reduction in
chest pain frequency that occurred with metformin is due to increased medical contact
and hospital visits during the study. GTN-use also exhibited a downward trend in the
placebo-treated group and the statistical significance achieved in the metformin-treated
group may be in part due to a higher baseline GTN-usage in this group (0.26 Vs 0.05
equating to a difference of GTN use once every 4 days in the metformin group compared
to once every 20 days in the placebo group). The change seen in the metformin group
could be seen as simply regression to the mean, and the baseline differences between the
groups from this respect make the changes difficult to interpret.
The above measures were recorded in patient diary charts but none-the-less are fairly
subjective. More objective measures in symptoms and indices of ongoing myocardial
ischaemia are obtained from the treadmill test results. Although a minor increase in
exercise capacity is seen in the metformin-treated group (an average increase from 6'05
to 6'13) this was insufficient to obtain statistical significance. However, this compares
with a small fall on average in exercise capacity in the placebo-treated group. The index
based on chest pain during the test improved significantly in the metformin group but
deteriorated non-significantly in the placebo group. This also provides some measure of
amelioration in overall anginal symptoms.
ST-segment depression during exercise fell significantly after treatment with metformin
from an average of 1.5mm at baseline to less than 0.9mm after treatment (p=0.008). This
compares with a small increase on average in ST depression in the placebo-treated group
from approximately 1.2mm to 1.3mm. There were also significant changes in the Duke
Score after metformin treatment with an average increase in the score of over 5 (p=0.002)
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compared to the placebo group whose average Duke score fell by just over 1.5 but was
not significantly different from baseline.
In summary, there are weak subjective improvements with metformin in anginal
symptoms and GTN-use compared to placebo. More objective benefits on non¬
invasive markers of myocardial ischaemia were also seen with improvements in ST-
segment depression and Duke Score during treadmill testing. The objective
improvement in the chest pain index during the ETT with metformin, reinforce the
improvement in overall symptoms. However, although trends towards slightly






Insulin Resistance - Measurement, Aetiology and Link to Cardiovascular Disease
Insulin sensitivity is a physiological concept which essentially describes how efficiently
whole body insulin-medicated glucose uptake occurs in an individual. Insulin sensitivity
varies widely in populations along a spectrum. 'Insulin Resistance' is the term used to
describe individuals at one end of this spectrum where insulin-mediated glucose uptake is
particularly inefficient. Although it is not accurate to describe these individuals as having
'abnormal' insulin sensitivity, there is now good evidence that metabolism weighted in
this direction does have significant clinical repercussions.
Several well-established cardiovascular risk factors cluster around 'insulin resistance' -
including hypertension, dyslipidaemia, and central adiposity but even correcting for these
factors, there is now strong prospective evidence that hyperinsulinaemia, as a marker for
insulin resistance, confers at least a modest independent cardiovascular risk. This seems
to be mediated by accelerated atherogenesis and there are compelling data demonstrating
increased atheroma loads with relative insulin resistance, both in the coronary circulation
and more generally as manifest by ultrasound studies of the carotid arterial system.
The 'gold-standard' method for assessing insulin resistance is by actually measuring
insulin-mediated glucose uptake under hyperinsulinaemic conditions - the so called
hyperinsulinaemic euglycaemic clamp technique. This is a very cumbersome, invasive
and time-consuming method but there are data showing that less invasive methods based
around measuring serum insulin and/or glucose under fasting conditions or post glucose
load, correlate to some degree with clamp-derived indices of insulin resistance.
Specifically, the 'quicki index' which is based on both serum insulin and glucose and
which incorporates a logarithmic and reciprocal transformation in its calculation has been
shown to have good correlations to the clamp technique especially in the obese, insulin-
resistant populations studied.
Insulin signalling involves a complex intracellular network which is initiated by self-
phosphorylation of the insulin receptor after binding to insulin. This produces in turn
activation of phosphatidylinositol 3-kinase (PI 3-kinase) which appears to be a central
mediator of the intracellular effects of insulin. This intracellular cascade (which involves
some elements independent of PI-3 kinase also) culminates in the translocation of
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GLUT4 to the cell membrane which facilitates the transport of glucose across the cell
membrane (see chapter 1, figure 4). There are other intracellular roles of insulin which
are less well-understood, such as the effect on vascular tone and it seems that PI-3 kinase
has a crucial role in these also.
The aetiology of insulin resistance is multi-factorial in most cases although extreme
forms have been described in association with discrete mutations affecting part of the
post-receptor signalling cascade. There are several different mechanisms by which
insulin resistance may be promoted with genetic influences forming a background on
which environmental factors such as body fat distribution and systemic inflammation can
interact. However, it is clear that these influences do not act in isolation and it is likely
that they work together, with even the possibility of positive feed-back and amplification
once the processes to promote insulin resistance have been initiated.
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Cardiac Syndrome X -
Myocardial Ischaemia, Insulin Resistance and Vascular Dysfunction
It is known that vasomotor disturbances are present in atheromatous coronary arteries and
it is likely that this phenomenon contributes to myocardial ischaemia in patients with
obstructive disease. Patients with 'Syndrome X' have no obstructive coronary atheroma
and yet there is strong evidence that at least a subgroup of these patients have myocardial
ischaemia, as manifest by abnormalities in myocardial lactate metabolism (see table 2,
chapter 2) under stressor conditions.
There is a wealth of data demonstrating impaired coronary vascular responses under
stress, in this population with normal coronary arteries angiographically (see table 3,
chapter 2) and this is potentially the mechanism producing myocardial ischaemia in these
patients. Furthermore, there is evidence to show that there is a generalised impairment in
vascular function, which is not confined to the coronary vascular bed.
The weight of evidence in the literature shows that patients with 'Syndrome X' are
insulin-resistant compared to healthy controls and this may be the mechanism leading to
impaired vasodilator capacity. The vasodilating effects of insulin are well-described and
specifically, it is known that nitric oxide (NO) generation by the enzyme nitric oxide
synthase is coupled to insulin signalling. Other factors such as abnormalities of
endothelin-1 (a potent vasoconstrictor) and relative oestrogen deficiency (which also has
vascular effects) may also contribute to the abnormal vascular responses seen in patients
with 'Syndrome X'.
Groups who have studied patients with 'Syndrome X' have reported a female
predominance and a link to relative insulin resistance along with some other features of
the metabolic syndrome. This pattern fits with the potential aetiological mechanisms
discussed. Although these patients have angiographically unobstructed coronary arteries,
there is evidence that many have sub-angiographic atheromatous coronary plaques.
It is becoming clear that the prognosis in this group is not as benign as previously
thought. The burden of morbidity related to ongoing symptoms, recurrent hospital
admissions and even repeat coronary angiography is very significant. There are also
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reports of these patients sustaining myocardial infarction and cardiac death, although the
frequency of these adverse events are much lower than the group of patients with
obstructive cardiac disease.
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Metformin in Insulin Resistance and Syndrome X (MIRS) Study-
Trial Design and Methods
This was a randomised double-blind placebo controlled trial designed to examine the
difference in women with 'Syndrome X' and healthy controls at baseline. The effects of 8
weeks of metformin on metabolic, anthropometric, vascular and ischaemic measures
were assessed compared to placebo.
Female patients were recruited on the basis of a normal coronary angiogram between
1998-2001 and there were 71 subjects who fulfilled the entry requirements of this trial in
having a documented exercise tolerance test showing at least 1mm of flat ST-segment
depression. The main exclusion criteria were diabetes, uncontrolled hypertension,
structural heart disease and significant renal or hepatic impairment. Of the 67 eligible
women, 59 agreed to initial assessment for this trial and 56 were enrolled into the study
ultimately. Anti-anginals were minimised and in most cases stopped for 4 weeks prior to
the study.
Patients and controls attended in a fasting state for blood tests (oral glucose tolerance test
in 'Syndrome X' patients only), peripheral microvascular assessment, clinical measures
of blood pressure and body mass index. Patients with 'Syndrome X' also had detailed
assessment of their chest pain and nitrate use, and underwent a standard exercise
tolerance test (full Bruce protocol) and echocardiography.
The 'Syndrome X' group were randomised to either metformin 500mg BD (n=27) or
placebo (n=29) for 8 weeks and then had all the investigations repeated to ascertain
whether this 8 week period of treatment had any impact on the metabolic, vascular or
ischaemic measures. Details of the study protocol and methods used are within chapter 3.
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Assessing Peripheral Microvascular Response
There are several techniques available for looking at vascular function both in the
coronary circulation and peripherally. These vary in the size of vessel looked at and the
degree of invasiveness associated (see table 1, chapter 5). Laser Doppler imaging was
used in this trial to assess peripheral microvascular vasodilation in response to
iontophoresis of acetylcholine (ACh) and sodium nitroprusside (SNP). This has the
advantage of being completely non-invasive and is specifically assessing the
microcirculation as opposed to larger vessel responses which are looked at by other
techniques.
The principles behind this technique and the specifics of the protocol used are discussed
in detail within chapter 5, but briefly, this technique uses the Doppler shift in the
wavelength of a reflected laser beam to calculate the change in cutaneous perfusion
during iontophoretic application of vasoactive drugs.
The reproducibility of this technique was looked at with repeat scans between arms and
repeat scans after 8 weeks. There are several methods of analysing the results, including
correction for skin resistance (which alters the delivery of drugs by iontophoresis) and
correcting for the baseline value of perfusion (which likely reflects baseline
microvascular tone). It was shown that the good results in terms of reproducibility are
obtained by using the raw value of perfusion but this is improved slightly by correcting
for skin resistance (method described in chapter 5). Correcting for the baseline perfusion
unit does not appear to be a useful exercise in promoting reproducibility of the results and
this suggests that baseline microvascular tone may be of some importance.
Inter-arm mean variation for the AUC response (area under the curve) was 2.7% for ACh
and 3.8% for SNP. Temporal variation (scans 8 weeks apart) had 3.5% average variation
for ACh and 4.7% for SNP. There are many factors which influence the perfusion
response obtained by laser Doppler imaging in conjunction with iontophoresis and some
are beyond control (such as emotional state of the patient). However, these data provide
some reassurance in that as long as a standardised protocol is performed under controlled
conditions, results with good reproducibility are obtained.
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Assessment at Baseline -
Comparisons Between Healthy Controls and Women with 'Syndrome X'
The 56 women in the 'Syndrome X' group were on average 5.5 years older and had a
body mass index (BMI) 3.5 m2/kg higher than the 25 healthy controls. Waist
measurements were also approximately 7cm lower in the controls group.
There were no significant differences between the groups in smoking history nor family
history of ischaemic heart disease or diabetes. During the trial period, anti-anginals were
minimised in the 'Syndrome X' group to such an extent that there were no differences in
the use of beta-blocker, calcium channel blockers, nicroandil or nitrate preparations, to
that of the control group. There was much greater use of aspirin and statins amongst the
'Syndrome X' group during the trial.
Women with 'Syndrome X' showed higher fasting serum insulin and a lower fasting
quicki index suggesting relative insulin resistance compared to controls. This was
associated with some other features of the metabolic syndrome compared to controls in
terms of higher systolic blood pressure (14mmHg on average) and dyslipidaemia
(triglycerides higher in 'Syndrome X' group). There were higher levels of serum
endothelial markers namely, von Willebrand factor (vWF), tissue plasminogen activator
(tPA), intracellular adhesion molecule (I-CAM) and vascular cell adhesion molecule (V-
CAM). High sensitivity C-reactive protein and serum leptin were higher in the
'Syndrome X' group reflecting as markers for inflammation and adiposity respectively.
However, once the difference in age and BMI between the groups were addressed,
differences between the groups remained only for fasting insulin and quicki index,
triglycerides, HDL-cholesterol, vWF and I-CAM, and serum leptin. These results are
summarised in table 4.1 and 4.2 within chapter 4.
Looking at microvascular function, there was significantly increased microvascular
vasodilation with ACh and SNP in healthy controls compared to women with 'Syndrome
X'. These highly significant differences persisted even after correction for the age and
BMI differences between the 2 groups. This suggests that as well as a blunted
endothelium-dependent response, there also exists impairment in the endothelium-
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independent response which points to more generalised vascular dysfunction, perhaps
involving the vascular smooth muscle.
Weak associations between the quicki index of insulin sensitivity and microvascular
function were seen in all of the women - 'Syndrome X and healthy controls - (r2=7% for
endothelium-dependent and 6% for endothelium-independent responses). This is
compatible with the link between insulin sensitivity and vascular function which has
previously been described.
These data are important and in some respects unique in that I have now extended the
spectrum of risk factor abnormalities in women with Cardiac Syndrome X to also include
vWF, ICAM-1, leptin and potentially t-PA and CRP. The elevation in leptin is of
particular interest since a recent report has linked leptin to vascular dysfunction
independently of other pathways (1). Moreover, there is plentiful evidence that
inflammatory pathways are relevant to vascular dysfunction (2). These observations are
relevant since many of these parameters are recent additions to the spectrum of
perturbances linked to the metabolic syndrome, and thus, in turn, to insulin resistance
Correlations between vasomotor dysfunction in the peripheral and coronary vascular beds
have been documented (3). If attenuated peripheral microvascular function serves as a
marker for coronary microvascular dysfunction then it may be possible to identify those
with coronary microvascular dysfunction non-invasively, on the basis of their peripheral
microvascular function. This has important implications for the potential identification of
patients with 'microvascular angina' within the group of'Syndrome X', as ECG criteria
are often unhelpful and can be difficult to interpret.
In conclusion, I have made several novel and potentially clinically important observations
in this study. I have extended the spectrum of metabolic and inflammatory derangements
evident in women with Cardiac Syndrome X and shown that they have markedly
impaired skin microvascular function as assessed by laser Doppler imaging, suggesting
the presence of generalised vascular dysfunction. Future prospective studies are required
to address whether this simple non-invasive technique has clinical utility in diagnosing
this syndrome.
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Effects of Metformin on Metabolic Parameters, Vascular Function and Ischaemic
Measures in Women with Cardiac 'Syndrome X'
I showed that metformin is relatively well-tolerated and in fact there was only an 11%
drop out rate for metformin compared to 24% with placebo. There were modest increases
in serum lactate during the 8 weeks of the trial both in the metformin and placebo groups.
The reason for the rise in the placebo group is not apparent, but it does lead to the
suggestion that the increase in lactate seen with metformin may not be due to metformin
treatment per se.
The women in the metformin group (n=24) were well-matched with the placebo group
(n=22) in terms of smoking, menopause and drugs use. There was a small excess in the
number of women taking calcium channel blockers in the metformin group. Both groups
were well-matched in terms of their baseline metabolic and anthropometric variables.
Looking at ischaemic measures, GTN use was greater in the metformin group at baseline
compared with the placebo group.
Regarding indices of insulin resistance, there was a small but significant reduction in
120min post-glucose serum insulin after metformin treatment. There was also a
significant difference between the change in fasting insulin between the metformin and
placebo group in favour of lower serum insulin with metformin. With the other features
of the metabolic syndrome in mind, HDL-cholesterol rose significantly post metformin
treatment but there was no significant change in blood pressure. Considering the serum
endothelial markers, only tPA fell significantly post metformin with no change in vWF,
D-dimer, I-CAM nor V-CAM. Metformin effected a net weight loss and subsequent
reduction in body mass index compared to the changes seen with placebo, but there was
no change in waist measurement, nor any statistically significant change in C-reactive
protein nor leptin. These data are summarised in table 12, chapter 7.
The microvascular function data showed improvement in the ACh (endothelium-
dependent) response after metformin but no significant change after placebo. No change
was seen in the SNP response after metformin or placebo. This suggests that the modest
improvement in insulin sensitivity with metformin effected favourable changes in the
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endothelium-dependent microvascular system, in line with the known vascular effects of
insulin.
These metabolic and vascular changes did have some impact on clinical measures of
ischaemic burden. There were significant reductions both in the recorded frequency of
chest pain and GTN use in metformin-treated patients. Although there was no significant
increase in treadmill exercise time, there was much improved ST-segment change with
metformin and a much improved Duke score suggesting improved overall treadmill
performance.
As far as I am aware this is the first placebo-controlled study to show that metformin
improves endothelial-dependent function in a non-diabetic patient group. Since abnormal
endothelial function may be causally linked to both diabetes (4;5) and CHD (6;7), these
findings are significant and concur with increasing suggestive evidence for vascular risk
reduction with metformin in type 2 diabetes (8-10) and more robust data for prevention of
type 2 diabetes in subjects with impaired glucose tolerance (11). This controlled study
also provides tantalising support for a metformin-induced reduction in myocardial
ischaemia in women with exercise-induced angina but normal coronary arteries. The
noted beneficial effects of metformin on vascular function, metabolic parameters and
ischaemia suggest that this drug may have the potential to not only improve clinical
symptoms but also to lessen vascular risk in the longer term. These findings are
important since a large number of patients worldwide, particularly women, may have this
condition and its prognosis is not as benign as previously considered (12).
Why should vascular function improve with metformin? If insulin resistance is a
precursor to endothelial dysfunction, it follows that ameliorating insulin resistance might
improve it. In fact, there was a significant reduction in tPA concentration (partially
endothelial derived) and it is notable that elevated t-PA has recently been shown to be an
independent predictor of both CHD events (13) and type 2 diabetes (14). These results
suggested that improvements in directly-measured vascular function could not be
accounted for by glucose or inflammation parameters, which did not alter in our non-
diabetic population of women. Thus, the findings confirm and extend work of De Jager
and colleagues who reported beneficial effects of metformin on circulating markers of
endothelial function were independent of glycaemic changes in patients with type 2
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diabetes (15). It should be noted that metformin has other complex intra-cellular actions,
one of which is activation of adenosine mono-phosphate kinase (AMP-kinase) (16),
which in turn has been shown to directly activate endothelial nitric oxide synthase
(17; 18). This mechanism in itself may contribute to the vasoactive effects of metformin
independently of its action on insulin action.
This study was powered to detect change in endothelial function but I was also interested
in examining any potential effects of metformin in reducing ischaemia given prior - albeit
uncontrolled - evidence of such benefits with metformin and troglitazone in patients with
diabetes and angina (reviewed in (19)). These data suggest that metformin may lessen
ischaemic burden as determined by reduction in maximal ST depression, Duke score and
episodes of chest pain. Again, the inclusion of a placebo group, which demonstrated
minimal alterations in any of these parameters, serves to strengthen the robustness of
these findings. Although other anti-anginals were stopped prior to this study, these
findings are important and suggest that metabolic and vascular function manipulation
might be a novel route to lessen myocardial ischaemia. Of interest, other current agents
being tested in ischaemic heart disease (e.g. trimetazidine) target metabolic manipulation
to improve symptoms and appear to be insulin sensitising (20). In addition, there is now
emerging evidence that the potent insulin sensitisers, peroxisome proliferator-activated
receptor-gamma (PPARy) activators regulate activity of endothelial NO synthase (21),
lessen anginal pain (22) and improve myocardial blood flow (23).
In summary, using a double-blind placebo controlled study, I have shown that metformin
improves endothelium-dependent vascular function, vascular risk parameters, and
ischaemic burden in women with a history of exercise-induced angina but normal
coronary arteries on angiography. Such effects suggest that metformin may have the
potential not only to improve clinical symptoms in this patient group, but also to lessen
their vascular risk in the longer term. In addition, it may have preventive and therapeutic
applications in other non-diabetic patient groups. Larger controlled studies are now
required to expand these novel findings.
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Appendix 1
Greater Glasgow Health Board
Glasgow Royal Infirmary - Research Ethics Committee Patient Consent Form
Brief Title of Project: The effects of Metformin in women with angina but who
have normal appearance of the blood vessels of the heart.
Patients Summary
I understand that a team of researchers under the supervision of Professors Cobbe and Greer
and Dr Sattar are investigating the effects of the drug Metformin on chest pain incidence and
exercise capacity in women with angina but normal coronary blood vessels on angiography.
The study involves the following:
1. If possible reducing the current 'cardiac' medications to a minimum for the duration of the
study (12 weeks)
2. Having a series of investigations performed 4 weeks later including :
• Fasting overnight followed by a sugar drink and blood sampling in the
morning.
• Measurement of the skin blood flow by LASER Doppler technology (this
technique is safe and painless and does not involve further blood sampling or
invasive procedures)
• A detailed exercise test on a treadmill
• An ultrasound scan of the heart (Echocardiogram)
• Recordings of blood pressure and heart rhythm
3. Thereafter, 1 will be randomised to receive either the drug Metformin (often used to treat
patients with diabetes) or matching placebo for a total of 8 weeks.
4. All the above investigations will be repeated in 8 weeks time apart from the
echocardiogram.
Giving a blood sample may be associated with minor discomfort. I understand that my
involvement in the study is entirely voluntary and that I may withdraw at any time without
any reason being given, and without my medical care and legal rights being affected. I also





agree to take part in the Research Project Study Programme described above.
Dr/Mr has explained to me the nature of my involvement, how it





Information Sheet on Study -
The Effects of Metformin in Women with Cardiac Syndrome X
Thank you for taking the time to read this information sheet in which we invite you to be involved in a
clinical study at Glasgow Royal Infirmary.
Background
Cardiac syndrome X refers to individuals who experience frequent episodes of chest pain like angina,
but who have a normal appearance of blood vessels around the heart. The condition is more common in
women, often beginning around the change of life (menopause), and may be related to an increased
susceptibility to diabetes. Treatment of women with this condition is difficult, although some success
has been noted with hormone replacement therapy (HRT). However, many women find HRT
unsuitable, so there is a need to develop other treatments. In this study, which is funded by the British
Heart Foundation, we plan to examine if the drug 'Metformin', commonly used to treat diabetes, can
help to reduce the frequency of chest pain in women with syndrome x.
What would your involvement entail ?
You have been asked because you have angina but normal-looking blood vessels around the heart. If
you would like to be involved, we will invite to the Royal Infirmary to ask you some questions and
examine you. If possible we will take you off all your cardiac medications for 4 weeks prior to, and for
the duration of the study (a total of 12 weeks). If this is not possible, you will be eligible for the study
so long as you remain on the same medications throughout the study. We will then perform a series of
investigations as listed below (1-5). Following these tests you will be randomised to receive either
Metformin at a dose of500mg twice daily or matching placebo (a dummy tablet which has no clinical
effect), for a total of 8 weeks. The identity of the tablet you receive will not be known to the
researchers or yourself. Some of the investigations below (1-4) will be repeated in week 8 of your
treatment. Apart from minor stomach upset often in the first week, Metformin is generally free from
side-effects. If the trial is successful, it is possible that Metformin may be used in future to treat women
with cardiac syndrome x.
Investigations to be performed
Your involvement would entail 5 different procedures:
1. Fasting overnight followed by a sugar drink and blood samples in the morning
2. Measurement of skin blood flow which we assess with LASER techniques along with topical
application of some chemicals. This particular technique is entirely safe and painless and takes
around one hour to complete.
3. We will put a heart rate monitor on you for 2 hours in the morning and measure your blood
pressure 3 times.
4. We will exercise you on a treadmill and measure your exercise capacity along with other
measures normally carried out with this procedure
5. We will perform an ultrasound scan of your heart (Echocardiogram). This involves applying
jelly to the front of the chest and scanning with a probe. It is entirely painless.
At the end of the study, if appropriate, we will put you back on all your previous medications and your
clinical care will continue as before. We will make arrangements for you to be seen at the cardiology
clinic for follow-up. The results will be published in a scientific journal.
If you require further information, please ask. If you are willing to participate please complete the
enclosed 'patient consent form' and we will arrange for you to be seen at the Royal Infirmary. Of course
it is important for you to know that your participation is confidential and that you can withdraw from the
study at any time, and that this will no affect your regular treatment or care.
Once again, thank you for taking the time to read this. Advances in our understanding of medical
conditions are dependant on willing volunteers like yourself, and we are very grateful for your co¬
operation and generosity of time.
Dr Sachin Jadhav (Clinical Research Fellow)
Dr Naveed Sattar (Clinical Senior Lecturer, Pathological Biochemistry)
Professor Stuart Cobbe (Professor of Cardiology)
Contact at Glasgow Royal Infirmary University NHS Trust
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Myocardial ischaemia is a common cause of morbidity and mortality. Essentially, it
occurs when the blood supply to the myocardium is too poor its for metabolic
demands to be met. The end-artery nature of the coronary circulation, with a relative
lack of anastomosis between the major coronary arteries, makes the condition more
prevalent in myocardium. When the myocardial metabolic demands, in particular for
oxygen, are not met, anaerobic metabolism manifests, with production of lactate,
leading to symptomatic angina. At the most serious end of the spectrum, myocytes
that remain ischaemic beyond a critical time period die, resulting in myocardial
infarction.
The importance of type 2 diabetes mellitus is well established as a cardiovascular risk
factor. The cardiovascular risk of patients with insulin resistance, with or without
glucose intolerance, has become apparent as described in a recent meta-analysis,
looking at hyperinsulinaemia as a surrogate marker '. Reaven described the forerunner
of what has become known as the Insulin Resistance Syndrome (also called Metabolic
Syndrome X) in 1988. Since then, the definitions have been extended such that a
cluster of inter-related cardiovascular risk factors including central adiposity,
hypertension, dyslipidaemia and disturbances of fibrinolysis, with abnormalities of
insulin metabolism at the core, are now described .
Here we collate available evidence to suggest that insulin resistance, in addition to
promoting physical obstructive atheromatous coronary disease, may lead to
myocardial ischaemia via the process of endothelial dysfunction. Based on these
observations, we suggest that amelioration of insulin resistance, whether by
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established or novel mechanisms, may at least in part restore normal endothelial
function and potentially ameliorate anginal symptoms.
Evidence for endothelial dysfunction as a causative factor in angina independent
of obstructive disease
In conventional angina there is evidence to suggest that endothelial function in the
myocardial vascular bed is abnormal. Coronary atherosclerosis is associated with a
reduced vasodilator response and a paradoxical vasoconstrictor response to
acetylcholine. This has been shown in response to both atrial pacing and bicycle
exercise during coronary angiography and these functional abnormalities may
contribute to ischaemia in patients with obstructive coronary disease 3"5. However, it
is difficult to implicate this as a direct cause of ischaemia due to co-existing flow-
limiting atheroma.
A subgroup of patients with angina has normal coronary arteries despite evidence of
ischaemia demonstrated using non-invasive methods. This defines the group termed to
have microvascular angina. There is good evidence to support the notion that these
patients also have impaired microvascular function mediated by abnormal endothelial
vasomotor responses and that this could potentially be an aetiological factor in
ischaemia. Impaired endothelial function has been demonstrated in subjects with
"Cardiac Syndrome X", using methods including brachial artery flow-mediated
dilatation 6 7and abnormal coronary vascular responses assessed by intracoronary
doppler 89. In fact, recent data published in abstract from support a correlation
between levels of endothelial dysfunction and ST-segment depression as a marker for
ischaemia in such women 10.
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It is postulated that this impairment of endothelial function results in failure of the
normal coronary vasodilatory response at times of stress, such that the arterial supply
does not match the enhanced demand, leading to the activation of anaerobic
metabolism and ischaemic pain. This group of patients provides an opportunity to
study functional vessel abnormalities in the absence of obstructive atheroma.
The Link between Insulin Resistance and Endothelial Dysfunction
Insulin resistance, as well as being the precursor for type 2 diabetes, has several
'pleiotrophic' effects. These include several of the features of the metabolic syndrome
including dyslipidaemia, as well as direct promotion of atheroma production.
Another such effect is its influence on vascular function. Impaired endothelial
function in type 2 diabetes has been shown using venous occlusion plethysmography
1112, high resolution brachial artery ultrasound 13, and more recently by laser doppler
imaging 14. In addition, Balletshofer et al have shown that clamp-derived indices of
insulin resistance correlate with endothelial responses in first degree relatives of
subjects with type 2 diabetes, using brachial artery ultrasound 15. Similarly, Jaap et al
described an association between insulin sensitivity and microvascular function in
non-diabetic subjects with fasting hyperglycaemia, using laser Doppler fluximetry in
response to local heating 16. Serne et al extended these observations by demonstrating
that microvascular function as assessed by laser Doppler flowimetry is associated with
insulin sensitivity even in normal subjects 17. Furthermore, in a study of the coronary
circulation in subjects with unobstructed coronaries, a strong correlation between
clamp-derived indices of insulin resistance and coronary vascular function assessed
by Doppler blood-flow recordings was noted 18.
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Other aspects of the insulin resistance syndrome have been associated with
endothelial dysfunction. Obese individuals without diabetes have endothelial
dysfunction both in the peripheral and coronary circulation 19 and a specific link to
central adiposity has been noted by some 20. Steinberg et al showed blunted leg blood
flow in response to arterial infusions of methacholine in obese, insulin resistant
subjects compared to controls. Importantly, whereas the production of euglycaemic
hyperinsulinaemia augmented blood flow in lean subjects, this response was not
apparent in obese 21. Endothelial dysfunction has also been documented in in-vivo and
ex-vivo experiments in subjects with hypertension and in association with
dyslipidaemia, particularly in those subjects with high triglycerides and low HDL-
cholesterol22"24.
A close correlation between insulin sensitivity and endothelial nitric oxide (NO)
synthesis is seen in healthy volunteers 25. A similar correlation is seen between insulin
sensitivity and vasoconstrictor responses to N-monomethyl-L-arginine (an NO
inhibitor), in a mixed group of men including patients with diabetes, hypertension and
healthy volunteers 26. Furthermore, the vasodilating effect of insulin is amplified in
the presence of metabolically active glucose in healthy subjects 21. This observation,
together with findings that insulin augments blood flow in lean subjects points
towards a key role for insulin and glucose metabolism in maintaining vasodilator tone
in vessels via NO. This is supported by the observation that exogenous insulin therapy
appears to improve endothelial function in patients with type 2 diabetes 28.
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The post-receptor signalling mediators involved in the production ofNO in response
to insulin in many ways parallel those which regulate insulin-mediated glucose
transport via GLUT4 translocation (see figure 1). It appears that activation of
phosphatidylinositol 3-kinase (PI3-kinase) is crucial in this signalling pathway. Cells
expressing an inhibitory mutant of PI3-kinase have a much attenuated NO response to
insulin. Downstream mediators of this effect may include protein kinase B (PKB) also
known as Akt, 29 possibly by phosphorylating endothelial nitric oxide synthase (e-
NOS)30. However, other pathways may also be involved and remain to be
characterised. In particular, intracellular Ca+2 concentrations are affected by insulin,
mainly by stimulation of the Na+-H+ exchanger and Na+-K+ ATPase and therefore
insulin resistance may have a direct Ca+2-mediated influence on vascular tone 31.
Microvascular angina, insulin resistance and endothelial dysfunction.
In parallel with the above observations, several groups have demonstrated relative
insulin resistance in postmenopausal women and non-obese men with microvascular
angina, together with lipid perturbances and higher blood pressure 32"36.
Furthermore, there are data to suggest that subjects with microvascular angina have a
reduced whole-body nitric oxide response to insulin 37. This leads to the hypothesis
that resistance to this effect of insulin could manifest in impaired endothelial function
via intermediates including NO.
Can improving insulin resistance improve endothelial function?
Whilst the above observations are compelling, proving a causal relationship between
insulin action and endothelial function requires intervention studies. Very recent
uncontrolled data show that intentional weight loss by means of a hypocaloric diet
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combined with exercise, and in some cases surgical liposuction, improves endothelial
vasomotor function as measured by haemodynamic responses to intravenous L-
arginine (NO precursor)38 .This improvement coincided with reduction in fasting
insulin and cytokine levels.
Metformin, the only biguanide in clinical use, has been available in the UK for over
30 years. Its exact mechanism of action remains unclear but it is thought to involve
increasing tyrosine kinase activity in the insulin receptor with intracellular effects
mediated via the PI3- kinase pathway on GLUT4 translocation as well as NO
production (figure 1).
One 12-week trial of metformin compared to placebo in individuals with type 2
diabetes showed improved endothelial function as measured by forearm
plethysmography, in the metformin group alone 39. Data recently published in abstract
form, reported significant improvements in endothelial-dependant microvascular
function , in a group of women with Cardiac Syndrome X, following 8 weeks of
metformin treatment compared with placebo 40. These observations concur with
preliminary animal data where chronic metformin therapy improved aortic vascular
properties in hyperinsulinaemic, fructose-induced hypertensive rats 41. Metformin has
other complex intra-cellular actions, one of which is activation of adenyl mono¬
phosphate kinase (AMP-kinase) 42, which in turn has been shown to directly activate
nitric oxide synthase 43. This mechanism in itself may contribute to the vasoactive
effects of metformin independently of its action on insulin metabolism.
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Modest weight loss during metformin therapy is well-described 44 and thus it is
difficult to dissect whether vascular effects are solely due to this. By contrast,
thiazolidinediones improve insulin sensitivity without reducing weight, with
redistribution of adipose tissue from visceral to subcutaneous deposits 45. Troglitazone
has been reported to improve endothelial function measured by flow-mediated
brachial artery diameter, after either four weeks 46 or four months of therapy 47.
Preliminary data have extended these findings to include an improvement in
myocardial blood flow, measured non-invasively using positron-emission
tomography, in non-diabetic insulin resistant individuals after three months of
troglitazone therapy 48. In animal models, rosiglitazone improved indices of insulin
resistance and myography-based measures of vascular function in fatty Zucker rats 49.
There is one report, however, showing a lack of effect to troglitazone on vascular
function assessed by plethysmography 50.
Can improving insulin resistance lessen anginal frequency?
Preliminary data suggests that in diabetic patients with angina , four months treatment
with troglitazone not only improves endothelial function, as assessed by brachial
artery ultrasound, but also treadmill exercise capacity 47. In a study published so far
only in abstract form, troglitazone has also had beneficial effects on both the
frequency of chest pain, and measures of endothelial function, in vasospastic angina
51, which is associated with insulin resistance and abnormal vascular function 52.
Another study, also in abstract form so far, demonstrated improved Duke Score
ischaemic measures in women with Cardiac Syndrome X following metformin
administration40. Finally, a non-randomised study of metformin, given post
myocardial infarction, to a large group of patients with varying glucose tolerance,
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suggested a significant lessening of anginal symptoms and fewer new infarcts in
those who received metformin compared to those who did not53.
Conclusion
Prospective data have established markers of insulin resistance as an independent
cardiovascular risk factor. We have suggested that insulin resistance is implicated in
the pathogenesis of endothelial dysfunction, and therefore via this route, myocardial
ischaemia. Indeed, there is tantalising evidence to show that insulin sensitisers may
improve not only insulin resistance and endothelial function, but also anginal
symptoms and exercise capacity in diverse patient groups. We suggest, therefore, that
further properly randomised studies are required to elaborate the potential of insulin-
sensitising agents in the treatment of angina.
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Table 1 : Summary of intervention trials looking at insulin sensitisers and outcomes of
endothelial function and symptoms.
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Fig 1
Schematic outlining insulin receptor and
NO production coupling in endothelium
eNOS
IRS : insulin receptor substrate
PI 3-kinase : phosphatidylinositol 3-kinase
PKB : protein kinase B
eNOS : endothelial nitric oxide synthase
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ABSTRACT
To characterise microvascular function, candidate risk pathways and metabolic
syndrome prevalence in women with cardiac Syndrome X, 52 non-diabetic women
with angiographically normal epicardial arteries but >lmm of planar ST depression
during exercise testing (cases) and 24 healthy controls of similar age were recruited.
In addition to fasting blood samples and anthropometric measures, forearm cutaneous
microvascular function following iontophoresis of acetylcholine and sodium
nitroprusside was assessed by laser Doppler imaging. Despite body mass index (BMI)
correction and a higher proportion on statin therapy, cases had elevated insulin
(p=0.016), triglycerides (p=0.018), Intercellular adhesion molecule (ICAM-1)
(p=0.021), von-Willebrand factor (vWF) (p=0.005), leptin (p=0.005) and lower high
density lipoprotein (HDL)-cholesterol (p =0.042) relative to controls. Consistent with
these data, 30% of cases but only 8% of controls fulfilled National Cholesterol
Education Program (NCEP)-defined metabolic syndrome (p=0.015). Finally, both
endothelium-dependent and independent microvascular function were markedly
impaired in the cases (p <0.001) and odds ratio for cardiac Syndrome X was 7.38
(95%CI 2.2 to 24.7) if acetylcholine response was <8710 flux units. In conclusion,
women with cardiac Syndrome X more commonly have metabolic syndrome and
related adiposity/metabolic /inflammatory derangements. They also have significantly
impaired skin microvascular function as assessed by laser Doppler imaging, consistent
with generalised vascular dysfunction, a finding with potential diagnostic
implications.
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The objectives of this study were: i) to assess whether endothelial function using a
novel non-invasive technique recently optimised in our laboratory (1;2) can
discriminate between women with cardiac Syndrome X (cases) and healthy controls;
ii) to determine whether circulating markers of several novel candidate risk
parameters were elevated in such cases; and, iii) to determine the proportion with
metabolic syndrome defined by the National Cholesterol Education Program (NCEP).
We recruited non-diabetic women with normal epicardial arteries and an electrically
positive exercise tolerance test (ETT). From 2630 diagnostic coronary angiograms
performed at Glasgow Royal Infirmary between 1998-2001 we identified 226 women
with normal coronary arteries. From examination of case records, 71 had a positive
ETT with >lmm of flat ST depression. Exclusion criteria included type 2 diabetes (2
patients), uncontrolled hypertension (1 patient), left ventricular hypertrophy (1
patient), valvular heart disease, age greater than 70 years and significant renal or
hepatic impairment. Suitable candidates were contacted by post and 52 participants
agreed to enrol. Anti-anginal and anti-hypertensive medication was minimised and in
most cases stopped for the duration of the study (table 1). The local ethical review
committee approved the protocol. Twenty-four healthy age-matched control subjects
were recruited locally by advertisement. The investigation conforms to the principles
outlined in the Declaration of Helsinki.
All subjects attended Glasgow Royal Infirmary fasting and had venous blood
samples obtained from the antecubital fossa. These were immediately centrifuged at
2000rpm for 10 mins with the serum then being transferred into aliquots for storage at
-80 °C. Analysis for lipid profile (beta-quant) and fasting glucose was undertaken
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immediately. All other analyses were undertaken at the end of the study in batches.
Blood pressure was measured using an Omron semi-automated in the supine position
in triplicate and a mean was recorded. Waist, hip, height and weight measurements
were recorded to calculate anthropometric parameters.
Microvascular function was assessed using laser Doppler imaging of the
forearm cutaneous vascular bed with the subject relaxed in the supine position in a
quiet, temperature and light-controlled environment, as described previously (3).
Perspex iontophoresis chambers were applied to the extensor forearm surface. The
cathode chamber was filled with a 1% sodium nitroprusside (SNP) solution (dissolved
in 0.5% sodium chloride) and the anode chamber 1% acetylcholine (ACh) solution
(also dissolved in 0.5% sodium chloride). Incremental current was applied with
concurrent laser Doppler imaging to record the perfusion response. The laser Doppler
imager (Moor Instruments Ltd) made use of a red laser (wavelength 633nm, power
lmW, beam diameter 1mm). The voltages across the circuit were recorded to enable
calculation of the skin resistance as previously described (2). The perfusion response
in flux perfusion units was calculated using Moor Instruments software package and
is presented as both area under the curve (AUC) for the scan and as a plot of flux
perfusion units against cumulative charge
Samples were analysed for tissue plasminogen activator (tPA), vWF (von
Willebrand factor), fibrin D-dimers, intercellular adhesion molecule (ICAM-1),
vascular cell adhesion molecule (VCAM), sensitive C-reactive protein (CRP), leptin
and insulin. t-PA, fibrin D-dimer (Biopool, Stockholm, Sweden), and vWF (Dako,
Copenhagen, Denmark) antigens were measured by ELISA techniques. The adhesion
molecules were assayed using commercially-available ELISAs quantification (R&D
systems Inc., Oxon UK) and C-reactive protein (CRP) (by double antibody sandwich
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ELISA with rabbit anti-human CRP and peroxidase conjugated rabbit anti-human
CRP: DAKO A/S, DK-2600 Glostrup, Denmark). Standard curves for CRP
measurement were linear up to 5mg/l and logarithmic thereafter. The inter-assay and
intra-assay coefficients of variation were less than 7% across the range of measured
results. Leptin was measured by radioimmunoassay and insulin was measured by a
Microparticle Enzyme Immunoassay (Abbott Laboratories) assay with a coefficient of
variation (CV) <8% and sensitivity of 0.8mU/l. Plasma glucose was measured using
the glucose oxidase method (Glucose Reagent Kit - Olympus AU5200, Olympus
Optical Co Ltd). Finally, lipid profile was measured using established methods
(Boehringer reagent kits, East Sussex, UK) in a laboratory meeting CDC
standardisation criteria.
All non-parametric data were logarithmically transformed. Comparison was
then made using a 2-sample t-test or ANOVA. Data are presented as mean and
standard deviation (SD). Adjustment for body mass index (BMI) was made by linear
regression analyses. The index of insulin resistance used was the 'Quicki' index
(1 /[(log insulin) + (log glucose)]). Log (fasting insulin) is also presented. The
percentage of cases and controls with metabolic syndrome were compared using the
Chi-square test. Receiver operating characteristic (ROC) analyses were performed to
determine the areas under the curves as a measure for comparing the predictive ability
for identifying potential cases of BMI and ACh response and of combination of BMI
and ACh response.
The cases and controls were similar in age, menopausal status, use of hormone
replacement therapy and in the proportion of smokers. Significantly (p<0.05) more
cases than controls had had a previous hysterectomy and a history of hypertension
during pregnancy (Table 1).
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The results of classical and novel candidate risk parameters are given in Table
2. Log insulin was lower and the Quicki index was significantly higher in the women
with cardiac Syndrome X. The cases also had higher systolic blood pressure,
triglycerides and lower HDL-cholesterol relative to controls despite significantly more
being on statin therapy. Moreover, serum concentrations of t-PA, vWF, V-CAM and
1-CAM-1 were also higher. No difference in D-dimers was detected. The cases had
significantly higher BMI, and waist circumference along with significantly higher
serum leptin. Raised inflammatory indices as reflected by a higher sensitive CRP,
were noted in the cases.
After adjustment for BMI (Table 2), between group differences persisted in
insulin (p=0.016), systolic blood pressure (p =0.017), triglycerides (p =0.018), HDL-
cholesterol (p=0.042), vWF (p =0.005), I-CAM (p=0.021), and leptin (p =0.005).
Marked differences were seen in peripheral microvascular function with
endothelium-dependent (ACh) responses being attenuated in the cases as manifest by
AUC, before and after correction for skin resistance (p <0.001) (see methods), and by
2-way ANOVA analysis of perfusion response against cumulative charge (p
<0.00001, Figure 1). Similar results were seen with SNP (endothelium-independent)
with a significant difference again with both AUC, raw and resistance-corrected
(p<0.001) and 2-way ANOVA (p<0.00001). The differences in AUC values remained
significant even after regression analysis to correct for the differences in BMI
between the 2 groups. The mean AUC and 95% confidence intervals are shown in
Table 2.
To test the potential clinical utility of microvascular function, we constructed
ROC curves as a summary of the sensitivity and specificity of ACh response in
differentiating cases from controls. The area under the ROC curve for ACh response
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was 0.782, which compared favourably with the value for BMI (0.732). Interestingly,
the combination of BMI and ACh response increased prediction to 0.824. Finally, we
determined that the LDI response to ACh that best differentiated cases from controls
was 3.94 log units (=8710 flux units). The likelihood odds ratio of being a case with
cardiac Syndrome X below this cut-off was 7.38 (95% CI, 2.20 to 24.7).
There were more smokers in the cardiac Syndrome X group as compared with
the controls, although this difference was not statistically significant (see Table 1).
However, since smoking can attenuate vascular function, 2-way ANOVA analysis
was repeated with all smokers excluded. Once again, case-control differences in both
ACh and SNP-mediated microvascular responses remained highly significant (data
not shown). Finally, the prevalence of metabolic syndrome as defined by NCEP was
nearly four-fold higher in women with cardiac Syndrome X as compared to healthy
controls (p<0.05, Figure 2).
Our data demonstrate that despite glucose concentrations within normal ranges,
women with cardiac Syndrome X have biochemical indices reflecting relative insulin
resistance (4-6). We made use of fasting insulin because others have demonstrated
good agreement between fasting insulin and clamp-derived indices of insulin
resistance, especially in obese populations (7).
Previous work has shown that patients with cardiac Syndrome X exhibit other
characteristics of the metabolic syndrome namely hypertension(8) and dyslipidaemia
(9), as well as some serum markers of abnormal endothelial function (9; 10). Our
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results confirm the differences in blood pressure and some lipid parameters (despite
more women in the cardiac Syndrome X group taking statins). However, our data are
unique in a number of respects in that we are the first group to extend these findings,
controlling for BMI, to abnormalities of novel independent coronary heart disease risk
markers linked to insulin resistance and endothelial function, namely leptin, tPA,
vWF and ICAM-1. CRP was also higher in absolute terms but BMI adjustment
reduced the difference (p=0.07) in accordance with the known effects of adiposity on
inflammatory status. Furthermore, the prevalence of NCEP-defined metabolic
syndrome was more than three-fold higher in cases than controls.
We noted that 27% of the cases (vs 4% of controls, p=0.021) reported
problems with hypertension during pregnancy. This finding suggests that impaired
peripheral microvascular function is associated with hypertensive complications
during pregnancy. Recent data from our group and others have confirmed that women
with a history of pre-eclampsia have impaired microvascular function by the
techniques of flow-mediated dilatation (11) and laser Doppler imaging (12).
Significantly, vascular impairment in women with cardiac Syndrome X extends
to the microvasculature of forearm skin as evidenced by the non-invasive technique of
laser Doppler imaging with iontophoresis. This is a novel technique which has been
used to demonstrate microvascular impairment in a number of other related areas
including diabetes (13), hypertension (14) and dyslipidaemia (15).
Our data complement the existing results in patients with cardiac Syndrome X,
obtained using plethysmography and brachial artery ultrasound (16-18) but is unique
in demonstrating endothelium-independent impairment compared to healthy controls.
This suggests that there may be a more generalised disorder of vascular smooth
muscle in these patients rather than just dysfunction at the level of the endothelium.
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Previous work has relied on the administration of sublingual nitrate in drawing
negative conclusions about endothelium-independent responses, whereas our data
were obtained by direct iontophoretic application of nitrate solution, iontophoretically.
This suggests that the sublingual delivery route may be inadequate when studying
endothelium-independent responses of systemic vasculture and intravenous/intra-
arterial administration may be necessary to draw conclusions about these responses
when using plethysmography and ultrasound techniques.
More of the cardiac Syndrome X patients were taking aspirin during the study
(73%) compared to none of the control subjects. Some groups have postulated that
this may reduce the ACh perfusion response when using laser Doppler (19). However,
data from our group shows that this effect is due to an increase in skin resistance
reducing iontophoretic drug delivery, and in fact no attenuation in the ACh response
is seen when correction for skin resistance is made (2), as was done in our present
study. Therefore, aspirin is unlikely to account for the impairment in ACh response
seen in the subjects with cardiac Syndrome X, and in any case, would not account for
the differences observed in the SNP response.
In conclusion, we have made several novel and potentially clinically important
observations in this study. Specifically, we have: extended the spectrum of metabolic
and inflammatory derangements reported in women with cardiac Syndrome X; shown
that such women more commonly have NCEP-defined metabolic syndrome; and,
finally, demonstrated that they have markedly impaired skin microvascular function
(both endothelium-dependent and independent) as assessed by laser Doppler imaging
- suggesting the presence of generalised vascular dysfunction. We suggest that future
prospective studies are required to address whether this simple non-invasive technique
has clinical utility in diagnosing this syndrome.
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Age* (years) 55.6+/-2.07 52.0+/-3.04 NS
Body Mass Index* (kg/m2) 28.58 +/- 1.24 25.1 +/- 1.58 0.001
Fasting Glucose* (mmol/L) 4.9+/-0.1 5.1 +/-0.2 0.022
Smokers 8 (15%) 1 (4%) NS
Hysterectomy 15 (29%) 1 (4%) 0.014
Peri/Postmenopausal 30 (58%) 16(67%) NS
Hypertension in Pregnancy 14 (27%) 1 (4%) 0.021
Statin therapy 21 (40%) 2 (8%) 0.003
Beta-blockers 1 (2%) 0 NS
Calcium Channel Blockers 4 (8%) 2 (8%) NS
Nicorandil 2 (4%) 0 NS
Nitrates 5 (10%) 0 NS
Hormone replacement therapy 14 (27%) 6 (25%) NS
Aspirin 38 (73%) 0 <0.001
Mean +/- 95% confidence interval of mean.
327
Table 2. Classical and novel riskfactor parameters in cases and controls








Total cholesterol (mmol/L) 4.97 (0.97) 4.93 (0.86) 0.839 0.838
HDL-cholesterol (mmol/L) 1.35 (0.35) 1.55 (0.35) 0.023 0.042
Triglyceride* (mmol/L) 1.37(1.7) 0.93 (1.6) 0.002 0.018
Systolic, hlood nressure fmmHv)









Waist (cm) 87.9(10.9) 80.2 (8.9) 0.002 0.855
Serum leptin (ng/ml) 36.9 (14.3) 20.8(14.3) <0.001 0.005
log fasting insulin* (mu/L) 7.86 (1.70) 4.77(1.86) 0.001 0.016
Quicki index 1" 0.65 (0.096) 0.75 (0.134) 0.001 0.009
Von Willebrand Factor* (%) 121.3 (1.46) 87.5 (1.56) 0.004 0.005
tPA (ng/ml) 7.91 (2.9) 6.13 (2.0) 0.003 0.082
ICAM-1* (ng/ml) 251.2 (1.3) 212.3 (1.2) 0.003 0.021
VCAM* (ng/ml) 331.3 (1.3) 290.3 (1.2) 0.012 0.067
C-reactive protein* (mg/L) 2.71 (2.9) 1.24 (2.7) 0.003 0.071
ACh (corrected) * (Units) 8375 (1.61) 13335 (1.44) <0.0001 <0.001
SNP (corrected) * (Units) 7096 (1.56) 12023 (1.52) <0.0001 <0.001
HDL = high density lipoprotein, tPA = tissue plasminogen activator, I-CAM-1 = intercellular adhesion
molecule
VCAM = vascular adhesion molecule, ACh = acetylcholine, SNP = sodium nitroprusside
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Plots of laser Doppler imaging-assessedperfusion response to iontophoresis of
acetylcholine (A Ch, left) and sodium nitroprusside (SNP, right) in healthy controls
(HC) compared to cardiac Syndrome X cases (SX). Values are correctedfor skin
resistance. The responses ofboth ACh and SNP are significantly different by 2-way
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Objective - to determine whether metformin, an insulin sensitizer, improves vascular
function or myocardial ischemia in non-diabetic subjects
Background - Metformin prevents diabetes and may reduce coronary events in
patients with diabetes but effects on microvascular function and angina are not clear
Methods We conducted an eight week double-blind randomised placebo-controlled
study of metformin 500 mg BD in 33 non-diabetic women with a prior history of
normal coronary angiography but two consecutive positive (ST depression > 1 mm)
exercise tolerance tests (ETT). All parameters were measured at baseline and 8 weeks
together with an in-vivo assessment of forearm (skin) microvascular function using
laser Doppler imaging combined with iontophoresis.
Results In comparison to placebo (n=17), metformin recipients (n=16) demonstrated
significant reductions in weight, and HOMA (p<0.05, intention to treat).
Endothelium-dependent microvascular responses improved significantly with
metformin (two-way repeated ANOVA, p=0.0003) but responses with placebo were
unchanged (p=0.50). A comparison of change in ACh responses between metformin
and placebo recipients was significant, whether analysed by a two-way ANOVA
(p<0.0001) or change in area under curves (mean change +392 perfusion units (20 to
764)). Endothelium-independent responses were not altered. Maximal ST depression
(-0.84 mm, -1.49 to -0.20, p=0.013), Duke score (6.1 units, 1.8 to 10.5, P=0.008) and
chest pain incidence [-0.11 episodes per day (-0.22, 0.00); p=0.056] improved in the
metformin relative to placebo recipients.
Conclusions Metformin may improve vascular function and decrease myocardial
ischemia in non-diabetic women with chest pain and angiographically normal
coronary arteries. Larger controlled trials of longer duration are warranted.
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Metformin is insulin sensitizer with a history of successful use in type 2 diabetes. In
the United Kingdom Prospective Diabetes Study, metformin was associated with a
39% lower risk of myocardial infarction compared to conventional therapy (1). In a
more recent study, metformin was associated with a near 40% reduced total and CHD
mortality when compared with sulfonylurea monotherapy (2). In a retrospective
analysis of the Prevention of Restenosis with Tranilast and its Outcomes Trial (3), use
of metformin in diabetic patients undergoing coronary interventions decreased
adverse clinical events, especially death and myocardial infarction (79% risk
reduction), when compared with patients treated with either a sulfonylurea or insulin.
Consistent with such data, metformin variably improves lipids and hemostatic
function in patients with type 2 diabetes (4). One placebo-controlled study in patients
with type 2 diabetes suggested metformin may improve directly measured vascular
function (5) independent of any weight change but such studies are lacking in non-
diabetic populations.
Current therapeutic options for a well-recognised group of patients with
anginal symptoms, a positive ETT but angiographically smooth coronary arteries are
limited (6). The condition, sometimes referred to as "cardiac syndrome X" is not as
benign as originally reported- patients presenting with unstable angina and non¬
obstructive atherosclerotic coronary artery disease have a 2% risk of death or
myocardial infarction at 30 days follow-up (6). It is more common in women where
the first presentation occurs either peri- or postmenopausally (7). Many such patients
are insulin resistant (8-10) and have associated metabolic and haemostatic
abnormalities (8,9). Aberrant flow mediated coronary vasomotion is pivotal in the
pathogenesis of this syndrome, and occurs as part of a more generalised (systemic)
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impairment in endothelial function (11). Indeed, some centres use systemic
assessments of vascular function in their diagnostic pathways for this group of women
(12). We recently suggested that insulin resistance, acting via endothelial dysfunction,
may lead to myocardial ischemia and that insulin sensitization via metformin or other
agents may lessen ischemia (13).
In the present study, we tested the hypothesis that metformin offers dual
benefits of improving vascular function and lessening ischemia in non-diabetic
women with angina, ischemic ETTs and normal appearing coronary arteries. Our
primary end-point was the effects of metformin on microvascular function (measured
by laser Doppler technology) in women previously categorised following
investigation in local hospitals as having Cardiac syndrome X (i.e. angina, a positive
ETT, and a normal coronary angiogram) and who also had a repeat positive ETT pre-
randomisation. The secondary aims of this study were i) to assess effects of
metformin on chest pain incidence, maximal ST depression and Duke score, and ii) to
examine whether metformin improved other metabolic parameters linked to insulin
resistance in such women.
METHODS
We recruited 33 women with smooth unobstructed epicardial arteries demonstrated on
coronary angiography between 1997-2001 at Glasgow Royal Infirmary. All of these
women had ongoing typical anginal-type chest pain and had previously documented >
1mm of flat ST-segment depression on treadmill exercise testing and a repeat positive
ETT at the pre-randomisation visit (i.e. all had two consecutive positive ETTs). Those
with even minor coronary plaque disease, insignificant upsloping ST-segment change
during exercise and coronary artery spasm at angiography were excluded. All women
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underwent pre-trial screening with blood tests and echocardiography. Other exclusion
criteria included age >70 years, diabetes, uncontrolled hypertension, valvular or other
structural heart disease and significant hepatic or renal impairment.
Ethical approval was gained and eligible patients gave written informed
consent to participate. Anti-anginal therapy was stopped or reduced for a four week
period before the trial in the majority of patients, in keeping with the procedure in
prior trial of hormonal replacement in cardiac syndrome X where all cardiac drugs
were stopped four weeks prior to active treatment or placebo (14). After this period, a
chest pain diary was provided to each woman and they were asked to record on a
daily basis the numbers of typical anginal type chest pains they had suffered. We
collated this information separately for four weeks prior to treatment and over the
eights weeks on treatment. All patients were invited to attend in the fasting state for
baseline assessments.
Laser Doppler Imaging
Microvascular function was assessed, as detailed before (15-18), using LDI with the
subject relaxed in the supine position in a quiet, temperature and light-controlled
environment. This was carried out before any blood tests were obtained pre-
randomisation and repeated in week eight. Briefly, drugs were administered
transdermally by iontophoresis, using perspex chambers applied to the extensor
forearm surface. The cathodal chamber was filled with sodium nitroprusside (SNP),
an endothelium-independent vasodilator (1% dissolved in 0.5% sodium chloride), and
the anodal chamber with acetylcholine (ACh) an endothelium-dependent vasodilator
(1% dissolved in 0.5% sodium chloride). We also employed vehicle (0.5% sodium
chloride) controls in the opposite forearm. Incremental current (expressed as charge,
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the integral of the current x time relationship, in milli Coulombs, mC) was applied
with concurrent laser Doppler imaging to record the perfusion response. The
perfusion response in flux perfusion units is presented as both the area under the curve
(AUC) for the scan and as a plot of the change in perfusion with drug administration
(in arbitrary Perfusion Units) against cumulative charge. The mean (± SD) between-
day coefficient of variation in healthy subjects for the ACh response was 6.4% whilst
the within-day, between-site coefficient of variation, measured in both forearms was
8.9%.
Blood Investigations
Fasting blood samples were collected and stored in aliquots at -80C for batch
analysis at the end of the study. Tissue plasminogen activator (tPA), von Willebrand
factor (vWF) (Dako, Copenhagen, Denmark) antigens, intercellular adhesion
molecule-1 (ICAM-1) (R&D systems Inc., Oxon UK) and high sensitivity C-reactive
protein (CRP) (DAKO A/S, DK-2600 Glostrup, Denmark) were determined by
ELISA techniques. The inter-assay and intra-assay coefficients of variation were less
than 7% across the range of measured results. Insulin was measured by a
Microparticle Enzyme Immunoassay (Abbott Laboratories) assay with CV <8% and
sensitivity of 0.8mU/l. Plasma glucose was measured using the glucose oxidase
method (Glucose Reagent Kit - Olympus AU5200). Finally, lipid profile was
measured using established methods (Boehringer reagent kits, East Sussex, UK).
Homeostatic model assessment (HOMA, fasting plasma insulin [pU/ml] x fasting
plasma glucose [mmol/l]/22.5), was used to determine insulin resistance.
336
Other Clinical Measures. Blood pressure was measured in triplicate following five
minutes rest in the supine position using an Omron 705-CPII and the average was
taken. Height and weight measurements were recorded to calculate BM1.
Exercise Tolerance Test. All patients underwent a full Bruce protocol treadmill test at
baseline and then again after 8 weeks of metformin or placebo. Exercise time was
noted and maximum ST-segment depression was recorded to the nearest 0.5mm to
avoid artefact contamination. The Duke score [calculated as total exercise time in
minutes - (5*maximal ST segment deviation) - (4*index)] was employed to provide
an objective measure of treadmill-testing performance. A chest pain 'index' of 0 is
assigned if no chest pain is experienced, while 1 is recorded for non-limiting pain and
2 for limiting chest pain. The Duke score has been shown to indicate prognosis in
suspected coronary disease(19).
Randomisation
Metformin (500 mg tablets) and identical placebo were administered in a double-blind
randomised fashion in a 1:1 fashion. Metformin and placebo were given with
instructions to take one tablet daily for 1 week increasing to twice daily for the
remaining 7 weeks of the trial. Randomisation was done in blocks of four with codes
being held by pharmacy until data analysis was completed. Compliance was checked
by pill counting. Subjects were asked to record side effects but to persevere with the
tablets unless symptoms were severe.
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Statistical methods
Data are presented as mean (SD) for all parameters other than chest pain incidence where
median (interquartile range) are given. Comparison of change in parameter concentrations
between groups was examined by the 2-sample t-test (or Mann Whitney U test for chest pain
incidence) and two-way ANOVA between groups (with group and cumulative charge as main
factors) for vascular function measures on an intention to treat analysis using last value
carried forward in the case of drop-outs. A p value<0.05 level was considered significant.
Change within groups was examined by paired t-test or Wilcoxon Sign Rank test (chest pain
incidence) or two-way repeated ANOVA for vascular function (baseline versus treatment and
cumulative charge as main factors). The p values reported for vascular function analyses
refer to the vasodilator response to ACh or SNP at baseline compared to the value obtained
following treatment with metformin or placebo (i.e. analysis confined within the treatment
group), or the difference between baseline and treatment for each vasodilator when
comparing metformin to placebo. Whether changes in parameters were associated was
assessed using simple Pearson correlation. Adjustment for change in weight was performed
by analysis of covariance.
RESULTS
Seventy-one women were screened for inclusion [Figure 1], Fifty-six women with
previously documented positive ETT but normal coronary angiograms were seen at a
pre-randomisation visit and of these only 33 had a repeat positive ETT, and they form
the study cohort. Sixteen women were randomised to receive metformin, 17 to
placebo. Statistical analysis was performed as pre-specified on an "intention to treat"
(ITT) basis. Compliance, as checked by pill-counting at the end of the trial, was good
with 85% of study completers demonstrating >90% compliance, and compliance not
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different between groups (p>0.50). Gastrointestinal side-effects were more prevalent
in the metformin group affecting 10 of the 16 women compared to 3 from 17 in the
placebo group (j2, p<0.05) but were transient in the vast majority.
Demographic characteristics
The baseline characteristics are given in Table 1. The women randomised to
metformin or placebos were similar for baseline characteristics including age, BMI
and smoking history.
Primary end-point analyses on vascularfunction
Blood flow response to ACh improved in women who were randomised to metformin
(two-way repeated measures ANOVA p=0.0003) (Figure 2a) but there was no
significant change within placebo recipients (Fig. 2b). Responses to SNP were
unchanged for both metformin and placebo groups (Fig. 2c,d). Comparing the change
in ACh response (treatment minus baseline) between metformin and placebo
recipients revealed a highly significant improvement in the former group relative to
latter (two-way ANOVA PO.OOOl), but there was no alteration for SNP (Fig 3a,b).
Comparison of AUC in metformin relative to placebo recipients was also significant
(change +392 perfusion units, 95%CI 20 to 764); p=0.04).
Metabolic effects
Analyses of metabolic changes are shown in Table 2. There was a significant
reduction in weight and HOMA (p=0.026 and p=0.045 respectively) and trend
towards reduction in t-PA antigen (p=0.09) in metformin relative to placebo
recipients.
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Exercise tolerance data and chest pain frequency
Baseline and follow up data for maximal ST depression and chest pain incidence in
the women treated with metformin and placebo are demonstrated in Figure 4a and
4b. Baseline values were not significantly different between two groups for either
parameter (p=0.23 and p=0.69, respectively). Significant improvements in both
maximal ST depression and chest pain incidence occurred in metformin recipients
(38% reduction, p=0.007 and 30% reduction, p=0.039, respectively), but such
parameters were unaltered in placebo recipients (p>0.45). Maximal ST improvement
was significantly larger for metformin than placebo (p=0.013); Median reduction in
chest pain episodes was larger for metformin than placebo and this difference
approached significance [-0.11 episodes per day (-0.22, 0.00); p=0.056], Duke score
improved by a mean of 6.1 units (95% CI 1.8 to 10.5, p=0.008) in metformin versus
placebo recipients. Of the 16 women randomised to active therapy, 13 had a reduction
in chest pain incidence in contrast with 6 of the 17 in placebo group (%2, p<0.01).
Effect ofweight change on primary end-point, change in HOMA and ST depression
In the 16 women randomised to metformin alone, reduction in maximal ST depression
correlated significantly only to reduction in t-PA antigen concentration (r=0.64,
p=0.01) and reduction in weight (r=0.55, p=0.024), the former association
independent of the latter. Changes in ACh responses and ischemic parameters did not
correlate. Importantly, metformin-induced changes in ACh-mediated vascular
response, HOMA and to a lesser extent ST depression were minimally attenuated by
adjustment for weight change differences by group (Table 3).
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DISCUSSION
This is the first placebo-controlled study to show that metformin improves
endothelium-dependent vascular function in non-diabetic subjects. Since abnormal
systemic / coronary endothelial function may be causally linked both to states of
insulin resistance (20,21) and to CHD (22,23), our findings are clinically relevant and
consistent with other favorable effects of metformin (1-3) and for its prevention of
type 2 diabetes in subjects at elevated risk (24). Our study also suggests metformin
may reduce myocardial ischemia in women with exercise-induced angina and normal
coronary arteries. The combined beneficial effects of metformin on vascular function,
metabolic parameters and ischemia suggest it potential to lessen vascular risk. These
findings are important as the prognosis of this common condition is not as benign as
previously considered (6).
We examined effects of skin microvascular function using LDI combined with
iontophoresis of vasoactive agents. Our group has considerable experience with this
technique, having demonstrated impaired skin microvascular function in obesity,
diabetes and in the post-prandial state, whereas others have linked it to insulin
resistance (15-18). The metformin-treated subjects demonstrated a clear improvement
in ACh response (Figures 2a, 3a), a finding also consistent in analyses of completers
(data not shown).
Why should vascular function improve with metformin? If insulin resistance is
a precursor to endothelial dysfunction, ameliorating insulin resistance should improve
it. Metformin induced a small but significant reduction in weight (~1 kg or 2%
relative to placebo) and a significant change in HOMA relative to placebo (>20%).
Although this reduction in HOMA was slightly attenuated (p=0.045 to p=0.08) after
adjusting for weight change, neither change correlated with improvement in ACh
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response. However, reduction in t-PA antigen (partially endothelial-derived)
concentration in the metformin group did correlate to reduction in maximal ST
depression; of note, elevated t-PA is an independent predictor of both CHD events
(25) and type 2 diabetes (26). Of interest, improvements in vascular function
occurred despite no significant changes in glucose or inflammation parameters. De
Jager and colleagues reported beneficial effects of metformin on circulating markers
of endothelial function were independent of glycaemic changes in patients with type 2
diabetes (27). Changes in vascular function were also not explained by change in
weight (Table 3). It should be noted that metformin has other complex intra-cellular
actions, one of which is activation of adenosine mono-phosphate kinase (AMP-
kinase) (28), which in turn has been shown directly to activate nitric oxide synthase in
H-2kb cells (29) and to exert this action by phosphorylation of the endothelial isoform
at serine 177 in human aortic endothelial cells (30). This is a plausible candidate
mechanism for the vasoactive effects of metformin, independent of its effects on
insulin action, weight or other parameters.
Our study was designed to detect change in endothelial function but we were
also interested in effects on ischemia given prior - albeit uncontrolled - evidence of
such benefits with metformin and troglitazone in patients with diabetes and angina
(reviewed in (13)). Our positive results on effects of metformin (but not placebo) on
maximal ST depression, Duke score and episodes of chest pain suggest a reduction in
ischemia. As such, our findings are important and in keeping with recent novel
approaches to target metabolic processes in the vasculature as a method of reducing
myocardial ischemia (31). Similarly, in studies of diabetes patients,
thiazolidinedione insulin sensitisers have been shown to lessen anginal pain (32),
improve myocardial blood flow (33), and regulate activity of endothelial NO
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synthase, the latter occuring at least in part via a peroxisome proliferator-activated
receptor-gamma (PPARy) action (34). Interestingly, a significantly lower incidence
of admission for angina was reported for the pioglitazone arm relative to placebo in
the recent PRO-ACTIVE study (35).
Limitations and strengths
We acknowledge that a more robust measure of myocardial ischemia would
have enhanced the study - nevertheless our women had a good history of exercise
angina, two consecutive positive ETTs and evidence of impaired systemic vascular
dysfunction, a collection of findings, we believe, would be considered satisfactory by
many cardiologists to make the diagnosis of cardiac syndrome X. Moreover, the
consistency of improvements in vascular, metabolic and ischemia data by chest pain
questionnaire and during the ETT in the metformin group, and in comparison to
change with placebo recipients is reassuring. We also accept that although the
measure of vascular function we used is well validated, it would have been optimal to
measure endothelial function in coronary arteries directly. That noted, to repeat
coronary angiography in a group with recently documented normal coronary
arteriography would have raised ethical issues. As regards study strengths, we
reiterate that, regardless of any effects on ischemic parameters, this is the first double-




In summary, using a double-blind placebo controlled study design we have
shown that metformin improves endothelium-dependent vascular function and
ischemia in women with a history of exercise-induced angina, reproducible positive
ETTs but normal coronary arteries on angiography. Such effects suggest that
metformin may have the potential not only to improve clinical symptoms in this
patient group, possibly via positive effects on microvascular function, but also to
lessen their vascular risk in the longer term. Larger studies are now required to









- 1 patient admitted with chest pain; 1 had GI side-effects; 2 had non¬
specific symptoms.
Figure 2
a. Baseline and on-treatment (8 weeks) microvascular responses to ACh in the 16
women randomised to metformin (p=0.0003, two-way repeated measures
ANOVA,)
b. Baseline and on-treatment (8 weeks) microvascular responses to ACh in the 17
women randomised to placebo (p=0.38, two-way repeated measures ANOVA)
c. Baseline and on-treatment (8 weeks) microvascular responses to SNP in the 16
women randomised to metformin (P=0.46, two-way repeated measures
ANOVA,)
d. Baseline and on-treatment (8 weeks) microvascular responses to SNP in the 17
women randomised to placebo (P=0.95, two-way repeated measures
ANOVA).
Figure 3
a. Change over 8 weeks in microvascular responses to ACh in metformin and
placebo groups (PO.OOOOl, two-way repeated measures ANOVA).
b. Change over 8 weeks in microvascular responses to SNP in metformin and
placebo groups (P=0.55, two-way repeated measures ANOVA).
Figure 4
a. Mean maximal ST depression during ETT (mm) at baseline and on-treatment
(8 weeks) in the 33 women randomised to placebo (n=17) or metformin
(n=16).
b. Median chest pain incidence prior to randomisation and on treatment in the 33
women randomised to placebo (n=17) or metformin (n=16).
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Body mass index (kg/m2)
Weight (kg)
Current smoker, n (%,)
Postmenopausal, n (%)
HRT use, n (%)
Aspirin, n (%)
Statin use, n (%>)



















Nitrate, n (%) 2 2
Calcium channel blockers, n (%>) 1 0
Nicorandil, n ("%>) 0 2
*No significant difference (P>0.10) in any baseline characteristics in metformin vs.
placebo group
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Table 3. Raw and weight change-adjusted differences in metformin versus placebo
recipients for change in vascular response (AUC for ACh-mediated perfusion),
HOMA and ST depression.
= — -
Beta SE P
AUC for ACh response 392 179 0.04
Adjustedfor delta weight 395 197 0.05
HOMA (raw difference) -0.52 0.25 0.045
Adjustedfor delta weight -0.49 0.27 0.08
ST depression (raw difference) -0.84 0.30 0.013
Adjustedfor delta weight -0.51 0.29 0.095
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Figure 3a (ACh) & b (SNP)
• Metformin (16)
• Placebo (17)
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Appendix 4
Endothelial function is negatively correlated to ST-segment depression
during exercise in women with anginal chest pain and normal coronary
arteries
S.T.Jadhav*, W.Ferrell \ J.Petrie1 , N.Sattar2, S.M.Cobbe.
University Departments of Medical Cardiology, Medicine1,and Pathological Biochemistry2.
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Background. Women with chest pain and normal coronary arteries present a common
and often difficult clinical scenario. A proportion have myocardial ischaemia, caused by
microvascular disease and it has been suggested that endothelial dysfunction with
reduced vasodilator capacity might be an aetiological factor. We set out to look at levels
of endothelial dysfunction in this group using a non-invasive technique, and compare
with an age -matched control group.
Methods. We recruited 51 women with both an electrically positive exercise tolerance
test (ETT) and a coronary angiogram in the previous two years demonstrating normal
epicardial vessels. The ETT was repeated with manual measurement of maximal ST
segment deviation. Endothelial function (EF) was assessed non-invasively in the forearm
cutaneous vascular bed by means of laser-doppler imaging in response to iontophoretic
application of acetylcholine (ACh) and sodium nitroprusside. An arbitrary cut-off point
of 10000 units (area under the curve) for the ACh response was used to categorise
subjects those with 'normal' or 'impaired' EF. Endothelial function was assessed in 25
control subjects using the same technique.
Results. 33 women in the chest pain group (65%) had impaired EF. There was a negative
linear correlation between the extent of ST depression and EF (r=0.44 p=0.001). All
women with greater than 2mm ST depression had impaired EF and no women with
'normal' EF had 2mm or more of ST depression. There were significant differences
between the EF of women in the control group compared to women in the chest pain
group (pO.OOOl).
Discussion. There was an association between endothelial dysfunction and ST changes
on ETT in women with chest pain and normal coronary arteries. EF in these women is
significantly impaired compared to matched controls. Our data suggest a potential novel
application of non-invasive assessment of endothelial function as an adjunct to ETT in




Women with Cardiac Syndrome X Exhibit Features of the Insulin
Resistance Syndrome and Impaired Peripheral Microvascular
Function.
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Background. Anginal chest pain despite angiographically normal coronary arteries in the
context of a positive exercise test is a common problem. A proportion of this group,
labelled as cardiac 'syndrome x' (CSX), have evidence of myocardial ischaemia. We
sought to characterise women with CSX in terms of their metabolic parameters and
peripheral microvascular function (MF) as compared with controls
Methods. We recruited 56 women fulfilling the criteria for CSX along with 25 healthy
matched controls (HC group). Fasting blood samples and clinical measurements were
obtained. Forearm cutaneous microvascular function was assessed by iontophoresis of
topically applied acetyl choline and sodium nitroprusside and laser Doppler imaging
Results. There were significant differences between the CSX and HC with regards to
indices of insulin resistance (p<0.001), systolic blood pressure (p<0.012), triglycerides
(p<0.01), HDL-cholesterol (p=0.012), C-reactive protein (p<0.005), body mass index
(BMI) (p<0.001) and serum leptin (p<0.001). Peripheral MF, both endothelium-
dependent and independent, was impaired in the CSX group compared to the HC group
(p<0.001) and circulating vascular markers (von willebrand factor, tissue plasminogen
activator, and cellular adhesion molecules) were also different between the 2 groups
(p<0.001). Adjusting for BMI attenuated the differences in the metabolic parameters as
did adjustment for insulin. However the differences were further attenuated after
correction for serum leptin. The differences in MF remained highly significant even after
adjustment
Discussion. Subjects with CSX exhibited features of the insulin resistance syndrome.
Attenuation of these differences after correction for leptin highlights the importance of
adiposity and insulin resistance in CSX. Impairment of both endothelial-dependent and
independent MF suggests not only endothelial dysfunction but more generalised vascular
smooth muscle dysfunction which may be important in the aetiology of myocardial
ischaemia. Adjusting for leptin and insulin did little to attenuate these differences in MF
suggesting other factors play a critical role
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Effects of Metformin on Microvascular Dysfunction, Metabolic
Parameters and Ischaemic Measures in Women with Cardiac Syndrome
X : a Randomised Double-Blind Placebo-Controlled Trial.
S.T.Jadhav*, N. Sattar2, W.Ferrell J.Petrie1 , S.M.Cobbe.
University Departments of Medical Cardiology, Medicine1, and Pathological Biochemistry2.
Glasgow Royal Infirmary, Alexandra Parade, Glasgow, G31 2ER
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Background. Insulin resistance and associated vascular dysfunction are potential aetiological factors for
Cardiac Syndrome X (CSX) - angina with positive exercise tolerance test but angiographically
unobstructed epicardial arteries. We sought to determine whether metformin would reverse the metabolic
derangements and vascular dysfunction, in such women, and as a result lead to less ischaemia.
Methods and Results. 56 non-diabetic women with angina, >lmm ST-segment depression on exercise
testing and angiographically normal coronary arteries were recruited. Metformin 500mg twice daily was
administered for 8 weeks in a double-blinded randomised placebo-controlled manner (DBRPCT). Baseline
and post-treatment data were collected - fasting blood tests, full Bruce-protocol ETT, anthropometric
measures. Laser Doppler imaging combined with iontophoretic application of sodium nitroprusside (SNP)
and acetyl-choline (ACh) to the forearm extensor surface, was used to assess endothelial independent and
dependant microvascular function.
At baseline women who took metformin (n=24) were well matched with those given placebo (n=22) in
terms of age, metabolic parameters, treadmill performance and microvascular function. Metformin
treatment resulted in significant reductions in fasting insulin (p=0.036), tissue plasminogen activator
(p=0.026), body mass index (p=0.003), and ST-segment depression during exercise (p=0.003), and
significant elevations in treadmill Duke score (p=0.001) and HDL-cholesterol (p=0.049), relative to
placebo effects. Endothelial-dependant microvascular function was significantly improved with metformin
group (p<0.001) with no change in the placebo group (Figure 1) but endothelial independent function did
not alter.
Discussion. These data show for the first time in the context of a DBRPCT that metformin treatment can
improve metabolic parameters, microvascular function and clinical outcome measures relating to ischaemic
burden in women with CSX. Future studies should examine whether metformin has a potential clinical role
in patients with the metabolic syndrome, who have angina and obstructive coronary disease, as vascular
dysfunction is a feature in this population also.
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